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Glutathione (GSH), a 3-amino acid compound is ubiquitously expressed in eukaryotic cells and 
is the most abundant low molecular weight thiol. The importance of GSH is highlighted by its  
multitude of effects. Within the vascular wall GSH plays a crucial role as an intracellular antioxidant 
and it possess the ability to act as a signalling intermediate and store for nitric oxide (NO). The 
importance of NO and its role in vascular wall homeostasis is well recognized. Within the coronary 
circulation, NO is the primary dilator of many of the large arteries and the smaller arterioles. In 
addition to controlling coronary vascular tone, the importance of NO is highlighted by its 
antithrombotic, antihypertrophic, and antriproliferative effects. During instances of cardiovascular 
disease and normal aging, increases in the production of reactive oxygen species occur. A portion of 
the deleterious vascular effects of reactive oxygen species are believed to be due to reduction in NO 
bioavailability as a result of increased ROS-mediated destruction of NO. Altered GSH production in 
humans has been demonstrated to reduce endothelial function. Conversely, supplementation with 
GSH augments endothelium-dependent dilation. The mechanisms by which these alterations in GSH 
influence vasomotor function have not been resolved. The purpose of the studies within this thesis 
was to examine the impact of chronic and acute GSH modulations on coronary vascular resistance 
(CVR) and endothelium dependent dilation. In all experiments vascular reactivity was assessed in the 
isolated perfused rat heart. The advantage of this technique is that it allows the global coronary 
vasomotor functioning to be examined. Hearts were allowed to stabilize for 30 minutes to allow for 
the development of spontaneous coronary vascular resistance, followed by a bradykinin (BK) dose-
response curve to assess endothelium-dependent dilation. The coronary circulation was then 
maximally dilated using an endothelium-independent agonist. In all cases BK-mediated dilation is 
expressed as a percentage of the endothelium-independent dilation. 
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Chapter 2 of this document examines the chronic nature of GSH depletion and examines 
whether GSH depletion augments the influence of natural aging. Animals (mean age 33 and 65 weeks) 
were randomized to receive L-Buthionine-(S,R)-sulphoximine (BSO) in the tap water in order to inhibit 
GSH synthesis, or regular tap water (normal controls). Following 10 days of BSO treatment, ventricular 
GSH content was reduced in the BSO group compared to the control (0.182±0.021 vs 2.022±0.084 
nmol/mg wet weight, p<0.05) and there was increased ventricular H2O2 content (1.345±0.176 vs 
0.877±0.123 pmol/µg PRO, p<0.05). Baseline CVR was significantly reduced in the older animals 
compared to the adult animals (3.92±0.34 vs 4.76±0.20 and 3.67±0.24 vs 5.12±0.37 mmHg/ml×min-1 in 
the control and BSO treated groups, p<0.05). Conversely, in the presence of LNAME there was a 
significant increase in CVR in the adult BSO group (14.15±0.99, p<0.05) compared to all other groups. 
In the absence of LNAME, maximal dilation (percent endothelium-independent response) was reduced 
in the older animals compared to the adult animals (77±10.3% vs 95.0±1.0% for older and adult 
control and 92.7±4.5% vs 98.6±0.6% for the older and adult BSO, main effect of age). In the presence 
of LNAME the adult BSO group had a significantly reduced sensitivity (EC50) compared to all other 
groups (-7.39±0.09 Log M, p<0.05). Additionally, adult BSO treated animals had an increase in eNOS 
protein content. These results demonstrate that chronic thiol depletion resulted in an increased 
reliance on NO in the adult BSO group only. 
In chapter 3 the beneficial effects of GSH supplementation on BK mediated dilation were 
examined. Acute GSH was administered in the perfusate at either 0 (control) or with 10 µM for 2 
reasons, 1) this concentration does not reduce basal coronary vascular resistance, allowing for a 
similar baseline CVR across conditions and 2) the 10 µM concentration is a physiologically relevant 
concentration of plasma/extracellular fluid GSH. The sensitivity to the endothelial agonist bradykinin  
was enhanced in the presence of GSH (-8.70±0.16 vs -7.94±0.06 LogM, p<0.01). The GSH effect was 
not dependent on NO production or utilization by soluble guanylate cyclase (sGC) as the enhanced 
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dilation in the GSH group was maintained despite NOS (LNAME) and/or sGC inhibition. When the 
hearts were supplemented with a ROS scavenger TEMPOL, enhanced dilation was seen in the control 
group, but was not further enhanced in the GSH group. The requirement for ROS was best 
demonstrated when both the CON and GSH groups were supplemented with both TEMPOL and 
LNAME. This condition resulted in similar sensitivity (-7.76±0.19 vs -7.75±0.17 LogM, p>0.05) and area 
under the curve (182.33±12.70 vs 170±13.86, p>0.05) between GSH and CON. Thus, it was concluded 
that the effects of GSH administration requires the presence of ROS and exerts its effect in the 
microvasculature. 
The study presented in chapter 4 examined the effects of acute thiol modulation (depletion) 
on CVR and endothelium-dependent dilation. Previous reports have suggested that a reduction in 
intracellular GSH causes impaired NO production, and functional data support this contention. 
However, a majority of the data regarding the effects of thiol manipulation are from endothelial-
removed vessels. The following agents were used to reduce GSH: the glutathione reductase inhibitor, 
BCNU; the thiol oxidizing agent, diamide; the thiol conjugating agent, ethacrynic acid (EA); and a 
thioredoxin inhibitor (CDNB). Preliminary data revealed that only CDNB (11.46±0.71 mmHg/ml×min-1) 
and EA (8.61±0.36 mmHg/ml×min-1) caused an elevation in CVR compared to the control (6.73±0.24 
mmHg/ml×min-1). Conversely, Diamide and BCNU did not significantly affect baseline CVR, or the BK 
mediated responses. In the presence of EA, there was an overall blunting of the BK-response curve as 
observed by reduced EC50 (-7.85±0.07 Log M) and maximal dilation (90.8±1.8 %, percent endothelium-
independent dilation) compared to the control group (-8.42±0.08 Log M and 97.7±1.6%). In the 
presence of CDNB the maximal dilation was 74.4±1.9% and the EC50 was -8.83±0.28 Log M. In addition 
to altering BK mediated responses, acute thiol depletion with all agents resulted in an increased 
minimal CVR with significant increases observed in the presence of CDNB and EA. There was a 
significant correlation with GSH:GSSG ratio and baseline (-0.547, p<0.05) and minimal CVR (r=-0.581, 
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p<0.05). This study demonstrates that modulation of the GSH:GSSG ratio using a variety of agents with 
diverse mechanisms elicits differential responses within the vasculature. Specifically conjugation of 
GSH and inhibition of thioredoxin significantly alters BK mediated response, where as BCNU and 
dimaide did not. These results suggest that a modulation in the GSH:GSSG ratio impairs endothelium-
dependent dilation and alters total dilatory capacity (baseline-minimal CVR) and thus may have 
implications for adequate tissue perfusion. 
Across all studies there were significant inverse correlations between GSH and GSSG with both 
baseline and minimal CVR. Therefore it is likely that changes in overall glutathione content plays a role 
in determining baseline and minimal coronary vascular resistance. These results demonstrate the 
complexity that manipulations of GSH have on both CVR and endothelium-dependent dilation, and 
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 Cardiovascular disease remains one of the leading causes of morbidity and mortality in the 
Western World, and is on the rise in many developing countries. Understanding the disease process 
and treatment strategies is essential in the prevention and treatment of disease. It has been 30 years 
since the discovery of endothelial derived relaxing factor (EDRF) which has subsequently been 
identified as nitric oxide (NO). Nitric oxide is generated by nitric oxide synthase (NOS), the most 
important isoform within the vascular wall being the endothelial specific isoform (eNOS). eNOS 
generates NO through a reduction/oxidation pathway converting L-arginine to NO. The importance of 
the identification of NO is highlighted by the pluripotent effects this molecule has at maintaining 
homeostasis within the vascular wall including vascular tone, as well as the inhibitory effects NO has 
on thrombosis, vascular smooth muscle proliferation and hypertrophy. The bioavailability of NO is 
reduced in disease states and is believed to be a contributing factor in the development of 
cardiovascular disease. 
 The ability of endothelium to respond appropriately to an agonist is a hallmark indicator of 
vascular health. However, NO is not the only dilatory agent released by the endothelium, as 
prostaglandins and non-NO-non-prostanoid derived vasodilatory agents have been identified. 
Furthermore, the identification of the release of endothelial derived contracting factors on endothelial 
stimulation has also been established. For the purpose of the current investigations, the primary focus 
is on NO given the prominent role it plays within the coronary circulation.  
 Free radicals or reactive oxygen species (ROS) are by-products of normal cellular respiration 
and immune responses. However in disease states, including cardiovascular disease, there is an 
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increased production of ROS, which results in pathological levels. These levels contribute to a 
reduction in NO bioavailability. For example, superoxide anion (O2∙-) rapidly combines with NO 
forming peroxynitrite (ONOO) which does not have the same antiproliferative or antithrombotic 
properties as NO. Within the vascular wall several key antioxidants play a role at mitigating the effects 
of free radicals including superoxide anion. A crucial intracellular antioxidant is glutathione (GSH). This 
ubiquitously expressed tripeptide is found within all eukaryotic cells. The role of GSH within the 
vascular wall extends beyond its antioxidant capabilities as GSH is also involved as a signalling agent 
used to alter protein function. The central focus of this thesis is examining the impact of modulating 
GSH levels chronically (chapter 2) and acutely (chapters 3 and 4) to determine how changes in GSH 




1.2.1 Glutathione metabolism 
Thiols are the product of sulphur metabolism and refer to compounds which contain a 
sulfhydryl group (-SH). Glutathione (reduced glutathione, GSH) is a 3 amino acid compound consisting 
of glycine, cysteine, the sulphur containing amino acid, and glutamate (1, 46, 65, 124, 160). 
Glutathione is ubiquitously expressed in all eukaryotic cells and is the most abundant of the low 
molecular weight thiols (46, 65, 160, 192). The concentration of GSH varies between 0.5-10 mmol/L 
depending on the specific tissues and cells being examined. The cytosolic compartment contains 85-
90% of the total cell GSH, ~10% is located within the mitochondria and a small amount is located in 
the endoplasmic reticulum and the nucleus. In plasma, GSH can be found at concentrations ranging 
between 2 – 20 µmol/L (38, 65, 150, 192). GSH can be oxidized to oxidized glutathione (GSSG), but it is 
kept primarily (99%) as GSH within the cell (46, 65, 124, 150, 160) by the widely expressed and highly 
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active enzyme glutathione reductase (GR, (123, 124)). The GSH:GSSG ratio is important at maintaining 
cellular oxidation/reduction (redox) potential. Therefore the activities of both GR and glutathione 
peroxidase (GPx) are key enzymes in the maintenance of cellular redox balance and control (65, 117, 
123, 150, 155, 160, 178). 
The generation of GSH is the subject of many reviews (1, 46, 123, 124, 160). The purpose of 
this section is to provide an overview of glutathione synthesis, the Ɣ-glutamyl cycle, and to highlight 
some of the key enzymes involved in the generation and transport of GSH. The synthesis of GSH 
(Figure 1.1) is controlled by 2 enzymes. Ɣ-glutamylcysteine synthetase (GCS) catalyzes the reaction 
between L-glutamate and L-cysteine utilizing one molecule of ATP and Mg2+ as cofactors (1, 46, 77, 
123, 124, 160). The activity of this enzyme is controlled by the availability of L-cysteine (1, 77, 124, 
160, 192), but can be inhibited by negative feedback as high levels of GSH can attenuate GCS activity 
(1, 46, 77, 123, 124, 160). The activity of GCS can also be modulated by 
phosphorylation/dephosphorylation and oxidative/nitrostative stress. In the presence of oxidative 
stress there is both a compensatory increase in the transcription and activity of GCS (77). 
Furthermore, studies have demonstrated that concentrations of nitric oxide (NO) < 1 mM promote 
cystine (oxidized cysteine) uptake (111) and activation of GCS (127) in endothelial cells. This suggests 
that within the vasculature, signalling by NO may help promote GSH synthesis. The final step in GSH 
synthesis involves the combination of the newly formed L-glutamyl-L-cysteine molecule with glycine. 
This step is catalyzed by glutathione synthase and also utilizes ATP and Mg2+ (1, 46, 77, 124, 160). 
Most of the research regarding the control of GSH synthesis has focused on the GCS as it is the rate 





Figure 1.1 Pathway of Glutathione Synthesis 
GSH is generated by 2 enzymes, each of which uses 1 molecule of ATP and Mg2+ as cofactors. The rate 
limiting step in this reaction is GCS, as it is controlled primarily be cysteine availability. ƔGT located on 
the outer cell membrane serves as an anchor for catabolic products of GSH and is used to secure and 
uptake the specific amino acids required for GSH synthesis. 
 
GSH can also be generated through a salvage pathway. This pathway involves Ɣ-glutamyl 
transpeptidase (Ɣ-GT). The Ɣ-GT is located on the outer cell membrane and aids in the transport of 
catabolised GSH and other glutathione complexes into the cell. Typically a cysteinylglycine component 
and a Ɣ-glutamyl amino acid component are transferred to the cytosol where they can then be further 
processed to amino acids and reused for glutathione synthesis (46, 65, 123). NO-induced increases in 
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GSH in endothelial cells requires the activity of Ɣ-GT, but it remains unknown if NO activates Ɣ-GT 
(127). Most cells possess the ability to export both GSH and GSSG by a group of GSH transeferases (46, 
65, 123). During instances of elevated GSSG, it is possible for GSSG to be exported from the cell, which 
can lead to a depletion of GSH (46, 65, 85). The function of the salvage pathway and Ɣ-GT is to recoup 
the extruded GSSG, and this represents a second mechanism for GSH synthesis as there is no direct 
transport of GSH into the cell. 
1.2.2 Control of coronary blood flow - the primary role of nitric oxide 
Ensuring an adequate supply of oxygen and nutrients to the myocardium requires a near 
constant supply of blood. This would explain why much attention has been directed at matching 
myocardial perfusion to the metabolic demands of the heart, and the existence of multiple and 
redundant pathways that ensure this relationship is sustained regardless of the metabolic demands 
(59, 129, 176, 185). The primary mechanisms controlling coronary artery tone can be classified into 4 
primary categories: metabolic, myogenic, neurohormonal, and endothelial and have been the subject 
of many reviews (59, 176, 185). A combination of these factors is used to determine myocardial 
perfusion and flow distribution with the relative importance of each mechanism varying as a function 
of the anatomical location of the vessel within the vascular network and depth within the myocardium 
itself. Large coronary arteries and arterioles rely heavily on endothelium-dependent mechanisms for 
maintenance of proper tone; conversely, the tone of smaller arterioles is more dependent on 
metabolic and myogenic mechanisms as they are often found deeper with the myocardial wall (27, 61, 
93, 129). The capacity to change coronary vascular resistance varies within the vascular network of the 
coronary circulation. Approximately 75% of the resistance of the coronary circulation is determined by 
arteries between 75 – 200 μm in diameter (35, 93, 115, 129), albeit resistance also varies according to 
the location of the vasculature within myocardial wall (34, 93, 129). Generally, as the size of the 
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coronary vessel decreases the pressure drop observed across the same vessel is increased (27). 
Therefore, the ability of the coronary vasculature to regulate perfusion and tone is dependent on the 
distinct functioning of each segment of the coronary arterial network (27).  
Nitric oxide is the primary dilator of large epicardial coronary arteries (61, 98, 176) as well as 
the mediator of flow-induced dilation in the coronary microcirculation (61, 93, 129). Furthermore, NO 
interacts with the α-adrenergic control of the coronary circulation by blunting the constriction induced 
by α-agonists (129). It is because of the multitude of effects of NO on the coronary circulation that 
make it arguably one of the most important vasoactive substances acting on the coronary circulation. 
Szekeres and colleagues (2001) demonstrated that arterioles dilate to a greater extent to the 
endothelium dependent dilators bradykinin (BK) and acetylcholine (ACh) than do the arteries. 
Additionally, arterioles demonstrate a greater amount of constriction in the presence of NOS 
inhibitors compared to large arteries (168). Interestingly, the eNOS protein content within the 
coronary vascular network is not reduced until reaching the smallest coronary arterioles (106), 
suggesting that NO production can occur to a similar extent throughout the vasculature of the heart. 
Therefore it is likely that NO can act as a dilator at all levels of the coronary vascular tree, despite the 
differences that exist as to what the primary dilatory agent is within a specific portion of the coronary 
vascular network. The general regulatory effects of NO and the role of reduced NO have been the 
subject of numerous reviews (26, 60, 64, 110, 145, 173) all of which highlight that the control of 
vasomotion is driven by NO and the bioavailability is controlled by production, destruction and 
sensitivity of the target tissue. The importance of prostacyclin and other endothelial derived 
vasodilators are not as important as NO with respect to coronary endothelial-mediated dilation, but 
may be important in pathological states (60, 71, 115, 176). The powerful influence of NO is 
demonstrated by the suppressive nature NO has on the dilation to other dilatory pathways in the 
coronary circulation (18). 
7 
 
This discussion demonstrates the important role NO plays as a dilatory agent within the 
coronary circulation. The importance of NO extends beyond its ability to maintain coronary perfusion 
as it plays an important role in the overall homeostasis of the vascular wall including antiplatelet 
capabilities, suppression of vascular smooth muscle growth and proliferation and the ability to 
suppress adhesion and atherosclerotic plaque development (26, 125). Therefore, alterations in the 
ability of the coronary vasculature to respond to endothelial stimulation are used as a surrogate of 
overall vascular health.  
 
1.3 Rationale for examining the interaction between thiols and vascular function 
1.3.1 The association between changes in GSH content and GSH:GSSG ratio and the risk of 
cardiovascular disease. 
Recent studies have demonstrated that genetic polymorphisms in the enzymes of glutathione 
synthesis are associated with increased risk of negative cardiovascular outcomes. Koide and 
colleagues found a genetic variation in the catalytic subunit of glutamate-cysteine ligase (GCL or GCS). 
This mutation resulted in a -129C/T leading to 3 distinct genotypes CC, CT and TT. After controlling for 
traditional risk factors the individuals with the CT and TT polymorphism were at an increased risk of 
myocardial infarction (MI) and demonstrated robust endothelial dysfunction, as assessed by coronary 
angiography, compared to the CC. Furthermore, this mutation (CT or TT) resulted in reduced ability to 
modulate the GCL activity in response to an acute oxidative stress challenge. This suggests that the 
inability to increase GSH is an important predictor of MI and strongly associated with endothelial 
dysfunction (101). Similarly, a mutation on the modifier subunit of GCL (-588C/T allele) was also found 
to be associated with MI (133) and subsequently with impaired ACh response demonstrated by 
increased constriction and an attenuated increase in flow in patients undergoing angiography (134). 
The -588T polymorphism was also associated with a reduced plasma level of GSH (133) and basal NO 
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bioavailability as demonstrated by a blunted response to infusion of l-arginine analogue, L-NMMA 
(134). These findings indicate that reductions in GSH are associated with an impaired bioavailability of 
NO and increased risk of MI. Despite this evidence more information is required to identify the 
mechanisms responsible for the altered endothelium-dependent dilation. Thus, by examining both 
acute and chronic manipulations in GSH a better understanding of the role that GSH plays in 
maintaining vasomotor health will be established. 
The reduction in GSH content may represent one aspect of increased risk of cardiovascular 
disease; however decreases in GSH will also alter cellular redox balance. The importance of the 
GSH:GSSG ratio and redox balance was highlighted by Ashfaq and colleagues who showed this ratio 
was significantly correlated with the Framingham risk score in an apparently healthy population (r = 
0.25, p<0.01). Furthermore, there was an inverse relationship between GSH content and carotid artery 
intima-medial thickness (r = -0.39, p<0.0001) (12). In a subsequent study in a slightly healthier 
population (Framingham risk score ~ 0.2±6.4), no relationship was seen between the GSH, GSSG, or 
the GSH:GSSG ratio and flow mediated dilation. However, significant inverse correlations were 
observed between extracellular disulfide of cysteine and FMD and the mixed thiolated disulfide and 
FMD (11). Conversely, in patients with chronic renal failure, endothelial function was correlated with 
GSH (r = 0.44, p<0.01), inversely related to GSSG (r = -0.4, p<0.05) and the GSSG:GSH ratio (r = -0.47, 
p<0.01). These relationships remained significant after controlling for classical risk factors (9). These 
studies highlight that the relationship between endothelial function and GSH content may only 
become apparent in situations where endothelial function is reduced, as no relationship was apparent 
in healthy individuals but was apparent in those with renal failure. However, in healthy individuals a 
relationship was seen between oxidized cystine and FMD (11) suggesting that plasma levels of cystine 




These studies lack a mechanistic insight into the relationship between GSH and coronary 
vasomotion, although they do suggest a strong independent relationship between GSH and 
cardiovascular events and endothelial dysfunction. This suggests that chronic impairment of GSH 
synthesis in humans is associated with increased risk of cardiac events and endothelial dysfunction. 
Despite this apparent limitation they do highlight that these polymorphisms and reduced GSH:GSSG 
ratio may result in impaired NO bioavailability. Therefore, in order to understand the relationship that 
exists between GSH or GSH:GSSG and endothelial function it is important to examine the mechanisms 
potentially responsible for this relationship utilizing alternative models. 
1.3.2 The antioxidant effects of glutathione and its role in vascular aging and vasomotor function 
GSH is a key component of the cellular antioxidant system, redox balance and cellular 
detoxification. GSH plays an integral role as an intracellular antioxidant (65, 155, 160, 178, 192). The 
primary antioxidant effect of GSH is its ability to be oxidized, thereby reducing H2O2 to water and O2 
(65, 178). This occurs via the enzymatic activity of GPx which serves to oxidize GSH to GSSG. GSSG is 
rapidly converted back to GSH by GR. The reduction of GSSG is accomplished through the oxidation of 
NADPH to NADP+, which is recycled to NADPH + H+ in the pentose phosphate pathway/cycle (1, 65, 77, 
117, 124, 178, 192). This same process accounts for the detoxification of lipid peroxides to lipid 
alcohols and water (Figure 1.2). In instances of extreme oxidative stress, the GSSG concentration can 
become increased and extruded from the cell by transferases or via the concentration gradient (38, 
77, 85, 117, 124). The loss of GSSG has the potential to decrease cellular GSH content. This may 
explain why during periods of increased oxidative stress the expression of GPx, GR, as well as GCS and 





Figure 1.2. Primary detoxification of peroxides by GSH and its associated enzymes 
Glutathione peroxidise (GPx) utilizes GSH as an oxidizing agent to reduce H2O2 and other peroxides. 
GSSG is rapidly reduced to GSH by glutathione reductase (GR) which utilizes NADPH as a cofactor. The 
pentose phosphate pathway (PPP) is the primary determinant of NADPH. GSH is presented as larger as 
it is found at higher concentrations within the cell (~10:1 GSH:GSSG).  
 
Other radicals that can be quenched by GSH include O2∙-, ∙OH, and reactive nitrogen species 
including NO. The reaction between O2∙- and GSH is independent of GPx, but a hydrogen ion is 
required. In this reaction, GSH is converted to a thiyl radical (GS∙) and superoxide is converted to 
water. The thiol radical GS∙ will rapidly react with protein thiyl radicals or another GS∙ to yield 
thiolated proteins (RSSG) or GSSG (65, 85). It is believed that this mechanism helps protect proteins 
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against oxidative damage using a reversible thiolation process (38, 65). This clearly highlights that GSH 
possesses the ability to act as a general ROS scavenger and suggests a mechanism for preserving 





Figure 1.3. Summary of antioxidant effects of GSH 
GSH possess several different antioxidant properties. While a majority of the antioxidant properties 
are focused on the enzymatic activities of glutathione peroxidase (GPx), glutathione reductase (GR), 
thioredoxin and glutaredoxin (omitted for clarity). GSH possess the ability to act as a scavenger for 
oxygen derived radicals such as O2∙- or OH∙, which requires the availability of an H
+ ion. These 
reactions yield a thiyl radical which is readily combined with a similar thiyl radical or sulphur residues 




Given the ability of GSH to mitigate the effects of free radicals it can be postulated that 
alterations in GSH influence vasomotor function by preventing the interaction between NO and O2∙- 
thereby improving NO bioavailability and preserving endothelial function. This effect is highlighted in 
the above discussion examining the vasomotor response in individuals with polymorphisms of the GCL 
(101, 133). In individuals with polymorphisms of GCL, NO bioavailability appeared to be reduced as 
demonstrated by the lack of constriction to l-arginine analogues and impaired dilation to endothelial 
agonists (101, 134). Furthermore, in animal preparations in which GSH had been chronically reduced, 
elevated levels of reactive oxygen species are a common observation (13, 19, 63, 67, 68, 107, 181, 
196). In these animal preparations, reduction in endothelium-dependent dilation is also commonly 
observed (13, 63, 68, 107). These results suggest that in conditions where GSH is chronically reduced, 
there is an increase in the amount of reactive oxygen species and impaired endothelial mediated 
dilation. With the exception of the changes in humans with the GCL mutations, the effects of GSH 
depletion on coronary vascular function have not been examined.  
Surprisingly there is limited data regarding changes that occur in GSH with aging. Total 
glutathione content of the vascular smooth muscle is reported to be increased with aging (112, 136), 
whereas in the endothelium GSH content has been reported to be reduced (157). In whole aortic 
homogenate, an age-dependent decrease in GSH, increase in GSSG and reduced GSH:GSSG ratio has 
been reported (62). These changes may explain why aging, like GSH depletion, is associated with 
increased ROS production (37, 95) and endothelial dysfunction (6, 37, 95). Several different 
mechanisms have been proposed for the vasomotor dysfunction with aging, albeit increased ROS 
production plays a pivotal role (for selected reviews see (24, 60, 125, 130, 190)). The importance of 
GSH at preventing and/or mitigating the effects of aging on vasomotor function has not been 
examined and warrants further investigation. This is the focus of chapter 2 in which the effects of GSH 
depletion and aging are examined in the coronary vascular bed. 
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1.3.3 GSH can modulate endothelium-dependent dilation and vascular tone 
 Given the apparent association between GSH and free radicals it is not surprising that GSH has 
been administered as an antioxidant to improve vasomotor functioning. Kugiyama and colleagues 
(1998) demonstrated that infusion of 1 mmol/L GSH into the coronary vascular bed was without effect 
on coronary vascular resistance. However, when GSH was co-infused with ACh, coronary dilation was 
observed. This dilation was in contrast to the coronary artery constriction observed in response to ACh 
alone (104). Subsequently, Prasad and colleagues demonstrated GSH could augment the dilatory 
responses in the peripheral circulation and suggested that NO bioavailability, was increased as 
demonstrated by increase in venous cGMP following co-infusion of GSH and ACh. In a subsequent 
study, Kugiyama and colleagues demonstrated that GSH reduced free radical production in the 
coronary sinus in those with and without vasomotor dysfunction, suggesting that GSH was acting as an 
antioxidant. One consensus that can be drawn from these studies is that while GSH possesses the 
ability to augment endothelial-mediated vasomotion, the effects appear to be limited to individuals 
with existing vasomotor dysfunction. The lack of effect of GSH at improving vasomotor functioning in 
isolated vascular ring preparations has similarly been observed in animal studies (5, 92).  
 Unlike the human studies, a unique dilatory effect of GSH itself has been observed in animal 
preparations. In humans, a large majority of GSH is found bound to proteins within blood such as 
haemoglobin (99). Thus when GSH is administered in vivo, GSH is likely broken down to individual 
components (ie cysteinyl-glycine see above) for uptake and GSH synthesis (4, 76). Conversely, the GSH 
reduction and breakdown is less likely to occur in a bicarbonate buffer which does not contain 
proteins (161). Akpaffiong and Taylor observed that GSH could dose-dependently dilate isolated aortic 
segments (5). In the isolated perfused heart, Cheung and Schulz (1996) demonstrated that GSH 
induced dilation required NO, sGC and free radicals (33). The requirement of free radicals warrants 
further investigation in light of the finding that GSH only augmented vasomotor function in the 
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presence of pre-existing vasomotor dysfunction. This is the focus of Chapter 3, which examines the 
mechanisms whereby acute GSH administration alters endothelial mediated vasomotor function. 
 
1.3.4 Acute oxidation/depletion of GSH and vasomotor functioning 
Given the complex nature and different pathways discussed in the following sections, Figure 
1.4 and Figure 1.5 provide schematic overviews of several of the pathways already discussed. They 
illustrate the effects of the different pharmacological agents related to GSH concentration (Figure 1.4) 






Figure 1.4. Influence of different thiol-altering pharmacological agents 
Different pharmacological agents influence different components of glutathione availability. EA, 
ethacrynic acid forms a conjugate with GSH resulting in a loss of GSH content. BSO, L-buthionine-S,R-
sulfoximine inhibits GSH synthesis through irreversible inhibition of glutathione cysteine synthetase. 
BCNU, 3-Bis(2-chloroethyl)-1-nitrosourea inhibits glutathione reductase, CDNB, 1-chloro-2, 4-
dinitrobenzene is an inhibitor of thioredoxin. Diamide is a thiol oxidizing agent. Note both TRx, 
thioredoxin and GRx, glutaredoxin are involved in the dethiolation of proteins, which helps maintain 






Figure 1.5. Interaction between GSH and vasomotor function 
The following figure is a composite of several different pathways leading to vasodilation. The primary 
role of endothelial-derived NO, is to activate sGC (soluble guanylate cyclise) which in turn increases 
sarcoplasmic reticulum Ca2+ uptake. NO can be inactivated by O2∙- thereby generating peroxynitrite 
(ONOO-). ONOO- can react with GSH to from nitrosoglutathione which itself has several roles. GSNO 
can act as stored NO which may also be released by BK. GSNO possess the ability to activate sGC as 
well as open K+ channels on both the endothelium and vascular smooth muscle to induce 
hyperpolarization. GSNO is also involved in the thiolation of SERCA by acting as a reactive 
intermediate. Additionally the antioxidant effects of GSH are shown with the exception of the direct 





1.3.4.1 Thiols and eNOS activity 
Several studies examining isolated endothelial cells have suggested that NO production may 
be impaired through depletion of intracellular thiols (72, 87, 132). More recently, it was determined 
that a portion of the reduced NO production may be mediated by a reduction in eNOS co-factors, and 
in particular NADPH (87) and tetrahydrobiopterin (164). This suggests that changes in overall thiol 
levels may result in an impaired redox state of the cell leading to the oxidation/reduction of eNOS 
cofactors. Interestingly, the phosphorylation of eNOS through a shear dependent mechanism required 
GR, as treatment with BCNU inhibited the phosphorylation of both Akt and eNOS (184). Using siRNA 
for glutaredoxin, it was speculated that glutathione reductase maintains Akt in a reduced state 
enabling the phosphorylation and activation (184). Taken together both the activity of eNOS and the 
availability of cofactors appear to be closely related to thiol status. 
Nitrosothiols (RNSO) can modify a wide array (>100) of different proteins at their cysteine 
residues yielding altered function (159). Erwin and colleagues demonstrated that in response to the 
endothelial agonist VEGF, there was a rapid de-nitrosylation and an increase in phosphorylation of 
eNOS (56). Several different sites of nitrosylation of eNOS have been identified both in humans (175) 
and animals (57). However, the nitrosylation of eNOS only at Cys101 appears to regulate eNOS activity. 
It was subsequently identified that de-nitrosylation at this site was important for eNOS trafficking to 
the caveolae and subsequent increased NO production (57).  
 These studies highlight that NO production may not necessarily be dependent on the level of 
intracellular thiols but rather that eNOS activation through agonist or shear requires the appropriate 
redox environment. The removal of a thiol group from a thiolated protein (RSSG) or the removal of a 
nitroso group from RSNO may be dependent on the activity of a family of enzymes including 
thioredoxin, glutaredoxin and other reducing enzymes (38, 65, 116, 189). It may be postulated that 
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the appropriate reducing cofactors for these reducing enzymes including GSH and GSSG and NADP+ 
and NADPH may influence the overall activity and redox balance (21, 86, 86, 150). 
In light of these findings, it is not surprising that endothelial-mediated dilation has been 
shown to be reduced in the presence of both BCNU and diamide (2). It was suggest that the impaired 
dilation was a result of an overall depletion of intracellular GSH, as replenishment of intracellular GSH 
with a GSH ester partially restored the endothelial-mediated dilation. It is also possible that in the 
presence of these reducing agents the activation of eNOS would be blunted, thus explaining the 
impaired dilation. An additional mechanism which may be attenuated in the presence of altered GSH 
content is altered Ca2+ uptake into the sarcoplasmic reticulum of the vascular smooth. A portion of 
NO-mediated dilation involves the nitrosylation and subsequent glutathiolation of the 
sarco(endo)plasmic reticulum Ca2+-ATPase leading to enhanced Ca2+ uptake into the sarcoplasmic 
reticulum (3). Therefore, acutely depleting GSH may result in impaired dilation as a result of impaired 
Ca2+ uptake. In conditions of prolonged oxidative stress, the thiolation site on SERCA can undergo 
irreversible modification resulting in the thiol site being oxidized to either sulfinic (R-SO2H) or sulfonic 
(R-SO3H) acids which impair its overall function (36, 38). There is very limited data on how acute 
changes in intracellular thiols affect endothelium-intact vascular preparations. It is important to 
understand how acute changes in thiols influence endothelium-dependent dilation as thiols represent 
not only an important antioxidant within the vascular wall, but also clearly play in role in the activation 
of eNOS and the availability of eNOS cofactors. It is therefore paramount to determine the influence 
of acute alterations in GSH content on intact vasomotor function in order to understand and identify 
how early changes in thiols, such that could be caused by oxidative stress, may impair vasomotor 





1.3.4.2 Interaction between intracellular thiol status and coronary vascular tone and the response to 
hypoxia 
Despite the impairment in endothelium-dependent dilation seen in the presence of thiol 
oxidation, acute thiol oxidation induces dilation of isolated coronary arteries. In denuded coronary 
arteries diamide was shown to dose-dependently, dilate precontracted arteries (88). In this 
preparation, the addition BCNU to inhibit GR, significantly augmented the dilation to diamide. This 
dilation was shown to be independent of the activation of K+ channels, sGC and oxygen derived 
radicals. It appeared to involved the closure of L-type Ca2+ channels thereby reducing Ca2+ entry into 
the vascular smooth muscle and inhibiting contraction (88). Similarly, inhibition of the pentose 
phosphate pathway (PPP), which is responsible for regenerating NADPH from NADP+, closely coupled 
to the reduction of GSSG to GSH has been shown to induce vascular smooth muscle relaxation. In the 
absence of the PPP, Gupte and colleagues demonstrated that the increase in NADP+ and subsequent 
reduced GSH:GSSG ratio resulted in a reduction in tone of endothelium removed coronary arteries 
(79). Similar to the previous finding using diamide, the dilation was partially mediated by an inhibition 
of L-type Ca2+ channels. However, unlike generalized oxidation-mediated relaxation (diamide), the 
inhibition of PPP also resulted in opening of K+ channels and inhibition of sarco(endo)plasmic 
reticulum Ca2+ release (79). More recently, hypoxic coronary artery dilation was shown to be related 
to reduced NADPH:NADP ratio which is closely coupled to the GSH:GSSG, such that the oxidation 
promoted coronary vasodilation (80). Interestingly, in the presence of a general thiol reductant, the 
dilation to: diamide (88), PPP inhibition (79) and hypoxia (80) were all attenuated, suggesting that 
thiol oxidation leads to dilation in endothelium-removed coronary artery preparations. Thiol-mediated 
relaxation in endothelium removed coronary arteries appears to be controlled by increases in 
NADP:NADPH and GSSG:GSH through the opening of K+ channels and the inhibition of Ca2+ entry into 
the vascular smooth muscle (190). These results suggest that in the absence of the modulatory effects 
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of the endothelium, overall thiol oxidation promotes a relaxed state of vasomotor tone in the 
coronary circulation.  
1.3.4.3 Stored NO 
The idea of RSNO as NO stores has gathered interest, as several studies demonstrated that the 
addition of NO scavengers to preparations containing NOS inhibitors, further reduced agonist-
mediated dilation, suggesting that NO may be released from a separate site other than eNOS (32, 40, 
70). Similarly, light-induced NO release is thought to be a result of the decomposition of nitrosothiols 
into NO and free thiol group (7, 8, 15, 120, 121). The ability of RSNO to induce relaxation appears 
complex and involves several different putative mechanisms including activation of endothelial K+ 
channels resulting in hyperpolarization of the vascular smooth muscle and stimulation of sGC (15). The 
origin and storage location of the NO stores has been shown to be localized to both the endothelium 
and vascular smooth muscle and does not necessarily require eNOS-derived NO to generate RSNO (7).  
Stored NO has been shown to mediate systemic decreases in mean arterial pressure. Davisson 
and colleagues demonstrated that in-vivo administration of ACh could repeatedly and consistently 
reduce mean arterial pressure (MAP); however, following the administration of LNAME, with each 
successive dose of ACh there was a progressive decline in the ability of ACh to lower MAP (41). Similar 
results were seen in the mesenteric vascular bed (41). These studies suggest that the reduction in 
blood pressure or mesenteric vascular resistance following NOS inhibition could be a result of release 
of NO from RSNO that are be progressively depleted in the presence of LNAME. In isolated porcine 
coronary arteries, repetitive BK curves did not alter maximal dilation of the arteries under control 
conditions; however, in the presence of LNAME, the BK dose-response curve was reduced and shifted 
~10 fold to the right (40). Taken together these results suggest that repeated exposure to agonists can 
cause a reversible depletion of NO stores which may contribute to blunted dilation following repeated 
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agonist exposure. A similar response is observed in photorelaxation, a condition completely 
dependent on the replenishment of NO stores and independent of endothelial stimulation (15). 
In the isolated perfused heart, BK mediated dilation was nearly abolished following prolonged 
incubation with LNAME; however, following a co-infusion of LNAME with BK, limiting only the de novo 
NO production, a similar dilatory response was seen compared to when BK was administered alone 
(39). It was concluded that BK mediated dilation occurred through NO and this NO was in part derived 
from preformed pools, as chronic but not acute eNOS inhibition resulted in a loss of vasodilation (39). 
Similarly, Batenburg and co-workers (2004) demonstrated that, p-hyroxymercurobenzoic acid, a thiol 
depleting agent, caused a significant reduction in BK-induced dilation which was not significantly 
further reduced with the addition of LNAME suggesting that depletion of GSH and therefore RSNO 
impaired dilation to BK (14). Interestingly, when the ability of nitrosothiols to be regenerated was 
inhibited with the thiol alkylating agent ethacrynic acid (EA), BK-induced dilation was not affected (14). 
This suggests that thiol depletion, and not replenishment, reduced BK mediated dilation in isolated 
coronary segments. In the absence of RSNO, NO release from preformed pools is abolished, yet when 
GSH is alkylated, NO can still induce relaxation. This may reflect the ability of BK to both activate eNOS 
and to release RSNO (15). That is why it is possible that at least part of the dilation mediated by NO is 
a result of stored NO, possibly GSNO releasing NO, which activates sGC as demonstrated in isolated rat 
hearts and purified NOS (119). Taken together these data suggest that in the isolated perfused heart, 
there appears to be a component of RSNO mobilization following BK stimulation, whereas the 
importance of RSNO in isolated vessels appears to be minimal depending on the mechanism of 
depletion. This suggests that the mobilization and activation of RSNO may be more important as 





1.4 The utility of the Langendorff heart in assessing coronary vasomotor function 
The primary outcome of the current work is coronary vascular resistance and endothelium-
dependent dilation. In order to assess these variables in the presence of altered GSH levels the 
Langendorff heart preparation was used. The utility of this section is to provide a detailed description 
of the experimental methodology, procedure as well as a rationale for experimental protocols. 
The isolated perfused heart system is based on the pioneering work of Oscar Langendorff circa 
1895 (50, 156, 166). Its basic design has the heart being cannulated through the ascending aorta. Thus 
the heart is being perfused in a retrograde fashion, which closes the aortic valves and allows the 
perfusate to flow through the coronary ostea and hence through the coronary vascular network which 
is returned to the right atria from the coronary sinus and inevitably ejected from the heart (156). 
Similar to in vivo, during systole the intramural pressure is greater than the perfusion pressure; and 
there is minimal to no coronary flow (50). There are two different methods to provide flow to the 
isolated heart: the constant pressure system, and the constant flow system (50, 156). In the constant 
flow system, flow is delivered by a peristaltic pump, thus flow is adjusted and manipulated by the 
experimenter. Conversely in the constant pressure system, the height of the reservoir above the heart 
determines the perfusion pressure. Regardless of the methodology chosen, coronary vascular 
resistance can be described based on Ohm’s law. The outflow pressure is essentially 0 mmHg 
(atmospheric pressure) therefore, in either the constant pressure or constant flow coronary vascular 
resistance (CVR) can be expressed as:  
CVR = Pinflow – Poutflow ÷ flow 
Given that the outflow pressure is essentially null, the inflow pressure, the perfusion pressure 
(PP) represents the total coronary vascular pressure. Poiseuille’s equation which describes the 
relationship between resistance, and the radius of tube and viscosity of the fluid states: 
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Resistance =  
                  
         
 
or 
Resistance  1/radius4 
This simplification of Poiseuille’s equation can be used in the Langendorff preparation as the length of 
the tube does not change (the perfusion tubing or the coronary vascular tree), nor does the viscosity 
of the perfusion solution. Therefore, changes in resistance of the system must reflect composite 
changes in vascular diameter (50, 52). 
The constant flow is ideal for the study of vasoactive substances (50) and is reported to be 
more reproducible (166) and easier to use (50). The downside of this method is that coronary 
autoregulation cannot adjust flow to allow for changes in heart rate or contractility, which could lead 
to relative ischemia as coronary flow cannot be increased to account for increases in O2 demand (156, 
166). Both the constant pressure and constant flow preparations are currently utilized in the study of 
coronary artery vasomotion. A recent report using both techniques shows that similar experimental 
outcomes are seen regardless of whether constant flow or constant pressure is used (167). Given the 
primary outcome measure was vasomotor function, it was decided that a constant flow Langendorff 
would be most appropriate. Therefore, changes in vascular tone (CVR) would be result in increases or 
decreases in PP, as flow would be held constant. In order to assign flow rate and avoid ischemia, flow 
rate was assigned to mimic the in vivo flow rate by assigning the flow rate based on the estimated 
heart weight derived from body weight (45, 50). This can be done as there is a close relationship 
between heart weight and coronary flow (50). This equation yields flow rates of ~7 ml/min/g heart 
weight, which is higher than the typical in vivo flows of 2-3 ml/min/g heart weight (156, 166). 
However, the oxygen carrying capacity of Kreb’s Henseleit solution is less than blood, therefore, the 
higher flow rates are used in this preparation to avoid ischemia and ensure adequate O2 delivery (156, 
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166). In the absence of a ventricular balloon total cardiac work is zero. However, in the presence of 
the left ventricular balloon the heart is performing isovolumetric work (52). Therefore, in order to 
meet the demands of the a heart performing isovolumetric work, the flow rate is set slightly higher 
than in vivo to overcome the reduced O2 carrying capacity and meet the metabolic demands of the 
perfused heart performing isovolumetric work which is less than the normal myocardial demands in 
vivo (52). The efficacy of this experimental choice is highlighted by the relative stability of this 
preparation over several hours and the ability of Langendorff hearts to increase contractility in 
response to increases in PP or in response to inotropic agents (52, 156, 166).  
The constant flow rate allows for an easier delivery of any vasoactive agents. In a constant 
pressure system, when a dilatory agent is delivered there is an increase in coronary flow. Therefore, in 
order to appropriately deliver the subsequent concentration changes in drug infusion rate or 
concentration have to be adjusted accordingly. The use of a constant flow system allows for a 
constant rate of drug infusion meaning that each stock concentration can be delivered at the same 
rate allowing the transit time from the infusion adaptor to the coronary vasculature to remain 
constant. 
 The advantage of using the Langendorff apparatus to study vasomotor functioning is 
highlighted by the previous discussion describing the complex nature and regulation of coronary blood 
flow across different microvascular networks within the coronary circulation. Thus, unlike isolated 
perfused vascular rings or isolated vascular segments mounted in a myography unit, the Langendorff 
technique allows the global assessment of vascular function not limited to a single segment of the 
vascular tree. Therefore, if there are compensatory pathways activated during disease states they will 
be captured using the Langendorff. For example, it has been reported that spontaneously 
hypertensive rats have preserved coronary artery dilatory function when assessed using the 
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Langendorff (96, 97), whereas studies of isolated coronary artery segments often report coronary 
artery endothelial dysfunction (137, 182). 
 The constant flow Langendorff utilizes a perfusion reservoir and aerator, hydrostatic pump, 
compliance chamber, cannula and heart chamber. Flow from the reservoir is delivered via the pump 
to the compliance chamber through water-jacketed tubing. The compliance chamber is used to ensure 
a laminar flow in the absence of air bubbles (Figure 1.6). The perfusate, a Krebs Henseleit solution, is 
gassed with 95%O2:5%CO2, delivered through water-jacketed tubing designed to maintain a 
temperature of ~37oC for delivery to the heart. Perfusion pressure is monitored using a pressure 
transducer, while an ultrasonic flow probe measures total flow. Both of these measures are done 
proximal to the aortic cannula thus representing total coronary perfusion pressure and flow. 
Using the Langendorff apparatus, it is possible to measure cardiac hemodynamics; however, 
this requires the use of a left ventricular pressure balloon as the perfusate is not delivered into the left 
ventricle; therefore, the heart is not doing any external work (50, 52). The pressure balloon must be 
small enough to fit into the left ventricle but big enough to allow for expansion within the ventricle. 
Once inserted into the left ventricle the balloon needs to be filled to yield a diastolic pressure of 
between 5-10 mmHg to mimic end diastolic pressure (50, 156). The pressure balloon and transducer 
can be used to generate several indices of cardiac function including left ventricular developed 









Figure 1.6. Constant flow Langendorff heart apparatus 
All glass wear and tubing were water-jacketed by ~37oC water. Aerated Kreb’s Henseleit buffer is 
pumped from the reservoir (A.) by pump (B.) to the bubble trap (C.) which ensures laminar flow is 
delivered to the heart. Flow rate is measured by an ultrasonic paratubular flow meter (D.) While a 
fluid filled pressured transducer continuously monitors perfusion pressure (E.). Similarly a left 
ventricular pressure balloon and associated pressure transducer (F.) generates left ventricular 
pressure tracing. Vasoactive agents are delivered into the system by a syringe pump (not shown) 
through an in-line infusion adapter (G.). Also omitted for clarity is the heart chamber a water jacketed 




In the experiments outlined within the current document, all hearts were allowed to develop 
spontaneous vascular tone and heart rate. Therefore, all hemodynamic variables represent the natural 
intrinsic characteristics of the hearts. Hearts which failed to achieve sufficient tone to allow for 
appropriate dilatory responses to endothelium-independent dilators were always excluded from the 
analyses. All hearts were allowed to equilibrate for at least 30 minutes at the in vivo flow. In most 
instances, this was sufficient to see a stabilization of the perfusion pressure and cardiac 
hemodynamics. If the PP was not stable following 30 minutes, additional time was given to allow for a 
stable PP. This ensured that dilatory responses were assessed from a stable tone to eliminate the 
confounding effects of potential increases in PP that could occur at the lower concentrations of the 
dilatory curves if the PP was not stable. 
 Once a stabilized perfusion pressure was achieved a dose-response curve to endothelial-
dependent or independent agonists was generated (Figure 1.7). This involved the infusion of the 
dilatory agent through an infusion adapter located just proximal to the aortic cannula. The infusion 
rate was 1% of the total coronary flow as this infusion rate was without effect on total coronary flow. 
Following the final concentration of endothelial agonist, hearts were dilated with an endothelial 
independent agonist which was used as a reference point of maximal dilation.  
 Therefore, the Langendorff apparatus provides the ability to assess both vasomotor function 
and cardiac hemodynamics. In this regard compared to other techniques examining vascular function 
in which a single vascular segment is used, the vasomotor responses observed using the Langendorff 
provide a global assessment of the coronary vascular bed. Therefore, changes that occur in response 
to treatment or pharmacological agents are observed across the entire organ and do not reflect 






Figure 1.7. Sample tracing 
This tracing was derived from a control rat in the middle of a bradykinin dose-response curve. Each 
channel is labelled for clarity. The left side of the tracing is a condensed view showing the infusion of 
bradykinin (dashed vertical lines). The right hand side is a continuation of the tracing demonstrating 






1.5 Summary and Purpose 
1.5.1 Global thesis purpose 
The outline of the above literatures illustrates that within the vasculature, the control of GSH 
represents an important antioxidant and signalling molecule. As demonstrated, changes in GSH are 
associated with altered contractile state and impaired endothelium mediated dilation. Additionally 
changes in GSH and its associated enzymes were shown to impair NO production. Given the dominant 
role that NO plays in the endothelium-dependent control, interactions between GSH and NO warrant 
further investigation within the coronary circulation. The advantage of using the Langendorff to 
examine vascular function allows for a systemic evaluation of the coronary vascular bed. This is 
important as this vascular bed has several different mechanisms of control on baseline vascular tone 
and vasomotor function. Despite advances in the understanding of the interactions between thiols 
and nitric oxide, few studies have examined the role of altering thiol levels as a tool to understand 
how these specific changes influence endothelial derived vasomotor function. 
Currently much of the information that has been generated regarding both acute and chronic 
thiol manipulations has typically focused on conduit vascular function (as is the case for chronic thiol 
manipulations), endothelium-removed coronary segments, or isolated cellular preparations  (as is the 
case for acute thiol oxidation/depletion). Furthermore few studies have examined the interactions of 
acute thiol modulations on vasomotor functioning specifically examining if GSH is merely acting as an 
antioxidant to improve vasomotor functioning. The global purpose of this thesis is to examine and 
characterize the effects of thiol manipulations on the coronary vascular network. The goal is to 
characterize both the basal coronary vascular resistance and endothelium-mediated vasomotor 
responses with a primary focus on nitric oxide. The results of the current experiments will provide 
novel insight into how changes in thiols influence vasomotor functioning. By examining these changes 
in the isolated perfused heart, the entire vascular bed can be examined thus allowing for a more 
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systemic approach. This will provide further insight from studies utilizing isolated vascular rings or 
cellular preparations and will build on previous work from both human and animal studies regarding 
the complex relationship between thiols vascular function. 
 
The global purpose of this thesis is to examine how changes in GSH influence coronary 
vascular resistance and coronary artery endothelium-dependent dilation. In order to address these 
complex relationships the following purposes and hypotheses were addressed. 
 
 
1.5.2 Chronic thiol depletion results in an age-dependent increased reliance on nitric oxide in 
determining coronary vascular resistance and endothelium-dependent dilation in the isolated perfused 
heart (Chapter 2). 
Purpose:  To examine and characterize the effects of 10 days of thiol depletion on coronary vascular 
resistance in adult and older Sprague-Dawely rats. 
Hypotheses: 
i. Older rats will have an increase in basal coronary vascular resistance (CVR) compared 
to adult rats. 
ii. Treatment with BSO will result in an increased CVR that will be further augmented 
with age. 
iii. NOS inhibition will cause a increase in CVR in all groups which will be most 
pronounced in the adult and older controls, as the thiol depleted animals will have a 




Purpose: To examine the effects of aging and 10 days of thiol depletion on endothelial mediated 
vasomotor function. 
Hypothesis: 
i. Both aging and thiol depletion will result in impaired endothelium-dependent 
vasodilation.  
ii. NOS inhibition (LNAME) will blunt the vasodilation primarily in the control groups as 
BSO will increase ROS production limiting NO bioavailability.  
 
1.5.3 Glutathione enhances endothelium-mediated coronary vascular dilation in a reactive oxygen 
species-dependent manner and independent of effects on NO production and soluble guanylate 
cyclase. (Chapter 3) 
Purpose: To examine the direct dilatory effects of GSH in isolated perfused rat hearts 
Hypotheses: 
i. GSH will dose-dependently induce vasodilation in the isolated perfused rat heart. 
 
Purpose: To examine the effects of GSH infusion on bradykinin-mediated dilation in the isolated 
perfused rat heart in the absence of differences in baseline CVR.  
Hypotheses: 
i. GSH will augment the dilatory response to bradykinin, this response will be driven 
primarily through increased NO bioavailability. 
ii. In the presence of NOS inhibition or sGC inhibition, no beneficial effect of GSH will be 
observed. 
iii. TEMPOL will not further augment the vasodilatory response seen in the presence of 
GSH as both are antioxidants. 
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Purpose: To determine if the effects of GSH infusion enhances NO utilization by examining sodium 
nitroprusside-mediated vasodilation in the isolated perfused rat heart. 
Hypothesis: 
i. Sodium nitroprusside-mediated vasodilation will not be altered by GSH infusion. 
 
1.5.4 Effect of thiol modulation on coronary vascular resistance and endothelium-dependent dilation in 
the isolated perfused heart (Chapter 4).  
 
Purpose: To examine the influence of different thiol depleting agents on coronary vascular resistance. 
Hypothesis: 
i. Glutathione reductase inhibition (BCNU) and general thiol oxidation (Diamide) will 
result in a decrease in CVR.  
ii. Thiol conjugation and thioredoxin inhibition will result in an increase in coronary 
vascular resistance as a result of impaired NO bioavailability. 
 
Purpose: To examine the relationship between GSH:GSSG ratio and baseline CVR, minimal CVR, and 
change in CVR. 
Hypothesis:  
i. A reduction in the GSH:GSSG ratio will result in an increased minimal CVR. 
ii. There will not be a relationship between GSH:GSSG and either baseline or total 
dilatory capacity as the baseline CVR will be reduced in some instances of thiol 
depletion but not others (see above). 
 





i. Treatment with all thiol oxidizing agents will impair endothelium-dependent dilation. 
ii. Given the hypothesized impairment in developing tone (see above), it is hypothesized 
that a portion of the impaired dilatory ability will be related to a reduced dilatory 
capacity. 
Purpose: To examine if the impairment in vasodilation is a result of altered smooth muscle sensitivity 
to nitric oxide: 
Hypothesis: 






Chronic thiol depletion results in an age-dependent increased reliance on nitric 
oxide in determining coronary vascular resistance and endothelium-
dependent dilation in the isolated perfused heart. 
 
2.1 Authorship 
 This study was part of a larger study that involving several different experiments examining 
aging and thiol depletion. Given the contributions of Steven G. Denniss to study design, and animal 
care and treatment I would like to acknowledge his contributions. Steven G. Denniss will appear as a 
co-author on this manuscript. 
2.2 Synopsis 
Previous reports have documented that both thiol depletion and aging are independently 
associated with increased production of reactive oxygen species (ROS) and vasomotor dysfunction. 
The purpose of the current experiment was to examine the effects that thiol depletion and aging have 
on coronary vascular resistance (CVR) and endothelium-dependent dilation in the intact coronary 
vascular bed. Adult male Sprague-Dawley rats (33 weeks) or older rats (65 weeks) were randomized to 
receive 10 days of L-Buthionine-(S,R)-Sulphoximine (BSO). Hearts were isolated and perfused using the 
Langendorff technique. Endothelium-dependent dilation was assessed via administration of 
bradykinin (BK) in the presence or absence of LNAME. BSO treatment, but not aging, resulted in a 
reduction in glutathione content of the left ventricle, and was associated with an increased production 
of ROS. Aging resulted in reductions in baseline CVR and in maximal-endothelium dependent dilation, 
but no effect of BSO treatment on these parameters was observed. Intriguingly, LNAME resulted in a 
greater increase in CVR and a greater blunting of endothelium-dependent dilation in the adult BSO 
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animals compared to all other groups. BSO treatment resulted in an age-dependent increase in eNOS 
protein content in the adult BSO group. Compared to controls, BSO-treated animals were less 
responsive to exogenous H2O2 administration with respect to reduction in CVR, an effect that may be 
explained by a BSO-dependent increase in catalase expression. The results of the current study 




Glutathione (GSH, reduced glutathione) is an intracellular antioxidant (155) important in 
maintaining vascular health (65, 146, 160). Changes in glutathione metabolism and reduction in tissue 
glutathione content have been shown to occur in humans with cardiovascular disease (28, 101, 133, 
134, 152), and to be associated with coronary artery endothelium-dependent dysfunction (134).   
Cellular glutathione deficiency can be experimentally induced in animals by administration of 
L-Buthionine-(S,R)-Sulphoximine (BSO); a selective inhibitor of the -glutamylcysteine synthetase (122, 
123). Several investigations have demonstrated that chronic inhibition of GSH synthesis with BSO 
induces oxidative stress (13, 19, 63, 67, 68, 107, 181, 196). In vivo studies suggest that the vascular 
function of BSO-treated rats is impaired as demonstrated by a blunted reduction in mean arterial 
pressure to acetylcholine (107) and enhanced elevation in blood pressure in response to 
phenylephrine (68). While in-vitro studies using isolated conduit arteries demonstrate only modest 
effects of BSO-mediated GSH depletion on endothelium-dependent dilation in response to ACh (13, 
63). This suggests that the larger effects observed in vivo, in intact vascular beds may be mostly 
dependent on the BSO-effects on the control of tissue vascular resistance, although this has not been 
specifically investigated.  
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Endothelial GSH and GSSG content have been reported to be lower in older compared to 
young animals (157), and it is plausible that alterations in GSH may be a contributing factor to the 
reduced endothelium-mediated vasomotor responses that accompany aging. Age-associated 
endothelial dysfunction has been reported in a variety of vascular beds under basal conditions, and in 
response to stimulation of the endothelium (6, 22, 29, 37, 95, 118, 131, 142, 157, 165, 179). Age-
associated reductions in NO bioavailability contribute to this functional effect, and likely include a 
ROS-dependent component, as vascular wall ROS content is increased in aging (22, 37, 43, 81, 95, 130, 
135, 142, 143, 165, 179). There is, however, limited data concerning the impact of manipulations of 
GSH on vascular function with age. 
Although it is evident that both thiol depletion and aging are associated with increased ROS 
production, there is a lack of data regarding the effects of thiol depletion on the coronary circulation, 
as most isolated tissue studies have strictly examined individual conduit arteries. The purpose of the 
current study is to examine the effects of thiol depletion and aging on coronary vascular resistance 
and endothelium-dependent control of vascular function in the isolated perfused rat heart. The 
advantage of this model in this experimental context is that it allows the assessment of vascular 
function across the entire coronary vascular bed, and is thus not limited to the responses of a single 
segment of the vasculature. It is hypothesized that older animals, and thiol depleted animals, will both 
demonstrate an elevation in baseline coronary vascular resistance and impairment of vasomotor 
function, associated with increased levels of reactive oxygen species and impairment of NO 
bioavailability. It is further hypothesized that BSO-induced GSH depletion will exacerbate age-related 
impairment of vascular function.
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2.4 Materials and Methods 
2.4.1 Animals 
A total of 50 adult (mean age 33 weeks) and 41 older animals (mean age 65 weeks) Sprague-
Dawley rats were used in this study. All animals were obtained from a breeding colony at the 
University of Waterloo. Animals from both age categories were randomized to receive either L-
Buthionine-(S-R)-sulphoximine (BSO; 30 mmol/L in tap water) or vehicle (tap water) ad libitum for 10 
days. The dose, duration and method of delivery were based on a previous report from our laboratory 
(63). Animals were weighed prior to randomization, and individually-housed for the duration of 
treatment in order to monitor food and fluid consumption. Animals were kept on a reverse 12:12 
light:dark cycle, and provided free access to food. Following the 10 day treatment, animals were 
weighed and sacrificed, and tissues were harvested as described below. All procedures were approved 
by the University of Waterloo Animal Care Committee. 
 
2.4.2 Langendorff Heart 
Animals were anaesthetized (60 mg/kg pentobarbital sodium; I.P.) and hearts were removed 
and prepared for a constant flow Langendorff protocol. Briefly, after removal the heart was immersed 
immediately in 4oC Krebs Henseleit (KH) buffer (composition in mmol/L NaCl 118, KCl 4.7, MgSO4·7H2O 
1.2, NaHCO3 24, KH2PO4 1.1, Glucose 10 and CaCl2·2H2O 1.25) to reduce myocardial contractility, 
oxygen consumption and ischemic injury (166). Hearts were then transferred to the aortic cannula 
which was dripping gassed (95%O2-5%CO2) 37
oC KH, cleaned of adherent tissue, and prepared for the 
insertion of a left ventricular pressure balloon.  
A constant flow protocol was utilized as this is most suitable for the study of the effects of 
vasoactive agents (50, 166). The constant flow rate was assigned to mimic in-vivo coronary flow using 
the following equation: Flow = 7.43 × ((body weight×0.0027+0.6)0.56) (45, 50). The pre-treatment body 
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weight was used in this calculation to avoid complications associated with BSO-induced changes in 
body weight. The flow probe and associated transducer (2PXL and TS410, Transonic Systems, Ithaca 
NY) and pressure transducer (MLT844, AD Instruments, Boulder Co) were positioned proximal to the 
aortic cannula for the measurement of total coronary flow and coronary perfusion pressure. A 
pressure balloon was inserted through the left atria, positioned in the left ventricle and adjusted to a 
diastolic pressure of 5 – 10 mmHg. Heart rate, left ventricular developed pressure (LVDP, left 
ventricular systolic pressure – left ventricular diastolic pressure), and ±dP/dt were derived from the 
left ventricular pressure tracing. The balloon was connected to a pressure transducer (MLT844, AD 
Instruments, Boulder Co). All data were collected using a Powerlab data acquisition board (4/sp, AD 
Instruments, Boulder Co) and stored digitally using Chart for Windows (5.5.1, AD Instruments, Boulder 
Co) for off-line analysis. 
 
2.4.3 Assessment of endothelium dependent dilation 
Hearts were allowed to stabilize for 30 minutes with or without the non-specific nitric oxide 
synthase inhibitor L-ωNitro-L-arginine (LNAME, 0.1 mmol/L) to allow for the development of 
spontaneous coronary vascular tone and heart rate. Hearts that failed to establish a stable 
spontaneous tone to allow for dilation to SNP or adenosine were excluded from the study. A total of 9 
hearts were excluded from the analysis (2 adult control, 1 adult BSO, 3 older control, 3 older BSO). 
Once the perfusion pressure stabilized, baseline hemodynamics were assessed by taking the average 
over 1 minute. 
Following the baseline measurements, a dose-response curve to bradykinin (BK, 10-11 – 10-6 M) 
was generated. For each concentration a total volume of 250 µl was infused at a rate of 1% of the 
coronary flow using a syringe pump (Cole Parmer 74900, Montreal PQ). Following the final 
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concentration of BK, the vasculature was maximally dilated by sodium nitroprusside (SNP 10-5 M) in 
order to obtain the minimal CVR value.  
 
2.4.4 Assessment of hemodynamics and endothelium-dependent dilation at an elevated flow 
Baseline tone was re-established by washout of SNP. The flow rate was then raised to yield a 
standard perfusion pressure of 75mmHg (High Flow). This perfusion pressure was chosen as it 
represents a physiologically relevant perfusion pressure and has been employed by previous studies 
assessing vasomotor function in isolated perfused rat hearts (50, 126). New baseline measurements 
were obtained (as above) and the BK dose-response curve was repeated at this elevated perfusion 
pressure (High Flow) condition. LNAME alone results in an elevated perfusion pressure in the constant 
flow preparation as a result of the decrease in NO production. If we were to match the flow rate to 
achieve 75 mmHg in the presence of LNAME the flow would have been significantly lower and hearts 
would have become ischemic. Therefore, we duplicated the flow rate that resulted in 75mmHg in the 
corresponding no drug condition for each group (adult or older CON and BSO) in the experiments 
conducted in the presence of LNAME (High Flow LNAME). This was done to ensure that group 
differences in flow rates remained consistent in the presence of LNAME despite differences that may 
exist in perfusion pressure as a result of NOS inhibition. Therefore changes in CVR associated with 
LNAME would be a result of changes in perfusion pressure not changes in flow. 
2.4.5 Does an acute oxidative challenge reveal impaired function in BSO-treated animals? 
 Given the accumulating evidence that H2O2 is a vasodilatory agent in this vascular bed (54, 149), 
and a recent report suggesting that BSO-treatment can enhance H2O2-mediated endothelium-
dependent vasodilatory responses (90), in a subset of hearts from the adult groups, responses to H2O2 
were assessed to determine if there was a differential response seen in the coronary circulation of 
CON vs BSO. Hearts were prepared and stabilized as described above, and endothelium-dependent 
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dilation was assessed by infusion of bradykinin (0.1, 10, and 1000 nM), followed by a washout and 
restabilization period. Once the perfusion pressure had stabilized, H2O2 was administered (10
-5-10-3 
M). This protocol was chosen on the basis that when these H2O2 concentrations are applied 
exogenously to tissue preparations they result in intracellular concentrations 10-fold less, and produce 
a range of intracellular H2O2 concentrations that results in effects from reversible cell signalling to 
oxidative stress and possible damage (163). Following the final concentration of H2O2, hearts were 
allowed to re-equilibrate, and endothelium-dependent dilation to BK was reassessed, as was the 
response to SNP. This was done to determine if the acute H2O2 challenge protocol caused irreversible 
impairment of endothelium-dependent dilation. 
2.4.6 Measurement of left ventricular glutathione, ROS, and H2O2 
Left ventricular glutathione was assessed using sample preparation and HPLC techniques as 
previously described by our laboratory (63) according to the methods derived by Reed and colleagues 
(141).  
 ROS production was measured as previously described by our laboratory (147). Briefly, left 
ventricle was homogenized in phosphate buffered saline (PBS) and centrifuged at 1000g for 10 
minutes, and the supernatant was extracted. The homogenate was diluted further in PBS and 
incubated with 5 µM of dicholorflouricine diacetate (H2DCF-DA, Molecular Probes, Invitrogen, 
Carlsbad, CA) in the dark for 15 minutes. Fluorescence was detected every 15 minutes at 
excitation/emission wavelengths of 488/525 nm using a SPECTRAmax GEMINI-XS (Molecular Devices, 
Sunnyvale, CA). The fluorescent signal generated following 1 hour was normalized to protein content 
determined by a bicinchoninic acid (BCA) protein concentration assay.  
H2O2 content in left ventricular homogenates was assessed using an Amplex Red Hydrogen 
Peroxide kit (Molecular Probes, Invitrogen, Carlsbad, CA). Amplex Red (10-acetyl-3,7-
dihydroxyphenoxazine) reacts with H2O2 in a 1:1 stoichiometry in the presence of peroxidase to 
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produce the oxidation product resorufin that can be measured fluorescently. 50µl of diluted tissue 
homogenate was added to 50µl of Amplex Red reagent (10µM Amplex Red stock and 0.2U/ml 
horseradish peroxidase in PBS) (51) and incubated in the dark at room temperature for 30min. 
Fluorescence was detected every 15 minutes at 530/590nm excitation/emission wavelengths. H2O2 
concentrations were calculated with reference to a contemporaneous H2O2 standard curve. Tissue 
concentrations are expressed relative to µg protein. Data reported represent H2O2 concentration at 1 
hour and subsequently normalized to the adult control group. 
 
2.4.7 Immunoblotting 
Immunoblotting was preformed as previously described by our laboratory (63). A portion of 
the left ventricular wall was homogenized in 20 volumes of extraction buffer (10 mM NaH2PO4, 1% 
SDS, 6 M urea, pH 7.4). Samples were centrifuged at 4oC for 2 minutes at 8000 rcf and the 
supernatants were collected. Total protein content was determined using BCA assay. Samples were 
then diluted to 1 µg protein/µl, and a sample containing 30 µg total protein was loaded for gel 
electrophoresis. Proteins were then transferred to polyvinylidene diflouride membranes (Roche 
Diagnostics, Mannheim Germany). Immunoblotting was preformed for eNOS (1:350, BD Bioscience, 
San Jose, CA), catalase (1:2500, Millipore (Chemicon), Billerica, MA) and superoxide dismutase 1 and 2 
(SOD1 and SOD2, 1:1000, 1:5000, Stressgen/Assay Designs Ann Arbor, MI). Membranes were 
subsequently incubated using horseradish-peroxidase conjugated secondary antibodies. Signals were 
detected using enhanced chemiluminescence detecting reagents (GE Healthcare (Amersham) Little 
Chalfont, UK) and a Syngene gel detection system (Syngene, Cambridge, UK). Protein density was 





All chemicals and reagents were purchased from Sigma-Aldrich (St. Louis, MO) or Bioshop 
Canada (Burlington, ON, Canada) unless otherwise indicated. H2DCF-DA and Amplex Red kits were 
purchased from Molecular Probes (Invitrogen, Carlsbad CA). 
2.4.9 Statistics 
All data are presented as mean ± standard error. Curves were fit to obtain EC50, maximal 
response, and area under the curve (AUC) using Prism (4.03, GraphPad Software, San Diego CA). 
Differences between groups were assessed using 2 way ANOVA (treatment by age), and significant 
results were subsequently analyzed using least squares difference post hoc test. For comparisons 
made between adult CON and BSO only a 1-way ANOVA was utilized. A p value <0.05 was considered 
statistically significant. All statistics were performed using Statistica 6.0 (StatSoft Inc, Tulsa Ok). 
 
2.4 Results 
2.4.1 Animal Characteristics 
 Of the 50 adult animals used in this study, 24 were used as controls (AC), and 26 were BSO-
treated (AB). Of the 41 older animals used, 20 were used as controls (OC), and 21 were treated with 
BSO (OB). The older animals had greater body, heart, and kidney weights compared to the younger 
animals (Table 2.1). Over the 10 day study period, treatment with BSO resulted in significant body 
weight loss in both the AB and OB groups. The loss in body weight may have been in part a result of 
reduced food consumption over the course of the treatment period (Table 2.1). BSO treatment was 




Table 2.1 Animal Characteristics 
     p values 




Age (weeks) 33 ± 1 34 ± 1 65 ± 1 65 ± 1 <0.05 NS NS 
Body weight pre (g) 501.3 ± 8.9 508.1 ± 5.4 567.3 ± 11.6 600.5 ± 10.0 <0.05 <0.05 NS 
Body weight post (g) 502.7 ± 9.3 487.0 ± 4.9 555.5 ± 11.8 549.8 ± 6.7 <0.01 NS NS 
Change in BW (g) 1.5 ± 1.8 -21.1 ± 2.9 -11.9 ± 2.4 -50.7 ± 6.7 <0.01 <0.01 NS 
        
Heart weight (mg) 1923 ± 33 1974 ± 28 2166 ± 38 2211 ± 38 <0.01 NS NS 
Kidney weight (mg) 1439 ± 33 1442 ± 24 1754 ± 57 1816 ± 44 <0.01 NS NS 
        
Fluid intake (ml/day) 45.8 ± 1.8 54.9 ± 2.2 57.0 ± 1.2 48.7 ± 2.6 NS NS <0.01 
Food intake (g/day) 23.4 ± 0.6 19.9 ± 0.5 23.9 ± 0.9 17.6 ± 0.9 NS <0.01 NS 
 
Data are presented as mean ± SE. Body weight pre refers to body weight prior to the initiation of BSO 
or vehicle, body weight post refers to body weight following 10 days of BSO or vehicle. *p<0.05 vs age 
matched control (n=20-26/group). 
 
2.4.2 GSH content and ROS levels in the left ventricle 
The GSH content in the left ventricle was reduced following 10 days of BSO treatment 
(2.022±0.084 vs 0.182±0.021 nmol/mg wet weight in the AC and AB, and 1.892±0.144 vs 0.175±0.025 
nmol/mg wet weight in the OC and OB respectively,  p<0.05 for treatment). Lower values were also 
observed for GSSG and for the GSH:GSSG ratio in both the BSO treated adult and older animals vs 
respective controls (Figure 2.1). 
The DCF assay is a non-specific index of ROS production, while the Amplex Red assay more 
specifically provides an index of H2O2. Treatment with BSO resulted in an increase in both of these ROS 






Figure 2.1. Ventricular thiol concentrations 
Data are levels of reduced glutathione (A), oxidized glutathione (B) and GSH:GSSG ratio (C). Data are 



























































































Figure 2.2. Levels of reactive oxygen species in the left ventricle 
Left ventricular (A) levels of general ROS (DCF) and H2O2 production (AR). Data are presented as 
mean±SE from adult control (filled bars), older control (horizontal hatch), adult BSO (empty bars), and 










































2.4.3 Hemodynamics under in vivo flow conditions 
 The hemodynamic data were obtained following the stabilization period both in the presence 
and absence of NOS inhibition, prior to the assessment of endothelium-dependent dilation. In the 
absence of NOS inhibition, the baseline CVR was reduced in the older rats compared to the adult rats 
(main effect for age p<0.01, Table 2.2). In the older group, the reduced CVR occurred despite a higher 
flow rate, which was assigned based on body weight (averaged across treatment groups: 11.53±0.09 
vs 10.95±0.06 ml/min in older vs adult, respectively, p<0.05). No other differences were observed in 
any other hemodynamic variables in the absence of LNAME (Table 2.2). Treatment with LNAME 
resulted in a significant increase in CVR across all groups. The LNAME-induced increase in CVR in the 
AB group was significantly greater than in all other groups (Table 2.2), and the LNAME-induced 
increase in CVR seen in the AC group was significantly greater than that achieved in either OC or OB 
(p<0.05, Table 2.2).  
In the presence of LNAME, BSO treatment resulted in a significant decrease in maximal rate of 
pressure development (+dP/dt), while no age differences were apparent for this effect (Table 2.2).  No 
other significant cardiac contractility effects were noted. 
 
2.4.4 Effects of endothelial stimulation on CVR  
Bradykinin (BK) dose-dependently reduced CVR in all groups (expressed as a % of the maximal 
reduction in CVR in response to SNP; Figure 2.3, Table 2.3). We found a significant age-dependent 
reduction in minimal CVR in older vs adult animals, and this resulted in a reduction in total dilatory 
capacity (difference between baseline CVR and minimal CVR, Table 2.3). Despite this discrepancy, 
maximal BK dilation, expressed as % of TDC, was greater in hearts of the adult animals compared to 
the older animals. This was associated with a reduction in the AUC with age, while no age-dependent 
differences were observed in the sensitivity (EC50) to BK in the adult compared to older animals in the 
absence of LNAME. 
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Table 2.2. Hemodynamic variables at in vivo flow rate 
 Adult Control Adult BSO Older Control Older BSO 
 No Drug 
     
Perfusion Pressure (mmHg) 51.90 ± 2.17 56.37 ± 4.03 43.99 ± 3.64 * 42.95 ± 2.72 * 
Flow (ml/min) 10.91 ± 0.09 11.03 ± 0.11† 11.25 ± 0.13 * 11.72 ± 0.08 *,† 
CVR (mmHg/ml×min-1) 4.76 ± 0.20 5.12 ± 0.37 3.92 ± 0.34 * 3.67 ± 0.24 * 
     
Heart Rate (beats/min) 229 ± 9 238 ± 12 213 ± 15 226 ± 7 
LVDP (mmHg) 117 + 7 108 ± 6 103 ± 11 103 + 8 
+dP/dt (mmHg/sec) 3959 ± 210 3661 ± 233 3277 ± 274 3564 ± 239 
-dP/dt (mmHg/sec) - 2105 ± 119 -1950 ± 118 -1726 ± 165 -1824 ± 136 
     
 LNAME 
     
Perfusion Pressure (mmHg) 90.77 ± 7.50 § 149.39 ± 10.12 68.88 ± 8.39 § 70.01 ± 5.90 §  
Flow (ml/min) 10.86 ± 0.15 10.57 ± 0.08 11.68 ± 0.15 * 11.81 ± 0.18 * 
CVR (mmHg/ml×min-1) 8.40 ± 0.77 § 14.15 ± 0.99 ‡ 5.94 ± 0.75 ‡,§ 5.96 ± 0.51 ‡,§ 
     
Heart Rate (beats/min) 226 ± 13 241 ± 14 218 ± 10 223 ± 8 
LVDP (mmHg) 122 ± 6 105 ± 8 112 ± 8 105 ± 6 
+dP/dt (mmHg/sec) 4086 ± 259  3442 ± 83† 4046 ± 215 3657 ± 215† 
-dP/dt (mmHg/sec) -2114 ± 136 -1852 ± 87 -1982 ± 144 -1866 ± 99 
 
Hemodynamic variables in the absence and presence of NOS inhibition (LNAME). *, p<0.01 main effect 
of age, †, p<0.05 main effect of BSO treatment; ‡, p<0.05 VS Adult con; §, p<0.01 vs Adult BSO. Data 




Table 2.3 Curve characteristics from in vivo flow rate bradykinin dose-response curve 
 
 
Adult Control Adult BSO Older Control Older BSO 
 No Drug 
Max (%) 95.0 ± 1.0 98.6 ± 0.6 77.0 ± 10.3* 92.7 ± 4.5 * 
EC50 (log M) - 8.15 ± 0.04 - 8.21 ± 0.07 -8.48 ± 0.31 - 8.14 ± 0.09 
AUC 231.9 ± 9.2 249.0 ± 9.3 201.9 ± 24.5* 209.3 ± 9.9 * 
TDC 1.61 ± 0.23 2.06 ± 0.31 0.73 ± 0.27 * 0.89 ± 0.18 * 
     
 LNAME 
     
Max (%) 94.5 ± 1.3 89.7 ± 2.2 91.4 ± 2.0 89.4 ± 1.7 
EC50 (log M) - 7.75 ± 0.07 † - 7.39 ± 0.09 - 7.70 ± 0.07 † - 7.75 ± 0.09 † 
AUC 178.4 ± 8.5 † 137.2 ± 9.6 165.1 ± 11.3 † 171.8 ± 9.0 † 
TDC 5.47 ± 0.68 † 10.72 ± 0.92 ‡ 3.21 ± 0.72 †,‡ 3.10 ± 0.45 †,‡ 
 
Curve characteristics in the absence (control) and presence of NOS inhibition (LNAME). Curves were fit 
as described in the methods section. TDC, total dilatory capacity (mmHg/ml×min-1).*, p<0.05 main 




Conversely, in the presence of LNAME, there was a marked decrease in the sensitivity to BK in 
the AB, as indicated by the rightward shift in the BK curve of this group compared to all other groups 
(Table 3). The AUC for the AB group was significantly reduced compared to all other groups (Figure 
2.3, Table 2.3). These results suggest that in the AB group there is a greater relative reliance on NO to 
mediate the baseline CVR as well as endothelium-dependent responses to BK over several 
concentrations (1 nM – 0.03 µM) than the other treatment groups. Therefore within a physiologically 
relevant range of BK (98), the AB appear to be more reliant on NO than other endothelium-derived 






Figure 2.3. Bradykinin dose-response curves derived at in vivo flow rate 
Data are from adult and older control (solid square and circle), and BSO adult and older animals (open 
square and circle) in the absence (A and B) and presence of NOS inhibition (C and D). The dashed line 
represents the adult CON no drug and the dotted line represents the older CON no drug (C). The 
dashed line in represents the adult CON LNAME and the dotted line represents the older Con LNAME 
(D). Data are presented as mean ± SE (n=7-13/group). 
  








































































































































2.4.5 Hemodynamics at High Flow 
Following the curves at the in-vivo flow rate, the flow rate was increased to yield a 
standardized perfusion pressure of ~75mmHg in the no LNAME groups to determine if this would 
result in altered CVR or BK-mediated responses. After a stabilization period, hemodynamics were re-
assessed at the higher flow rate. Despite the fact that all groups had a perfusion pressure of ~75mmHg 
(p=NS, Table 2.4), the flow rate required to achieve the 75 mmHg perfusion pressure was significantly 
greater in the older animals compared to the adult (grouped by age: 18.30±1.31 vs 14.29±0.42 
ml/min, p<0.05). Therefore, there was an age-dependent reduction in baseline CVR in the older 
groups (Table 2.4). Similar to the lower flow condition in the absence of LNAME, there were no group 
differences in any of the measures of cardiac function (Table 2.4). In the presence of LNAME there was 
also a main effect of age on CVR, such that adult animals had a greater CVR than the older animals 
(Table 2.4). There was a trend for an elevated +dP/dt in the presence of LNAME control groups 
compared to the BSO groups (p=0.070, main effect for treatment) and no differences were seen in any 




Table 2.4. Hemodynamic variables at High Flow 
 Adult Control Adult BSO Older Control Older BSO 
 No Drug 
     
Perfusion Pressure (mmHg) 75.47 ± 0.85 83.66 ± 6.49  77.46 ± 3.99 73.06 ± 1.30 
Flow (ml/min) 14.57 ± 0.61 14.00 ± 0.59 20.26 ± 2.52 * 16.84 ± 1.22 * 
CVR (mmHg/ml×min-1) 5.27 ± 0.25 6.06 ± 0.49 4.30 ± 0.87 * 4.53 ± 0.38 * 
     
Heart Rate (beats/min) 250 ± 12 228 ± 16 219 ± 20 222 ± 11 
LVDP (mmHg) 92 ± 4 86 ± 5 97 ± 13 104 ± 10 
+dP/dt (mmHg/sec) 3787 ± 187 3424 ± 222 3367 ± 389 3909 ± 358 
-dP/dt (mmHg/sec) -1657 ± 70 -1485 ± 75 -1709 ± 193 -1766 ± 153 
     
 LNAME 
     
Perfusion Pressure (mmHg) 138.67 ± 8.85‡ 168.49 ± 14.42† 107.40 ± 7.51†,‡ 96.94 ± 4.98†,‡ 
Flow (ml/min) 14.16 ± 0.44 14.29 ± 0.10 18.57 ± 0.12 †,‡ 16.48 ± 0.28 †,‡,§ 
CVR (mmHg/ml×min-1) 9.86 ± 0.68 11.80 ± 1.02 5.79 ± 0.41 * 5.93 ± 0.35 * 
     
Heart Rate (beats/min) 248 ± 13 247 ± 17 226 ± 6 239 ± 10 
LVDP (mmHg) 97 ± 14 90 ± 8 105 ± 6 95 ± 7 
+dP/dt (mmHg/sec) 3636 ± 363 3169 ± 236 a 3997 ± 215 3445 ± 248 a 
-dP/dt (mmHg/sec) -1692 ± 249 -1514 ± 105 -1744 ± 73 -1695 ± 99 
 
Hemodynamic variables in the absence (control) and presence (LNAME) of NOS inhibition at a 
standardized perfusion pressure.*, p<0.05 main effect for age, †, p<0.05 VS Adult con; ‡, p<0.05 vs 





In the high flow condition, the maximal endothelium-dependent dilation in older animals 
remained blunted compared to the adult (105.4±1.4% vs 98.6±3.3, p=0.05, grouped by age). However, 
the older animals demonstrated a slight increased sensitivity to BK compared to the adult animals 
(EC50; -8.18±0.11 vs -7.86±0.10 log M, p<0.05, grouped by age). There was no difference in the AUC 
between the groups (Figure 2.4, Table 2.5). 
In the presence of LNAME, there was a marked reduction of the endothelium-dependent 
response to BK observed in the AB group; unlike the LNAME effect at lower flow this resulted in 
blunting of both the maximal response and AUC compared to all other groups (Figure 2.4, Table 2.5). 
Also unlike the LNAME effect at lower flow, there were no differences in the EC50 across the groups in 
the high flow conditions. Similar to the lower flow conditions, however, there was a reduction in TDC 
seen in the older animals compared to the adult animals in both the presence and absence of LNAME 
(Table 2.5).  
 
Table 2.5 Curve characteristics from High Flow bradykinin dose-response curve. 
 
 
Adult Control Adult BSO Older Control Older BSO 
 No Drug 
Max (%) 104.8 ± 1.5 106.1 ± 2.5 99.0 ± 7.6 * 98.4 ± 2.1 * 
EC50 (-logM) 7.80 ± 0.05 7.95 ± 0.15 8.23 ± 0.19 * 8.14 ± 0.19 * 
AUC 218.1 ± 7.6 230.1 ± 15.2 244.7 ± 25.3 226.6 ± 21.7 
TDC 1.94 ± 0.18 2.71 ± 0.33 1.15 ± 0.62 * 1.45 ± 0.87 * 
     
 LNAME 
     
Max (%) 89.8 ± 4.7 † 66.8 ± 6.8 92.1 ± 3.9 † 94.3 ± 2.5 † 
EC50 (-log M) 7.30 ± 0.13 7.13 ± 0.13 7.42 ± 0.09 7.37 ± 0.11 
AUC 127.2 ± 15.9 83.6 ± 9.9 146.4 ± 12.0 * 147.1 ± 9.7 * 
TDC 6.58 ± 0.60 7.84 ± 0.86 2.81 ± 0.34 * 2.83 ± 0.24 * 
 
Curve characteristics in the absence (control) and presence of NOS inhibition (LNAME). Curves were fit 
as described in the methods section. TDC, total dilatory capacity (mmHg/ml×min-1). *, p<0.05 main 






Figure 2.4. Bradykinin dose-response curves at High Flow 
Data are from adult and older control (solid square and circle), and adult and older BSO animals (open 
square and circle) in the absence (A and B) and presence of NOS inhibition (C and D). The dashed line 
represents the adult CON no drug and the dotted line represents the older CON no drug (C). The 
dashed line in represents the adult CON LNAME and the dotted line represents the older CON LNAME 
(D). Data are presented as mean ± SE (n=7-13/group). 
  












































































































































2.4.6 Effects of H2O2 on Coronary Vascular Resistance 
Given that H2O2 is believed to act as a dilatory agent in the coronary circulation (148, 149), and 
that a previous study speculated that H2O2 was a mediator of endothelium-dependent effects 
observed in BSO treated adult animals (90), we wanted to assess if there was an effect of BSO 
treatment on the management of an acute exogenous H2O2 stimulus in the intact coronary vascular 
bed of AB animals. Prior to the assessment of H2O2-mediated effects, we confirmed that the responses 
to BK were similar between the CON and BSO animals. There were no differences in the dilation to 1 
µM BK between the adult control and adult BSO groups (94.2±1.4% vs 91.9±1.6%; Figure 2.6). After 
washout of BK, H2O2 was administered at increasing concentrations (10
-5 – 10-3 M) and a dose-
dependent decrease in CVR was observed in CON, reaching 100% of the BK dilation. The response to 
H2O2 was blunted at several concentrations in BSO vs CON (Figure 2.5). Following the final 
concentration of H2O2, hearts were allowed to recover and redevelop a stable perfusion pressure. 
Once a stable perfusion pressure was achieved we assessed if there were alterations to the BK 
response, and found no differences between the adult CON and adult BSO animals following the H2O2 
exposure (Figure 2.6). These results demonstrate that the BSO-treated animals were less sensitive to 






Figure 2.5. H2O2 induced dilation  
Results are from adult control (■)and adult BSO (□). Decrease in CVR was expressed relative to 
maximal endothelium dependent dilation (1 µM BK). Data are presented as mean±SE (n=7-8/group). 


































Figure 2.6. Bradykinin responses prior to and following H2O2 dose response curves 
Bradykinin responses from adult control (filled bars) and adult BSO (empty bars) prior to, and 
following H2O2 exposure from adult CON (horizontal hatch), and adult BSO (vertical hatch). Data are 
presented as mean±SE (n=7-8/group).  
 
 
2.4.7 Effect of BSO treatment on protein expression 
 An age dependent, BSO-induced increase in LV eNOS protein content was noted in the AB 
group compared to all other groups (Figure 2.7). Treatment with BSO induced a significant increase in 
left ventricular catalase protein expression in both adult and older animals (Figure 2.7). No differences 


































Figure 2.7. Relative change in protein expression following 10 days of BSO treatment 
Data are expressed relative to adult control. eNOS protein expression (A) and catalase protein 
expression (B). Above each graph is a representative immunoblot of (n=2/group) in the order that they 
appear on the graph. *, p<0.05 vs all groups, †, p<0.05 main effect of BSO treatment. Data are 
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The primary finding of this study is that chronic thiol depletion in adult animals resulted in an 
increased reliance on NO for maintaining CVR and endothelium-dependent dilation, as supported by 
the observation that the increase in CVR and blunted endothelium-dependent responses in the 
presence of LNAME was greater in AB compared to AC. Furthermore, we demonstrated that this effect 
of BSO was age-specific, as no BSO-dependent increased reliance in NO was observed in the older 
animals, despite the fact that marked reduction in ventricular thiols and elevated ROS production still 
occurred in older BSO vs older control animals. In the older animals there was a reduction in the 
amount of spontaneous coronary vascular resistance and this appears to be unrelated to NO 
production, as it also was evident in the presence of LNAME. Intriguingly, coronary vascular sensitivity 
to H2O2 was lower in hearts from BSO treated animals compared to those from controls. This may be 
explained by the compensatory increase in catalase protein content seen with BSO treatment.  
 
2.5.1 Effects of BSO treatment and aging on endothelium-dependent dilation 
 Studies which have examined the effects of BSO on systemic and conduit vascular function 
demonstrated that endothelium-mediated NO-induced dilation is reduced (13, 63, 68, 107), likely due 
to elevated oxidative stress associated with BSO treatment (13, 67, 181). In contrast, in the current 
study we observed an increased reliance on NO in the coronary circulation of adult BSO-treated 
animals. It appears that this effect is age-dependent as the adult BSO animals achieved a greater CVR 
and a greater blunting of the BK-mediated dilation in response to LNAME compared to the adult 
controls while no differences were observed between the older controls and older BSO animals, 
despite reduction in GSH content, and elevated ROS.  
We expressed vasodilation responses relative to the degree of maximal SNP-stimulated 
reduction in CVR (minimal CVR). Expressing the responses in this manner does not account for 
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differences that may exist in capacity to dilate, as the change in CVR (from baseline to minimal CVR) is 
used as the total dilatory capacity. Importantly, we found that both baseline CVR and minimal CVR 
were reduced in the older animals, and overall this resulted in a reduced total dilatory capacity with 
age. Thus, unlike other studies from the coronary circulation (6, 37, 95, 172), we observed only a 
modest decrease in maximal BK-mediated dilation with aging at either flow condition. However, when 
we express the dilation relative to baseline vascular resistance, we also show that maximal BK-
mediated dilation is blunted with age (31.4±1.5% vs 15.0±2.0% in adult vs older, p<0.05), similar to the 
effect reported in previous studies (6). It is also possible that our aging effect was smaller than 
previous reports as our older animals tend to be younger than old animals from other aging studies 
(eg (6, 37, 154)). Our older animals were chosen specifically to examine if thiol depletion would 
accelerate the aging-induced endothelial dysfunction. Although the older rats utilized may not be 
considered senescent, we demonstrated that the older animals had endothelial dysfunction as 
demonstrated by reduced maximal dilation and total dilatory capacity. Had BSO treatment accelerated 
these age-related changes as hypothesized, the current model would have been ideal to demonstrate 
a dynamic range of effects. 
 
2.5.2 Effects of BSO treatment on eNOS protein expression 
We have extended previous findings from other tissues (13, 63, 90, 195) by demonstrating 
that BSO treatment causes an increase in eNOS protein expression in the left ventricle of adult 
animals. It is possible that this is mediated by increased H2O2 as has been previously suggested (53). 
Further support for this as a potential mechanism is the intriguing finding that despite the effect of 
BSO treatment on catalase expression, H2O2 levels were still elevated in left ventricular homogenates 
from BSO treated vs control animals. It is also noteworthy, however, that although there was a general 
BSO effect at increasing H2O2 regardless of the age cohort, the increase in eNOS protein content was 
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limited to the adult BSO group. This suggests that the mechanisms are more complex and that aging 
modifies the signals causing eNOS adaptations to BSO, and/or the sensitivity of eNOS regulation to 
those signals. In support of this finding we found that catalase protein content was slightly, but non-
significantly elevated with age (p=0.06). Thus if H2O2 is accounting for the increase in eNOS protein 
content, the ability of a small increase in catalase to reduce H2O2 production in the OC group could 
account for the age-dependent effect of BSO treatment to increase eNOS protein content observed. 
This is supported by the amplex red H2O2 production data, which demonstrated that relative increase 
in ROS production was greater between the AC and AB group compared to the OC and OB groups. 
 
2.5.3 Effects of aging on coronary vascular resistance 
The reduced amount of spontaneous tone that we observed as a result of aging is in 
agreement with previous reports from isolated perfused hearts (6, 89) and isolated arterioles (154). 
The myogenic response is blunted in isolated coronary arterioles from old animals compared to young 
animals, an effect that was also present in response to agonist induced constriction (154). It was 
further demonstrated that the impaired ability to constrict and develop spontaneous tone could be 
abolished either through LNAME or denudation, suggesting that increased endothelium-derived NO 
was involved in blunting the constriction (154). In contrast, in the current study, the effect of age on 
CVR persisted despite NOS inhibition, suggesting that the age-dependent reduction in CVR was not 
dependent on an increase in NO production. In response to LNAME, the percentage increase in CVR 
from baseline was similar in the adult controls (42%) compared to the older control (38%). Under the 
lower in vivo basal level flow conditions there are not differences in the relative contribution of NO 
between the adult and the older animals. Thus, our aging results are in contrast to both Amrani and 
co-workers (6) and Ishihata and colleagues (89) who found that NO production in isolated, perfused 
hearts was reduced in older animals. Under the higher flow conditions, however, we did find that the 
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LNAME effect was blunted in the old animals as the LNAME-induced increase in CVR was only ~18%, 
compared to 47% seen in the adult animals. It would therefore appear that under our lower flow 
conditions designed to mimic a basal in vivo flow rate, basal NO production is maintained; however 
when flow rate is increased, this reveals an age-dependent relative reduction in NO production. We 
found no differences in eNOS protein content in the LV with age, suggesting that the reduction in NO 
production seen under the High Flow is not related to differences in eNOS content and therefore likely 
reflects changes in either eNOS activation or NO destruction. Our data would suggest that enhanced 
NO destruction is not the case as ROS production in the LV was not significantly increased with age. It 
is therefore, likely that the attenuated increase in CVR in the older rats in the presence of LNAME is 
related to altered eNOS activation which was more apparent under conditions of higher shear stress 
(158). 
As already suggested, alterations in the myogenic response could account for the reduction in 
CVR seen in the older animals (154). It is possible that other mechanisms could contribute to the 
observed age-dependent reduction in CVR including alterations in the expression of K+ channels (94). 
The reduction in CVR seen with age likely relates to heterogeneous nature of the coronary circulation 
(93, 105) and may reflect a compensatory change to maintain cardiac perfusion and function. 
 
2.5.4 Effects of BSO treatment on cardiac contractility 
We found that chronic BSO treatment did not alter any measures of left ventricular function 
assessed in the Langendorff preparation. This is consistent with a previous report using acute 
administration of BSO (108). In the current study, however, NOS inhibition did reveal an interesting 
contractility effect of chronic BSO treatment, as the maximal rate of ventricular pressure development 
(+dP/dt) was reduced in BSO-treated adult rats in the presence of LNAME compared to controls in the 
presence of LNAME. In the older controls, we found that NOS inhibition resulted in an increased 
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+dP/dt, whereas no changes were seen in contractility in the other groups (Tables 2 and 4). It is 
plausible that in the older control animals that NOS inhibition removed excess NO which can cause a 
blunting of contractility (102, 139) whereas in both BSO groups this was not observed, possibly as a 
result of excess ROS reducing basal NO availability in the myocardium. Although this phenomenon was 
not directly assessed in the current study, we did observe increases ROS production in the BSO treated 
animals and, speculatively, the effect of BSO may be mediated in part by altered sarco(endo)plasmic 
reticulum function, as previously demonstrated in diaphragm (177). 
 
2.5.5 Effects of exogenous H2O2 on coronary vascular resistance and endothelium dependent responses 
We observed that BSO treatment impaired the ability of coronary vasculature to dilate to 
H2O2. This is inconsistent with the hypothesis put forward in a previous report suggesting that 
endothelial-mediated vasomotor function is enhanced with BSO treatment as a result of endothelium-
dependent H2O2 mediated dilation (90). A possible explanation for the reduced dilation to H2O2 
observed herein is that increased expression of catalase in the hearts of BSO-treated compared to 
control animals resulted in better management of the exogenous H2O2 stimulus. The increase in 
catalase may also explain why a larger increase in H2O2 production was not observed in heart 
homogenate. It is clear that the sensitivity of the coronary vascular bed to H2O2-mediated vasodilation 
is reduced in BSO treated vs control animals. Thus, the previous speculation regarding H2O2-mediated 
enhancement of endothelium-dependent dilation to be possible, it would require very large local 
increases in H2O2 in the vascular environment. 
 
2.5.6 Summary 
The current study reveals that BSO treatment age-dependently increases the reliance on NO in 
the intact coronary circulation of the adult BSO group. This is based on observations of greater CVR, 
blunted endothelium-dependent responses in the presence of NOS inhibition, and increased eNOS 
63 
 
expression in the adult BSO group (vs older) only. Furthermore, we have demonstrated that isolated 
perfused hearts from older animals fail to develop as much spontaneous coronary vascular resistance 
as the adult animals, and that BK-stimulated, endothelium-dependent coronary vasodilation is 
reduced with age. Our results indicated that the age-dependent reduction CVR is not dependent on 
increased NO as in the presence of LNAME, a similar relative increase in CVR was observed at the in-
vivo flow rate compared to the adult animals. A portion of the impaired endothelium dependent 
vasodilation may be masked, as the capacity to dilate is smaller in the older animals with lower basal 
tone. Despite an increased H2O2 production seen in the left ventricle of BSO animals, the vasculature 
of these animals is less sensitive to exogenous H2O2 as demonstrated by the attenuated decrease in 
CVR compared to control animals. In summary, both thiol depletion and aging differently impact 
vasomotor function in the isolated perfused rat heart. These changes may reflect differential 
adaptations to different modes of chronic oxidative stress, and that the effects of age and BSO-
dependent chronic glutathione depletion do not appear to be additive. 
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Glutathione enhances endothelium-mediated coronary vascular dilation in a 
reactive oxygen species-dependent manner and independent of effects on NO 
production and soluble guanylate cyclase 
 
3.1 Synopsis 
The purpose of this investigation was to determine the effects of acute physiological GSH 
administration on NO-mediated coronary artery dilation. Endothelial function was assessed in 
isolated, perfused hearts. A dose-response curve to GSH was conducted to determine a threshold 
concentration of GSH. We demonstrate that 30 µM GSH was sufficient to reduce coronary vascular 
resistance, and maximal dilation was achieved with 1 mM. Subsequently, GSH was administered at 
concentrations of 0 (CON), 1 µM or 10 μM (GSH10) and dose-response curves to the endothelial 
agonist bradykinin (BK) were constructed. These GSH concentrations were chosen because of the 
physiological relevance, and because the effects of GSH on BK action could be assessed independent 
of baseline differences. The sensitivity (EC50) to BK was enhanced in GSH10 vs CON (p<0.05). This 
enhancement remained in the presence of nitric oxide synthase inhibition (LNAME) and/or soluble 
guanylate cyclase inhibition. Treatment with TEMPOL enhanced the sensitivity to BK in CON similar to 
GSH10 and GSH10+TEMPOL. Conversely, the GSH10-dependent enhancement observed in the presence 
of LNAME did not occur in the presence of LNAME+ TEMPOL. Collectively, these results suggest that 
GSH enhances BK-mediated dilation through an antioxidant-dependent mechanism, unrelated to NO 
production or guanylate cyclase-dependent effects of NO. These results suggest a mechanism 
whereby the effects of endogenous reactive oxygen species are modulated by physiologically relevant 
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levels of GSH.  This mechanism could help protect/enhance endothelium-dependent vascular function 
in health and in disease conditions of elevated vascular oxidative stress. 
 
3.2 Introduction 
Reduced glutathione (GSH) is an important antioxidant and contributes to the maintenance of 
vascular health via its role in mitigating the effects of free radicals (65, 146, 160). Several 
investigations have examined the effects of acute GSH administration on endothelial function in 
patients with suspected and known cardiovascular disease. Kugiyama and colleagues (1998) found 
that infusion of either GSH or ACh alone into the coronary arteries of patients undergoing angiography 
did not alter vessel diameter or blood flow. However, when GSH was co-infused with ACh, the normal 
healthy dilatory response to ACh was observed (104). Similarly, Prasad and colleagues demonstrated 
that GSH enhanced the ACh-induced reduction in femoral vascular resistance compared to ACh alone 
(138). In these studies, the effects of GSH administration were more pronounced in individuals with 
endothelial dysfunction than in those with normal vasomotor responses (103, 104, 138). It is plausible 
that the effects of acute GSH administration are most prominent in individuals with existing 
endothelial dysfunction, due to the action of GSH as an antioxidant protecting NO bioavailability in 
those with cardiovascular disease. 
Direct vasodilatory effects of GSH were not observed in the human studies discussed above 
(103, 104, 138). However, animal studies utilizing pre-contracted arteries, and isolated perfused 
hearts have demonstrated that GSH alone is capable of inducing vasodilation (5, 33, 66, 92). In isolated 
perfused rat hearts, Cheung and Schultz demonstrated that GSH dose-dependently increased coronary 
flow in a constant pressure preparation. These vasodilatory effects of GSH were mediated through a 
pathway involving nitric oxide, sGC and free radicals (33). The Cheung and Schultz report establishes 
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that GSH can directly influence vascular tone, and therefore could potentially alter signalling pathways 
known to mediate endothelium-dependent vasorelaxation. However, the issues of whether there are 
significant effects of physiological levels of extracellular GSH on the action of endothelium-dependent 
vasorelaxation pathways, and the mechanisms involved have not been directly addressed. It is 
important to address these issues experimentally in order to understand both the physiological role of 
GSH in vascular function, and the clinical utility of GSH in cardiovascular disease states. 
The purpose of the current study, therefore, was to investigate the hypothesis that acute, low 
dose GSH infusion co-administered with an endothelial agonist would augment endothelium-
mediated reductions in coronary vascular resistance in the isolated perfused rat heart, and that this 




Male Sprague-Dawely rats (n=105, mean age 40 weeks) were group housed (4/cage) in a 
temperature- and humidity-controlled environment, and kept on a reverse 12 hour light/dark cycle. 
Food and water were provided ad libitum. All procedures were approved by the University of 
Waterloo Animal Care Committee. The investigation conforms with the Guide for the Care and Use of 
Laboratory Animals published by the US National Institutes of Health (NIH Publication NO. 85-23, 
revised 1996). 
 
3.3.2 Langendorff Heart 
Animals were anaesthetized (60 mg/kg pentobarbital sodium, i.p.), and the heart was 
removed and immersed in 4oC Krebs Henseleit (KH) buffer (composition in mmol/L NaCl 118, KCl 4.7, 
MgSO4·7H2O 1.2, NaHCO3 24, KH2PO4 1.1, Glucose 10 and CaCl2·2H2O 1.25) to reduce myocardial 
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contractility and ischemic injury (166). Hearts were transferred to the aortic cannula which was 
dripping gassed (95%O2-5%CO2) 37
oC KH and secured with suture. The time from excision to the 
establishment of flow was less than 1 minute, and the heart was at the ‘in-vivo’ flow in approximately 
2.5 minutes. 
We utilized a constant flow protocol as this is best suited for the study of vasoactive agents 
(10, 32). The constant flow rate was assigned to mimic in-vivo coronary flow where Flow=7.43×((body 
weight×0.0027+0.6)0.56) (45, 50). A flow probe and associated transducer (2PXL and TS410, Transonic 
Systems, Ithaca NY) and pressure transducer (MLT844, AD Instruments, Boulder Co) were positioned 
proximal to the aortic cannula for the measurement of total coronary flow, and coronary perfusion 
pressure. A pressure balloon was inserted through the left atria into the left ventricle and adjusted to 
achieve a diastolic pressure of 5 – 10 mmHg. Heart rate, left ventricular developed pressure (LVDP, left 
ventricular systolic pressure–diastolic pressure) and +dP/dt were derived from the left ventricular 
pressure tracing. All data were collected using a Powerlab data acquisition board (4/sp, AD 
Instruments, Boulder Co) and stored digitally using Chart for Windows (5.5.1, AD Instruments, Boulder 
Co) for off-line analysis. 
Hearts were stabilized for 30 minutes to allow for the development of spontaneous coronary 
vascular tone and heart rate. Preparations which failed to establish spontaneous tone were excluded 
from the study. Once the perfusion pressure had stabilized, baseline hemodynamic measurements 
were made by taking an average over 1 minute.  
 
3.3.3 Series 1 GSH dose-response relationship in isolated perfused hearts 
Following baseline measurements, increasing concentrations of GSH (1.0 µmol/L – 1.0 mmol/L) 
were administered. Each concentration was infused at 1% of total coronary flow for 10 minutes (33). A 
10 second average around the peak response to each concentration was used to derive the dose-
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response relationship for GSH-induced vasodilation. Following the maximal dose of GSH, sodium 
nitroprusside (SNP, 10 µM) was used to induce endothelium-independent dilation.  
 
3.3.4 Series 2 Effect of GSH administration on BK-mediated dilation in isolated perfused hearts 
Hearts were infused with either 0 (CON), 1 µM (GSH1) or 10 µM (GSH10) of GSH. These 
concentrations were chosen for two reasons: 1) Series 1 experiments demonstrated that these GSH 
concentrations do not cause a decrease in basal coronary vascular resistance, allowing for a similar 
baseline CVR across conditions, and 2) the 10 µM concentration is a physiologically relevant 
concentration of plasma/extracellular fluid GSH (65). Steady state baseline measures were made, 
followed by a dose response curve to bradykinin (BK, 10-11 – 10-6 M). After the final concentration of 
BK, the vasculature was dilated with adenosine (ADO 10-5M), and endothelium-independent dilation 
to exogenous NO was also assessed using SNP (10-9 – 10-4 M). Each dilatory agent was infused at a rate 
of 1% of the coronary flow using a syringe pump (Cole Parmer 74900, Montreal PQ). L-ωNitro-L-
arginine (LNAME, 0.1 mmol/L) was used to inhibit nitric oxide synthase, 1H-
[1,2,4]oxadiazolo[4,3]quinoxalin-1-one (ODQ, 3 µmol/L) was used to inhibit soluble guanylate cyclase, 
and the superoxide dismutase (SOD) mimetic, 4-Hydroxy TEMPO (TEMPOL, 0.1 mmol/L) was used as a 
non-thiol exogenous antioxidant. Therefore, ‘no drug’ refers to the condition in the presence or 
absence of GSH (CON no drug/GSH no drug) in the absence of other pharmacological agents. Only one 
drug protocol was performed per heart. 
Changes in coronary vascular resistance were reported as a percentage of the maximal decrease 
in CVR induced by ADO, using the following equation: [((CVRBL–CVRA)–(CVRBL–CVRc))÷(CVRBL–
CVRA)]×100. Where CVRBL is baseline CVR, CVRA is minimal CVR (adenosine) and CVRC is the CVR at the 
concentration of interest. No differences in the absolute minimal CVR elicited by adenosine were 
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observed across groups (p>0.05). Curves were fit to obtain EC50, maximal dilation, and area under the 
curve (AUC) using Prism (4.03, GraphPad Software, San Diego CA).  
 
3.3.4 Series 3 Effect of GSH administration on ACh-mediated responses in isolated aortic rings 
 In a subset of animals (n=8/group), the thoracic aorta was isolated for wire myography as 
previously described (63, 74, 75). Rings (2mm axial length) were mounted on a myography unit 
(Radnoti, Morovia, CA), immersed in Kreb’s bicarbonate buffer gassed with 95%O2/5%CO2, stretched 
to a resting tension of 5g (12), and allowed to equilibrate for 30 minutes with or without 10 µM GSH. A 
cumulative dose-response protocol to ACh (10-9 – 10-4 M) was performed in vessels contracted with 
phenylephrine (0.1 µM). Curves were fit as described above. 
 
3.3.5 Measurement of left ventricular glutathione content 
Following the experimental protocol, hearts were gently blotted and weighed. A portion of 
the left ventricle was snap frozen in liquid nitrogen. Glutathione was assessed using HPLC as 




Chemicals were purchased from Sigma-Aldrich (St. Louis, MO), Bioshop Canada (Burlington, 
ON, Canada) and ODQ which was purchased from Cayman Chemicals (Ann Arbor, MI). All drugs were 
diluted to their final concentrations in KH buffer.   
 
3.3.7 Statistics 
Data are presented as mean±standard error (SE). Differences between groups were assessed 
using ANOVA for planned comparisons for each drug condition between the CON and GSH. Significant 
results were subsequently analyzed using Least Squares Difference post hoc test. To assess the 
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changes that the pharmacological agents had within the specific groups data was normalized to the 
control no drug condition and compared using ANOVA to allow for within group comparisons. A p 
value <0.05 was considered statistically significant. All statistics were performed using Statistica 6.0 
(StatSoft Inc, Tulsa OK). 
3.4 Results 
3.4.1 Series 1 GSH dose-response relationship in isolated perfused hearts 
Glutathione caused a dose-dependent reduction in coronary vascular resistance (Figure 3.1). 
This reduction became significant at ~30 µM. At 1 mM GSH the reduction in CVR was similar to that 
observed in response to maximal SNP. Given that both 1 µM and 10 µM GSH failed to significantly 
reduce CVR, and that these levels are in the physiological range of extracellular fluid GSH values, these 
concentrations were chosen for subsequent studies to examine how GSH would influence 
endothelium-dependent, agonist-mediated vasodilation in Series 2 experiments. 
 
3.4.2 Series 2 Effect of GSH administration on BK-mediated dilation in isolated perfused hearts 
Baseline characteristics for the CON, GSH1 and GSH10 groups are presented in Table 3.1. There 
were no differences in heart weight or body weight between any of the groups, and acute 
administration of GSH did not result in a change in left ventricular GSH content. Likewise, no group 





Figure 3.1 GSH mediated dilation 
Acute administration of GSH led to a dose-dependent dilation of isolated perfused rat hearts. * p<0.05 
vs  baseline. Data are mean±SE (n=10). 
Table 3.1. Baseline characteristics 
 CON GSH1 GSH10 
Body weight (g) 511.7 ± 13.5 484.9 ± 12.5 514.4 ± 9.9 
Heart weight (mg) 1836 ± 34 1828 ± 48 1907 ± 37 
    
GSH (nmol×mg wet weight-1 ) 2.181 ± 0.109 1.936 ± 0.040 1.988 ± 0.173 
GSSG (nmol×mg wet weight-1) 0.228 ± 0.010 0.197 ± 0.010 0.209 ± 0.018 
 
No differences were noted between the CON and GSH10 groups. GSH content was determined using 
HLPC as described in the methods section. Data are presented as mean±SE (n=7-40/group for physical 

























































Table 3.2. Hemodyamics values in the presence of no drug, NOS and sGC inhibition 
 CON GSH10 
 No Drug LNAME ODQ No Drug LNAME ODQ 
CVR 
(mmHg÷(ml/min)) 





240 ± 9 226 ± 14 253 ± 17 218 ± 12 237 ± 14 240 ± 7 





4225 ± 262 4196 ± 565 4267 ± 525 4402 ± 243 3998 ± 518 4702 ±372 
 
For details on specific comparisons refer to text. CVR; coronary vascular resistance, LVDP; left 
ventricular developed pressure, +dP/dt; maximal rate of pressure development.  Data are presented 
as mean±SE (n=7-14/group). *, p<0.05 vs respective no drug,† p<0.05 vs CON+LNAME (planned 
comparison).  
 
Acute GSH administration at 1 or 10 µM did not alter maximal BK-induced endothelial-
mediated dilation compared to controls (Figure 3.2). However, acute administration of 10 µM GSH, 
which is similar to the concentration seen in the plasma/extracellular fluid (65), did enhance the 
sensitivity (lowered the EC50 value) to BK in the GSH10 group compared to CON (2.93±1.09 vs 
12.19±1.37 nM), and this was associated with increased area under the curve (264.4±13.8 vs 
191.1±10.2). Conversely, the effects of 1 µM of GSH did not reach significance for EC50 (7.12±1.90 nM) 
or AUC (229±17.3) compared to CON. Thus, the GSH1 group was excluded from subsequent studies in 
this series designed to identify the mechanisms responsible for GSH effects on responses to BK 





Figure 3.2 Bradykinin mediated dilation is augmented in the presence of GSH 
Dilatory curves from the control (■)and GSH10 (□).The presence of GSH increases the sensitivity to BK 
in the 10 µM group but not the 1 µM group (A). In the presence of LNAME (0.1 mM), the GSH effect 
persisted (B). ODQ (3 µM) had minimal effect in both groups (C). Maximal dilation refers to minimal 
CVR elicited by adenosine (10 µM). The long dashed (control) and short dashed (GSH10) are included 
for clarity. Data are presented as mean±SE (n=7-8/group) *p<0.05 vs respective control curve 










































































































  CON GSH10 
EC50 (log M) -7.94 ± 0.06 -8.70 ± 0.16 
Max (%) 91.2 ± 3.9 85.9 ± 1.9 
AUC 191.1 ± 10.2 264.4 ± 13.8 
  CON GSH10 
EC50 (log M) -7.59 ± 0.10 -8.06 ± 0.15 
Max (%) 89.7 ± 4.3 91.9 ±1.0 
AUC 158.7 ± 11.4 211.8±11.9 
  CON GSH10 
EC50 (log M) -8.02 ± 0.04 -8.32 ± 0.06 
Max (%) 85.2 ± 2.7 91.3 ± 2.2 






3.4.3 Effects of NOS inhibition on BK-mediated responses in the presence of GSH 
To assess the role of NO production in mediating the increased sensitivity to BK observed in 
the presence of 10 µM GSH, LNAME (0.1 mM) was employed (Figure 3.2). LNAME increased the 
baseline CVR in both the CON and GSH10 groups (Table 2), but GSH10 blunted the LNAME-associated 
increase in CVR (Table 3.2, Figure 3.3). No differences were noted between groups in any indices of 
cardiac function. LNAME reduced the sensitivity to BK (increased the EC50 value) in the CON group, yet 
failed to significantly reduce the sensitivity in the GSH10 group compared to GSH10 no drug condition 
(Figure 3.3). Thus, the effect of GSH10 to increase sensitivity to BK remained intact in the presence of 
NOS inhibition (Figure 2; EC50 = 6.94±3.33 vs 30.00±11.40 nM), as did the enhancement in the AUC 
(211.8±11.9 vs 158.7±11.4).   
 
3.4.3 Effect of sGC inhibition on BK-mediated responses in the presence of GSH 
Having established that GSH still enhanced vasodilation to BK even in the presence of NOS 
inhibition, we sought to determine if there was a sGC dependency of the GSH effect, independent of 
NO production. This would allow us to test the possible role of ‘stored’ NO, such as nirosothiols, acting 
through sGC in mediating the GSH effects (14, 16, 30, 174).  In the presence of the sGC inhibitor ODQ, 
no differences were observed in the hemodynamic variables versus the no drug group (Table 3.2). In 
the control condition, ODQ (3 µM (33, 151)) did not alter the sensitivity, the AUC, nor maximal dilation 
to BK compared to the no drug control group (Figure 3.3). Increasing the concentration of ODQ to 10 
µM (as some previous studies have employed (14)), also did not affect responses to BK (n=6, Appendix 
Figure A3). The lack of effect of ODQ on EC50 and CVR in the control group demonstrates that the 
sGC/cGMP pathway is not necessary to mediate the observed effects of GSH, thus suggesting that if 
there is any NO involvement in mediating the GSH effects it is due to sGC/cGMP-independent effects 
of NO (23, 128). Similarly, in the presence of GSH10, ODQ had no significant effect on sensitivity (EC50, 
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5.16±0.80 vs 2.93±1.09 nM), yet resulted in a small decrease in the AUC compared to the GSH10 
responses in the absence of ODQ (230.7±9.0 vs 265.4±13.8, Figure 1.3).  
The sensitivity to BK remained enhanced in the presence of GSH10+ODQ compared to 
CON+ODQ (EC50, 5.16±0.080 vs 9.53±0.71 nM), as was the AUC (230.7±9.0 vs 194.5±9.9) (Figure 3.2). 
These results suggest that the observed effects of GSH do not require an obligatory role of sGC 
activation.   
 
3.4.4 The effect of combined NOS and sGC blockade on the BK-mediated responses in the presence of 
GSH 
In the presence of combined NOS and sGC inhibition, the GSH10 effect persisted, such that 
sensitivity to BK (EC50, 4.28±0.46 vs 16.92±3.07 nM) and AUC (248.2±9.7 vs 183.1±6.2) remained 
enhanced (Figure 3.3, Appendix Figure A4). This suggests that the effects of GSH can be independent 
of both NO production and NO-dependent sGC activation, and that another non-NO dependent 
pathway contributes to the GSH effect. 
 
3.4.5 Effect of GSH on vasodilatory responses to exogenous NO 
In order to differentiate whether GSH affected the ability of vascular smooth muscle to 
respond to NO, the vasorelaxation effects of sodium nitroprusside were assessed. SNP dose-
dependently decreased CVR in both groups. No differences were observed between the CON and 
GSH10 groups (Figure 3.4).Thus the GSH10 effects appear to be independent of changes in vascular 
smooth muscle NO-dependent vasodilatory capacity, as both the SNP- and ADO-mediated responses 





Figure 3.3 Summary of curve parameters 
Effects of pharmacological agents on the sensitivity, EC50 (A), AUC (B) and maximal dilation (C) in the 
control (■)and GSH10 (□).*, p <0.05 vs control no drug; †, p<0.05 vs GSH10 no drug. ‡ p<0.05 vs CON a 













































No Drug   LNAME ODQ   LNAME  TEMP      TEMP+




















Figure 3.4. Sodium nitroprusside mediated dilation 
Exogenous NO dose-dependently decreased CVR in the control (■) and GSH10 (□) groups. No 
differences were seen between groups. Dilation is expressed as a percentage of minimal CVR elicited 
by adenosine (10 µM). Data are presented as mean±SE (n=6/group). 
 
 
3.4.6 Effect of GSH and exogenous non-thiol antioxidant on the dilatory responses to BK 
The activity of GSH may be mediated in part by its antioxidant-dependent effects. We 
assessed whether the observed effects were thiol-specific, or were general antioxidant effects by 
determining whether addition of a non-thiol antioxidant would alter the effects of GSH10 on the BK-
mediated responses.  In the control group, the addition of excess SOD mimetic TEMPOL resulted in a 
leftward shift of the BK dose-response curve (Figure 3.5). The enhanced response seen in the CON 
group in the presence of TEMPOL was a result of an increase in sensitivity (EC50, 3.68±0.78 vs 

































  CON GSH10 
EC50 (log M) -7.40 ± 0.07 -7.41 ± 0.07 
Max (%) 96.3 ± 0.8 94.1 ± 1.12 
AUC 329.3 ± 10.5 325.9 ± 3.8 
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12.19±1.37 nM) and an increase in AUC (275.0±17.2 vs 191.1±10.2) compared to the no drug 
condition.  
In the presence of TEMPOL, no changes were noted in any hemodynamic variables between 
the CON and GSH10 groups (Table 3).  In addition, in the presence of TEMPOL there were no 
differences in the sensitivity to BK (EC50, 3.68±0.78 vs 3.51±0.47 nM), the AUC (275.0±17.2 vs 
286.3±10.4), or maximal dilation (95.6±2.0 vs 99.2±1.8%, Figures 3.3 and 3.5) between the CON and 
GSH10 groups. Furthermore, TEMPOL did not alter the response to SNP in either the CON or GSH10 
group (Appendix Figure A5). The fact that TEMPOL had a pronounced effect in the CON group, yet 
failed to augment the response in the GSH10 suggests that there is likely a reactive oxygen species 
buffering component responsible for the GSH10 effect on BK mediated dilation that is superseded in 
the presence of excess TEMPOL.  It is noteworthy that physiological GSH (10 µM) is quantitatively as 
effective as excess TEMPOL in augmenting the responses to BK.   
 
The effects of NOS inhibition and ROS scavenging on the effects of GSH administration 
Co-treatment with LNAME+TEMPOL resulted in an increase in CVR in CON which was not 
reduced by GSH10 under these conditions (Table 3.3). In the CON group, the presence of 
LNAME+TEMPOL resulted in reduced sensitivity (EC50=21.38±10.17nM) compared to the no drug 
condition (12.19±1.37 nM), and slightly enhanced sensitivity compared to the LNAME only group 
(30.01±6.94 nM). The area under the curve and maximal dilation were not different from the control 
no drug condition (Figure 3.3). Taken together these results demonstrated that LNAME+TEMPOL 
abolished the increased sensitivity seen in the presence of TEMPOL alone, suggesting that the 
observed effect of TEMPOL is NO production-dependent.   
In the GSH10 group, the presence of LNAME+TEMPOL resulted in a significant increase in the 
EC50 compared to the GSH10 no drug condition (20.77±7.69 vs 2.93±1.09 nM). This is in contrast to the 
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effect of GSH10+LNAME (11.38±3.33 nM) which did not alter the EC50 compared to the GSH10 no drug. 
Thus in the presence of GSH10, LNAME+TEMPOL was able to augment the sensitivity where as LNAME 
alone was not. There was a significant decrease in the AUC in the GSH10 group in the presence of 
LNAME+TEMPOL (170.57±13.86) compared to the GSH10 no drug (264.4±13.8) and GSH10 LNAME 
(211.8±11.9). No changes were observed in maximal dilation amongst these groups (Figure 3.3). 
In the presence of LNAME+TEMPOL the curve characteristics were similar between the GSH10 
and the CON; EC50 (20.77±7.69 vs 21.38±10.17 nM), AUC (170.0±13.9 vs 182.3±12.7) and maximal  
dilation (92.8±1.0 vs 95.2±0.5%).   
 
Table 3.3. Hemodynamics in the presence of TEMPOL and LNAME and TEMPOL 
 CON GSH10 
 TEMPOL LNAME+TEMPOL TEMPOL LNAME+TEMPOL 
CVR (mmHg÷(ml×min-1)) 5.25 ± 0.35 10.74 ± 1.88* 5.76 ± 0.44 10.68  ± 0.78* 
Heart rate (beats×min-1) 228 ± 12 258 ± 13 238 ± 7 248 ± 9 
LVDP (mmHg) 110 ± 5 130 ± 3 106 ± 5 102  ± 12 
+dP/dt (mmHg×sec-1) 3793 ± 242 4677 ± 224 3576 ± 153 3709  ± 408 
 
Data are presented as mean±SE (n=3-10/group). For details on specific comparisons refer to text. CVR; 
coronary vascular resistance, LVDP; left ventricular developed pressure, +dP/dt; maximal rate of 





Figure 3.5. Endothelium dependent dilation in the presence of TEMPOL 
Hearts were perfused with TEMPOL (0.1 mM) (A) or TEMPOL (0.1mM)+LNAME (0.1 mM) (B). TEMPOL 
increased the sensitivity to BK in the control group (■) compared to the respective no drug condition 
but not the GSH10 group (□). LNAME induced a rightward shift in equally in both groups. The no drug 
curves from the CON (long dash) and GSH10 (short dash) are included for clarity. Data are mean±SE 
(n=3-10/group). 




































































  CON GSH10 
EC50 (log M) -8.48 ± 0.09 -8.48 ± 0.06  
Max (%) 95.6 ± 2.0 99.2 ± 1.8 
AUC 275.0 ± 17.2 286.3 ± 10.4 
  CON GSH10 
EC50 (log M) -7.76 ± 0.19 -7.75 ± 0.17 
Max (%) 95.3 ± 0.5 92.8 ± 1.0 





3.4.7 Series 3 Effect of GSH administration on ACh-mediated responses in isolated aortic rings 
 There were no differences in precontraction to 0.1 µM phenylephrine between CON and 
GSH10 groups (69.1±2.7% vs 72.2±2.2%, percent of KCl contraction). Dose-response curves generated 
using the endothelial agonist ACh, revealed no differences between CON and GSH10 groups in 
sensitivity, AUC, or maximal dilation (Figure 3.6). This lack of GSH10 effect on isolated conduit artery 
suggests the effects of GSH on endothelium-dependent responses observed in the isolated perfused 




Figure 3.6. Effect of 10 µM GSH on endothelium dependent dilation in isolated aortic segments 
Rings were precontracted with phenylephrine (10-7 M) and dose dependently dilated with ACh. No 
differences were seen in the control group (■) compared GSH10 group (□). Data are presented as 
mean±SE (n=7/group).  
































  CON GSH10 
EC50 (log M) -7.19 ± 0.10 -7.22 ± 0.13 
Max (%) 82.6 ± 3.3 86.7 ± 0.13 




The primary findings of this study are that exogenous glutathione, at a physiological 
concentration that does not alter basal CVR, enhances BK-mediated dilation of the intact coronary 
vascular bed in isolated perfused hearts in a manner that is dependent on reactive oxygen species. 
Furthermore, the effects of GSH on endothelium-mediated dilation appear to be independent of NO 
production or NO signalling mediated by sGC. The results we obtained in both the isolated perfused 
heart and conduit vasculature suggest that the mechanism of the ROS-dependent effects of 
physiologically relevant GSH infusion may occur in the coronary resistance vasculature.  
Contrary to our hypothesis, the GSH10-dependent improvement in BK-mediated dilation 
observed in the current investigation does not appear to be mediated through the ability of NO to be 
produced, or the activation of sGC, as demonstrated by the enhanced sensitivity and increased AUC in 
the GSH10 group that persists despite LNAME and/or ODQ. In the control group, the presence of the 
SOD mimetic TEMPOL was sufficient to augment the EC50 of the LNAME curve so that it was not 
different from the no drug condition. However, the GSH10 LNAME+TEMPOL and the CON 
LNAME+TEMPOL groups had similar baseline CVR and BK dose-response curve characteristics. The 
baseline CVR observed in the presence of LNAME+TEMPOL in the GSH10 group was greater than that 
observed in the presence of LNAME alone, and the GSH10 LNAME+TEMPOL group had an increased 
EC50 and reduced AUC of the BK dose-response curve compared to the GSH10 LNAME condition. These 
results suggest that the scavenging of ROS by TEMPOL, abolishes the GSH effects.  
The effects we observed on CVR in the GSH10 group with LNAME vs LNAME+TEMPOL are 
intriguing as we did not observe any basal effects on CVR in response to GSH10 in the LNAME+TEMPOL 
group. The blunted LNAME-induced increase in CVR in the presence of GSH suggests that, unlike 
TEMPOL, GSH is not merely scavenging ROS and improving NO bioavailability. If this were the case 
then the CVR in the presence of LNAME would be similar in the GSH10 group compared to the control. 
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It is possible that in the presence of increased CVR, as a result of LNAME, the GSH itself could be 
inducing a direct vasodilatory effect (as occurs under normal CVR conditions at higher [GSH] as 
demonstrated in series 1 experiment). The fact that, in the presence of LNAME+TEMPOL, CVR in the 
GSH10 group was similar to that in the CON group suggests that when ROS are quenched (by TEMPOL), 
the protective/dilatory effects of GSH are abolished. This is supported by reported findings using a 
similar preparation in which the dilatory effects of GSH alone (no additional endothelium-dependent 
agents present) were abolished in the presence of exogenous SOD (33)). Thus, it is likely that the ROS 
management characteristics of GSH allow this molecule to enhance endothelium-mediated vasomotor 
function and therefore control changes in CVR observed in the current study, independent of NO 
bioavailability.  
A reduction in NO-bioavailability as a result of increased reactive oxygen species is a hallmark 
of cardiovascular disease (26, 145). Given the importance of NO in mediating vasodilatation in the 
coronary circulation (98, 110), a reduction in oxidative stress should enhance NO bioavailability. Our 
study clearly demonstrated that the addition of either GSH or TEMPOL separately increased the 
sensitivity to the endothelial agonist BK. In the current study, we thus report a relevant and novel 
physiological role of GSH in mediating endothelium-dependent control of the coronary vasculature 
that was reactive oxygen species-dependent. 
In previous human studies (103, 104, 138), GSH effects were most pronounced in individuals 
with pre-existing endothelial dysfunction. Here we demonstrate that the GSH is able to enhance 
endothelial function in normal animals, but that the enhanced function was not further augmented in 
the presence of ROS scavenging. Given that endothelial dysfunction is associated with increased levels 
of reactive oxygen species (26, 60, 145) and that the GSH effects were more apparent in the presence 
of reactive oxygen species and endothelial dysfunction, this suggests that the effects of GSH are likely 
mediated in part by its antioxidant-dependent effects. In the current study, had GSH been acting 
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solely to increase NO bioavailability through ROS scavenging, then in the presence of LNAME we 
would have demonstrated a similar blunting of the BK dose-response curve in our CON and GSH10 
groups. However, this was not the case, as the BK curve remained enhanced in the GSH10 group 
despite NOS inhibition and/or sGC inhibition. This further suggests that the presence of GSH is not 
merely acting as an exogenous antioxidant protecting NO bioavailability with respect to the findings of 
the current study. 
In agreement with our observations from aortic segments from healthy animals, Akapffiong 
and Taylor (5) and Jia and Fruchgott (92) failed to demonstrate an effect of GSH on ACh-mediated 
responses in thoracic aortic segments. Interestingly, in the SHR animals which were shown to have 
endothelial dysfunction, likely mediated in part by increased ROS, 1 µM GSH enhanced the ACh 
mediated response (5). These findings suggest the requirement of ROS for GSH to augment 
endothelium-dependent dilation.  
In the isolated aorta preparation it is necessary to pre-contract the tissue (with PE) in order to 
then evaluate vasorelaxation effects, unlike in the isolated perfused heart in which spontaneous tone 
is present. The experiments in the isolated perfused heart demonstrated that GSH was without effect 
on spontaneous tone. Similarly, GSH10 did not alter the amount of contractile tone obtained with PE in 
the isolated vascular preparation. The effect of GSH on endothelium-dependent dilation as result of 
NO production was evaluated using BK in the heart preparation and ACh in the aortic preparation; 
both agents result in elevations in endothelial cell cytosolic calcium and the consequent activation of 
eNOS and other pathways (125, 180).  Based on our observations of the effects of GSH observed in the 
intact coronary bed, but not in the isolated conduit artery preparation, we postulate that the effects 
of GSH administration are possibly more pronounced in the resistance portion of vascular beds, and in 
the presence of ROS.  
85 
 
During our protocol, no increase in left ventricular GSH occurred, and the GSH10 was without 
effect on cardiac function, similar to the results of Cheung and Schulz (33). This would suggest that the 
observed enhancement of BK mediated vasodilation/drop in CVR in the presence of GSH is a direct 
vascular effect. Furthermore, the endothelium-dependent effects we observed in the presence of GSH 
are likely not simply related to the interaction between GSH and NO, and do not reflect the ability of 
the vascular smooth muscle to either utilize NO, or dilate to adenosine. 
 While our results suggest that the GSH-dependent effects on BK-mediated dilation are 
mediated primarily through a ROS-dependent pathway, it is possible that GSH acts through a separate 
vasodilatory pathway, independently of ROS or NO. For instance, bradykinin and other endothelial 
agonists can cause dilation through cyclooxygenase (COX)-derived prostaglandins including 
prostacyclin (78). However, Cheung and Schulz (33) demonstrated that the vasodilatory effects of GSH 
alone (in the absence of endothelial agonists) are independent of COX.  Furthermore, preliminary data 
from our laboratory demonstrate that inhibition of the COX pathway with indomethacin does not alter 
BK-mediated vasodilation/decline in CVR in isolated perfused rat hearts (Appendix Figure A6). Thus, in 
the current study it is unlikely that GSH effects are mediated by COX-derived vasodilators yet the lack 
of abolishment of dilation in the presence of LNAME and/or ODQ further suggests that a non-NO, non-
prostanoid dilator is active in the isolated perfused heart. It is this pathway that may be altered by 
GSH infusion. It can be speculated that the GSH10 enhancement in BK-mediated dilation may relate to 
increased Ca2+ uptake in the vascular smooth muscle. This is consistent with the limited existing 
functional and biochemical evidence (3), demonstrating that this process is a ROS-dependent process, 
requiring the gluathiolation and increased the activity of vascular smooth muscle sarco(endo)plasmic 
reticulum Ca2+ ATP-ase (3). It is also possible that the presence of GSH was sufficient to alter the redox 
status through its antioxidant effects (103) and therefore increase open probability of smooth muscle  
K+ channels (115) or increase the utilization of nitrosothiols which can act on K+ channels and have 
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been suggested to be a source of endothelial derived hyperpolarizing factor in the coronary circulation 
(14-16). Further experiments specifically designed to test hypotheses related to the involvement of 
these or other mechanisms will greatly enhance the understanding of the importance of GSH to 
vascular function in health and disease.    
In conclusion, our results demonstrate that physiologically relevant concentrations of 
extracellular GSH can significantly augment endothelium-mediated responses in the isolated perfused 
rat heart We identified, for the first time, that acute GSH enhanced BK-mediated endothelium-
dependent dilation through a pathway requiring ROS, but not dependent on NO production or 
activation of sGC. By minimizing ROS through the addition of TEMPOL we were able to abolish the 
enhancement seen in the presence of NOS inhibition. These results extend previous findings from 
both animal and human studies by identifying a novel pathway whereby GSH enhances endothelium-
dependent dilation. We speculate that acute GSH administration enhances endothelium-mediated 
vasomotor responses through a direct vascular effect, by interacting with endogenous ROS 
management in the microcirculation. 
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Effect of thiol modulation on coronary vascular resistance and endothelium-
dependent dilation in the isolated perfused heart 
 
4.1 Synopsis 
Despite recent advances in the understanding of the role of thiols in vascular health, the effect 
that acute modulation of reduced glutathione (GSH): oxidized glutathione (GSSG) ratio (GSH:GSSG) has 
on endothelial intact preparations has not been studied extensively. The purpose of the current study 
was to examine how acute manipulations of GSH:GSSG ratio would impact coronary vascular 
resistance and endothelial-mediated dilation in the isolated perfused heart. Hearts were perfused 
with diamide, bis-chloronitrosourea (BCNU), ethacrynic acid (EA), or 1-chloro-2,4-dinitrobenzene 
(CDNB) in order to alter GSH:GSSG ratio. We found that there was a significant inverse correlation 
between GSH:GSSG and baseline coronary vascular resistance (CVR, r=-0.55, p<0.05) such that the 
lower the GSH:GSSG the higher the baseline vascular tone. Endothelium-dependent dilation was 
preserved in the presence of BCNU and dimaide but markedly attenuated in the presence of CDNB 
and EA. Despite this differential response we found a significant inverse correlation between 
GSH:GSSG and minimal CVR (r=-0.58, p<0.05) suggesting that the lower GSH:GSSG, the higher the 
minimal CVR. The BK mediated response seen in the presence of CDNB was bi-phasic and 
demonstrated early onset of dilation followed by a recontraction. EA resulted in an overall reduction 
in maximal dilation and sensitivity to BK. The results of the current studies demonstrate that 
alterations in the GSH:GSSG ratio affect baseline CVR and minimal CVR and therefore have 
implications for adequate tissue perfusion both dependent and independent on the ability of the 




Regulation of intracellular thiols plays an integral role in the suppression of reactive oxygen 
species (ROS) and maintenance of vascular health (65, 146, 160). Population based studies have also 
demonstrated that changes in the ratio of reduced glutathione (GSH) to oxidized glutathione (GSSG) 
glutathione, is a potential predictor of cardiovascular events (12). Clinical findings indicate that the 
GSH:GSSG is lower in patients with chronic kidney disease (9), diabetes mellitus (42), and aging (114).  
Collectively, these findings suggest that altered redox signalling is involved in several different disease 
states, and may be related to altered thiol antioxidant capacity. These relationships have been 
established based mostly on studies related to chronic alterations, but few studies have examined 
how an acute change in intracellular thiols impacts endothelium-intact vasomotor function.  
Given the association between NO and cardiovascular disease (125), it could be postulated 
that alterations in GSH:GSSG would alter NO production and endothelium-dependent vascular 
function, and thus may be an important early determinant in cardiovascular disease development. 
There are several lines of evidence which suggest that acute alterations in the GSH:GSSG ratio have 
implications for the generation and production of NO. Isolated endothelial cells have reduced NO 
production (72, 132) and cGMP accumulation (87) following thiol depletion. Similarly, alterations in 
thiol metabolizing proteins including thioredoxin and glutathione reductase are also associated with 
impaired NO production (164). These studies indicate that in isolated cellular preparations, 
manipulation of intracellular thiols impairs NO production. The loss of NO production as a result of 
thiol depletion is a potential mechanism of altered endothelial dependent dilation in the presence of 
thiol oxidation (2). There is, however, a limited amount of data which has examined how acute 
reduction in the GSH:GSSG impacts endothelium-dependent dilation and whether or not the 
responses are related to NO production.  
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 In the absence of the endothelium, thiol oxidization has been shown to promote a reduced 
contractile state in isolated coronary vessels (79, 80, 88). For example diamide resulted in a dose-
dependent dilation, which was further enhanced through the inhibition of glutathione reductase (GR) 
and mediated by altered Ca2+ entry into the vascular smooth muscle through the closure of L-type Ca2+ 
channels (88). Furthermore, hypoxia promotes an oxidized state, and it appears that the hypoxic 
coronary dilation is mediated by increases in the NADP:NADPH which increases the GSSG:GSH ratio 
and promotes the opening of K+ channels and altered Ca2+ handling by the smooth muscle (190). It is 
evident that thiol depletion alters coronary vascular tone in the absence of the endothelium; however 
the modulatory effects of the endothelium on vascular tone in response to thiol depletion has not 
been assessed. 
 There is growing evidence to suggest that alteration in GSH:GSSG, and acute changes in 
intracellular thiols can have an impact on NO bioavailability and vasomotor function. However, there 
are a limited number of studies which have examined how acute changes in intracellular thiols, in 
particular GSH, impact endothelium dependent vasomotion. Given the long term associations of 
altered GSH:GSSG seen in vasomotor dysfunction, it is important to examine the extent to which acute 
modulations of GSH:GSSG impact vasomotor tone and function to provide insight into the potential 
mechanisms underlying the relationship between GSH:GSSG and vasomotor function. The purpose of 
the current investigation was to examine the extent to which alterations in the GSH:GSSG ratio impact 
coronary vascular resistance and endothelium-dependent dilation in the isolated perfused heart. 
Several different agents designed to manipulate the GSH:GSSG via divergent mechanisms were 
employed to study the effects on endothelium-dependent dilation. Given that reductions in GSH:GSSG 
are known to impair NO production, it is likely that the extent to which GSH:GSSG is altered will be 





Male Sprague-Dawely rats (n=172) weighing approximately 300g (mean age 10 weeks) were 
used in the current experiment. Animals were group housed (4-5/cage) in a temperature and humidity 
controlled environment, and kept on a reverse 12 hour light/dark cycle. Food and water were 
provided ad libitum. All procedures were approved by the University of Waterloo Animal Care 
Committee. 
 
4.3.2 Langendorff Heart 
Hearts were prepared for the Langendorff procedure. Briefly, animals were anaesthetized 
with 60 mg/kg of pentobarbital sodium (I.P.), the heart was removed and immersed immediately in 
4oC Krebs Henseleit solution (KHS, composition in mmol/L NaCl 118, KCl 4.7, MgSO4·7H2O 1.2, NaHCO3 
24, KH2PO4 1.1, Glucose 10 and CaCl2·2H2O 1.25). Hearts were then transferred to the aortic cannula 
which was dripping gassed (95%O2-5%CO2) 37
oC KHS, secured with suture, and cleaned of adherent 
tissue. The time from excision to the establishment of flow was less than 1 minute, and the time until 
the heart was at the ‘in-vivo’ flow was approximately 2.5 minutes. 
We utilized a constant flow protocol as this is best suited for the study of vasoactive agents 
because the constant flow rate allows for a constant drug infusion rate (50, 166). The constant flow 
rate was assigned to mimic in-vivo coronary flow using the following equation: Flow = 7.43 × ((body 
weight×0.0027+0.6)0.56) (45, 50). A flow probe and associated transducer (2PXL and TS410, Transonic 
Systems, Ithaca NY), and a pressure transducer (MLT844, AD Instruments, Boulder Co) were 
positioned proximal to the aortic cannula for the measurement of total coronary flow, and coronary 
perfusion pressure. A pressure balloon was inserted through the left atria and advanced into the left 
ventricle and adjusted to achieve a resting diastolic pressure of 5 – 10 mmHg. The balloon was 
connected to a pressure transducer (MLT844, AD Instruments, Boulder Co). Heart rate, left ventricular 
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developed pressure (LVDP, left ventricular systolic pressure – left ventricular diastolic pressure) and 
±dP/dt were all derived from the left ventricular pressure tracing. All data were collected using a 
Powerlab data acquisition board (4/sp, AD Instruments, Boulder Co) and stored digitally using Chart 
for Windows (5.5.1, AD Instruments, Boulder Co) for off-line analysis. 
A 30 minute stabilization period was included to allow for the development of spontaneous 
coronary vascular tone and heart rate. Hearts which failed to establish spontaneous tone were 
excluded from the study. Once the perfusion pressure had stabilized, baseline measurements 
including coronary vascular resistance (CVR, perfusion pressure ÷ flow), heart rate, and left ventricular 
developed pressure ±dP/dt) were made continuously and data points were extracted by taking an 
average over 1 minute.  
 
4.3.4 Assessment of vasomotor function 
Following the stabilization period, hearts were exposed to increasing concentrations of 
bradykinin BK (10-12 – 10-6 M). After the final concentration of BK, adenosine (ADO 10-5 M) was 
administered to assess minimal CVR. Endothelium-independent dilation to exogenous NO was 
assessed by SNP (10-10 – 10-4 M). For each agent a total volume of 250 µl was infused at a rate of 1% of 
the coronary flow using a syringe pump (Cole Parmer 74900, Montreal PQ) to yield the final desired 
concentration. Only 1 curve was generated per heart in order to limit potential time and order effects 
of the different agonists.  
The following agents were used to alter thiol status: diamide (1 or 10 µM), a thiol oxidizing 
agent; bis-chloronitrosourea (BCNU 10 or 100 µM), a glutathione reductase inhibitor; ethacrynic acid 
(EA, 10 µM), a thiol alkylating agent; or 1-chloro-2,4-dinitrobenzene (CDNB, 20 µM), a thioredoxin 
inhibitor. No differences between 10 or 100 µM BCNU were observed for GSH:GSSG therefore the 




-4 M) was used to inhibit nitric oxide synthase, the superoxide 
dismutase (SOD) mimetic 4-Hydroxy TEMPO (TEMPOL, 10-4 M) was used as a non-thiol exogenous 
antioxidant, and the preferential COX-1 inhibitor (SC560 3×10-7 M) and the preferential COX-2 
inhibitor (NS398, 10-6 M) were used to assess the potential role of cyclooxygenase-derived products in 
the responses.  The group name ‘no drug’ refers to the condition in the presence or absence of an 
indicated thiol manipulating agent, but in the absence of any other pharmacological agents (LNAME, 
TEMPOL, SC560, and NS398). 
Changes in coronary vascular resistance were reported as a percentage of maximal decrease in 
CVR induced by ADO, by using the following equation: [((CVRBL – CVRA) – (CVRBL – CVRc)) ÷ (CVRBL-
CVRA)]×100. Where CVRBL refers to baseline CVR, CVRA refers to minimal CVR elicited by ADO and CVRC 
refers to the CVR at the concentration of interest. Curves were fit to obtain EC50, maximal dilation and 
area under the curve (AUC) using Prism (4.03, GraphPad Software, San Diego CA). Total dilatory 
capacity (TDC) was determined by examining the total change in coronary vascular resistance (CVRBL-
CVRA).  
 
4.3.5 Measurement of left ventricular glutathione content and reactive oxygen species 
Following the experimental protocol, hearts were gently blotted and weighed. A portion of 
the outer wall of the left ventricle was snap frozen in liquid nitrogen. Glutathione was assessed using 
HPLC as previously described by our laboratory (63) according to the method derived by Reed and 
colleagues (141).  
 
4.3.6 Assessment of reactive oxygen species production 
Hydrogen peroxide production was assessed using the Amplex Red Hydrogen Peroxide kit 
(Molecular Probes, Invitrogen, Carlsbad, CA) as previously described by us (147). Diluted left 
ventricular homogenate was added to 50µl of Amplex Red reagent (10µM Amplex Red stock and 
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0.2U/ml horseradish peroxidase in PBS) (51) and incubated in the dark at room temperature for 
30min. Fluorescence was detected every 15 minutes using at 530/590nm excitation/emission 
wavelengths. H2O2 concentrations were calculated using a H2O2 standard curve (R
2≥0.998). Tissue 
concentrations are expressed relative to µg protein as determined from a bicinchoninic acid (BCA) 
protein concentration assay.  
General ROS production was measured as previously described by our laboratory (147). The 
left ventricular homogenate was diluted further in PBS and incubated for 15 minutes in the dark at 
37oC with 5 µM of dicholorflouricine diacetate (H2DCF-DA, Molecular Probes, Invitrogen, Carlsbad, 
CA). Fluorescence was detected every 15 minutes at excitation/emission wavelengths of 488/525 nm 
and subsequently normalized to protein content. 
For each measure of ROS production the total change in ROS was assessed by calculating the 
difference between the fluorescent signals at 1 hour from the baseline signal. Thus the values 
presented represent the increase from initial ROS content. 
 
4.3.7 Chemicals 
All chemicals were purchased from Sigma-Aldrich (St. Louis, MO) or Bioshop Canada 
(Burlington, ON, Canada). SC560 and NS398 were purchased from Cayman Chemicals (Ann Arbor, MI). 
All drugs were diluted to their final concentrations in KHS.   
 
4.3.8 Statistics 
All data are presented as mean ± standard error (SE). Differences between groups were 
assessed using ANOVA. Significant results were subsequently analyzed using Least Squares Difference 
post hoc test. Correlational analysis was performed using Prism (4.03, GraphPad Software, San Diego 
CA). A p value <0.05 was considered statistically significant. All statistics were performed using 




4.4.1 Animal Characteristics 
Baseline characteristics for the animals can be found in Table 4.1. There were no apparent 
differences in the rat body weights across treatment groups; however, hearts that were treated with 
CDNB, EA and Diam10 had elevated heart weights compared to the control animals (Table 4.1). Acute 
treatment with all thiol manipulating agents (with the exception of DIAM1) resulted in a lowering of 
the GSH:GSSG ratio (Table 4.1). Despite the effect that thiol manipulation had on GSH:GSSG, only 
modest effects were observed on ROS production (Table 4.1). 
Table 4.1. Animal Characteristics 
 CON CDNB EA BCNU DIAM1 DIAM10 
Body Weight (g) 308.01±3.59 312.16±3.91 312.16±4.95 315.25±8.82 316.46±6.04 312.39±5.27 
Heart Weight 
(mg) 
1321±17 1568±22* 1378±20* 1333±32 1350±34 1471±26* 








0.082±0.010 0.002±0.000* 0.065±0.011 0.093±0.010 0.088±0.013 0.074±0.008 
GSH:GSSG 16.01±1.54 2.25±0.64* 10.29±1.80* 11.87±0.52* 12.98±1.04 10.31±0.83* 
       
General ROS  
(RFU/µg PRO) 
44.0±1.9 43.3±2.0 36.3±1.1 * 50.5±2.8 * 58.3±2.1 * 39.6±2.4 
H2O2  
(ρmol/µg PRO) 
1.28±0.15 1.41±0.07 1.24±0.06 1.55±0.06 * 1.42±0.06 1.61±0.11 * 
Data are presented as mean±SE (n=7-59/group for body and heart weights). Thiols were assessed using 
HPLC (n=5-10/group). General ROS was measured using DCF fluorescence, H202 was measured using 
amplex red (n=5-10/group). *,p<0.05 vs CON 
 
 
4.3.2 Effects of acute thiol depletion on cardiac hemodynamics 
Acute treatment with the different thiol manipulating agents differentially altered the amount 
of spontaneous vascular tone developed. Treatment with CDNB, EA and DIAM1 all resulted in greater 
baseline coronary vascular resistance compared to the control group, while BCNU and DIAM10 were 
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without effect (Table 4.2). Across all treatment groups a significant inverse relationship existed 
between GSH:GSSG ratio and the baseline CVR (r = -0.53, p<0.05, Figure 4.1). A significant decrease in 
left ventricular systolic pressure was observed in all treatment groups compared to the control, and 
this was associated with a blunted LVDP in all groups (Table 4.2). Treatment with CDNB, and DIAM10 
resulted in significant blunting of +dP/dt and –dP/dt, whereas BCNU, EA and DIAM1 were without 
effect (Table 4.2). Correlational analysis revealed significant relationships between GSH:GSSG and HR, 
LVsysP and +dP/dt (Figure 4.1). 
 
Table 4.2 Baseline Hemodynamics 
 Con CDNB EA BCNU DIAM1 DIAM10 
CVR  
(mmHg/ml×min-1) 
6.73±0.24 11.46±0.71* 8.61±0.36* 6.13±0.36 9.02±0.65* 6.61±0.27 
       
HR (BPM) 265±11 298±7* 284±7 278±8 273±9 271±13 
LVsysP (mmHg) 131±5 94±4* 114±4* 114±5* 114±9* 95±8* 
LVDP (mmHg) 122±5 85±5* 106±4* 106±4‡ 106±9‡ 87±7* 
       
+dP/dt (mmHg/sec) 4053±143 3066±140* 3736±139 3939±127 3681±298 2585±119* 
-dP/dt (mmHg/sec) 2405±100 -1690±98 * 2163±67 2141±93 2102±179 1643±123* 
 
Data represent the steady state hemodynamics following 30 minutes of stabilization. CVR coronary 
vascular resistance; LVsysP, left ventricular systolic pressure; LVDP, left ventricular developed 
pressure; ±dP/dt, maximal or minimal rate of pressure development; ‡p≤0.058 *p<0.05 vs CON Data 





Figure 4.1. Correlational analyses between GSH:GSSG and selected hemodyamic variables  
GSH:GSSG was inversely correlated with baseline CVR, and heart rate are significantly correlated with 
left ventricular systolic pressure and +dP/dt (n=29/graph). All Correlations were significant p<0.05. 
 
4.4.3 The mechanism of thiol oxidation has varying affects on BK induced endothelium-dependent 
dilation. 
Following the stabilization measurements, BK dose-response curves were generated for all 
conditions. BCNU, DIAM1 and DIAM10 were all without effect on BK mediated dilation (Table 4.3). 
Conversely, both CDNB, and EA significantly altered the BK dose-response curve compared to the 
control group (Figure 4.2). Treatment with CDNB resulted in a slightly earlier onset of dilation yet 
resulted in a significant redevelopment of vascular tone (reduced dilation) at the higher 
concentrations of BK. Conversely, EA resulted in a rightward shift and an overall reduction of the BK 
dose-response curve compared to the controls (Figure 4.2, Table 4.3).  













































































































r = -0.547 r = -0.423
r = 0.382 r = 0.397
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Table 4.3. Curve Characteristics  
 CON CDNB EA BCNU DIAM1 DIAM10 
Maximal Dilation (%) 97.7±1.6 74.4±1.9 * 90.8±1.8* 96.0±3.4 97.6±1.1 101.7±1.6 
EC50 (- Log M) 8.42±0.08 8.83±0.28 * 7.85±0.07 * 8.28±0.08 8.21±0.08 8.26±0.03 
AUC 261.6±9.0 248.1±14.4 195.6±11.5 * 254.0±7.0 262.4±9.5 250.2±5.1 
 
Data represent mean±SE (n=7-12/group). Curves were fit as described in the methods section. 





Figure 4.2 Bradykinin dose-response curves  
Data are from CON (●), CDNB (■), and EA(□). CDNB elicits an earlier onset of dilation with significant 
blunting at the top end of the curve. EA results in a generalized blunting of the response. Dose-
response curves for BCNU, DIAM1 and DIAM10 were excluded for clarity as they overlapped with the 
control group. Data are presented as mean±SE (n=9-12/group). *, p<0.05 EA vs CON ‡,p<0.05 CDNB vs 
CON 




































4.4.4 Thiol modulation alters minimal CVR and total dilatory capacity. 
Following the BK dose-response curves all hearts were exposed to adenosine (10-5 M) to elicit 
maximal endothelium-independent dilation in the coronary vascular bed. Adenosine resulted in a 
significant reduction in CVR in all groups. However, the minimal CVR achieved in the presence of 
CDNB, EA and DIAM1 was significantly greater than the minimal CVR achieved by the CON group 
(Figure 4.3a). Despite having greater minimal CVR the total dilatory capacity was also greater in the 
CDNB, EA and DIAM1 compared to the control (Figure 4.3b) due to the fact that these groups also all 
had elevated baseline CVR (Table 4.2). There was a significant correlation between the GSH:GSSG ratio 
and minimal CVR such that the greater the ratio, the lower the minimal CVR (r=-0.581, p<0.05  Figure 
4.4). There was no relationship between thiol status and TDC (r=-0.305, p>0.05). 
 
4.4.5 Effect of exogenous NO on the dilatory responses in the presence of thiol depletion 
Given that we found impaired BK-mediated dilation in the presence of both EA and CDNB we 
sought to determine if the altered dilation was as a result of altered ability of the smooth muscle to 
respond to NO. The NO-donor SNP was therefore employed in the presence of these two agents. SNP 
dose-dependently dilated the coronary vasculature. No differences were observed in maximal dilation, 
sensitivity or AUC between the groups (Figure 4.5). Thus, the impaired ability to dilate in the presence 






Figure 4.3. Effect of thiol manipulation on minimal CVR and total dilatory capacity 
Absolute minimal CVR elicited following administration of adenosine 10 µM (A).Total capacity to dilate 
as assessed by the change from baseline CVR to absolute minimal CVR elicited by ADO (B). Included in 
A are the baseline CVR values for each condition demonstrated by the solid line above the minimal 
CVR. *p<0.05 vs CON Data are mean±SE (n=7-21/group).  











































































Figure 4.4. Relationship between GSH:GSSG ratio and minimal CVR 
 An elevated GSH:GSSG ratio is associated with a lower minimal CVR (n=38). 
  

































Figure 4.5. Endothelium independent dilation  
SNP-induced dilation from the CON (●), CDNB (■), and EA(□). No differences were observed between 
the 3 groups. Data are presented as mean±SE (n=8-9/group). 
 
 
4.4.6 Effect of NOS inhibition on BK mediated responses in response to CDNB and EA 
In the presence of NOS inhibition, all hearts experienced increases in CVR; however, the CVR 
achieved by the control group in the presence of LNAME (14.00±0.76 mmHg/ml×min-1) was 
significantly greater than that of EA+LNAME (10.45±0.95 mmHg/ml×min-1, p<0.01), and no differences 
were seen between CON+LNAME and CDNB+LNAME (13.00±0.64 mmHg/ml×min-1, Figure 4.6).  
In the presence of NOS inhibition, all groups experienced a reduction in the endothelium 
dependent dilation in response to BK (Figure 4.7). Maximal dilation was significantly blunted in the 
CDNB+LNAME compared to CON+LNAME (17.5±5.6 vs 73.3±7.2%) whereas EA+LNAME (82.6±2.9%) 
was not. Despite the reduction in overall dilation, redevelopment of tone was still observed in the 
presence of CDNB+LNAME (Figure 4.7). The AUC was greater in the EA compared to the controls 












 CON CDNB EA  
MAX 96.8±0.5 96.7±1.6 95.3±0.7 
EC50 -7.52±0.10 -7.49±0.17 -7.54±0.14 
AUC 366.4±8.15 367.3±17.7 355.4±12.5 
 






















(152.9±7.2 vs 113.8±10.4). LNAME had a profound effect on the sensitivity (EC50) in the control group 
(-7.29±0.07 Log M) compared to CDNB (-8.54±0.52 Log M, p<0.01) but the EC50 in CON+LNAME was 
not different compared to EA+LNAME (-7.61±0.04 Log M, Figure4.6).  
 
 
Figure 4.6 Comparison of baseline CVR and curve characteristics in the presence of NOS inhibition 
and ROS scavenging 
Data highlight the effects that LNAME and TEMPOL had on control (white), CDNB (black) and EA (gray). 
For details on specific comparisons refer to text. †, p<0.05 for the relative effectiveness compared to 
the control. Data were normalized to the respective no drug condition for control (white), CDNB 
(black) and EA (gray) to allow for differences in the effectiveness of NOS inhibition or ROS scavenging  
to be compared to the respective control condition in the presence of the same drug. Data are 
presented as mean±SE (n=7-21/group). 
  



































































































Figure 4.7 Effect of thiol depletion and NOS inhibition on bradykinin mediated dilation 
Hearts were allowed to equilibrate for 30 minutes in the presence of LNAME (0.1 mM) followed by 
dose-response curve to BK. Data are from the CON (●), CDNB (■), and EA(□) in the presence of 
LNAME. The solid (CON) dashed (CDNB) and dotted (EA) represent the no drug BK mediated 
responses. Data are presented as mean±SE (n=9-11/group). *, p<0.05 vs CON 
 
4.4.7Effect of TEMPOL on the baseline CVR and the BK-dose-response curve 
Given that the changes in CVR and EC50 in response to LNAME were greatest in the CON we 
sought to determine if the acute thiol oxidation resulted in an increased ROS-mediated alteration in 
NO. Therefore, the SOD mimetic TEMPOL was added to the perfusate to scavenge superoxide, thereby 
improving NO bioavailability. The CVR achieved by CON+TEMPOL (7.82±0.18 mmHg/ml×min-1) was not 
different than EA+TEMPOL (8.37±0.46 mmHg/ml×min-1), but was less than CDNB+TEMPOL 
(10.70±0.86 mmHg/ml×min-1, p<0.01, Figure 4.6)  
















 CON CDNB EA  
MAX (%) 73.3 ± 7.2 17.5 ± 5.6 82.6 ± 2.9 
EC50 (Log M) -7.29 ± 0.07 -8.04 ± 0.66 -7.61 ± 0.04 
AUC 113.8 ± 10.4 98.2 ± 15.2 152.9 ± 7.2 
 
















The presence of TEMPOL resulted in a rightward shift of the dose-response curve to BK in all 
groups (Figure 4.8). As such there were no differences in the EC50 across all groups, yet the AUC was 
significantly greater in the CON (237.4±14.0) compared to either the CDNB (144.5±20.1) or EA 
(167.9±18.9). Furthermore, the maximal dilation of the CDNB (24.2±15.1%) was significantly blunted 
compared to the CON (98.4±1.7%). What is most intriguing is the enhanced (compared to CDNB no 
drug) redevelopment of vascular tone at the higher concentrations of BK observed in the presence of 
CDNB+TEMPOL. 
 
Figure 4.8. Effect of an SOD mimetic on the bradykinin dose-response curves  
Hearts were allowed to equilibrate for 30 minutes in the presence of TEMPOL (0.1 mM) followed by 
dose-response curve to BK.  Data are from the CON (●), CDNB (■), and EA(□).The solid (CON) dashed 
(CDNB) and dotted (EA) represent the no drug BK mediated responses. Data are presented as 
mean+SE (n=7-8/group). *p<0.05 vs CON. 
  














 CON CDNB EA  
MAX (%)  98.4 ± 1.7  24.2 ± 15.1 88.4 ± 3.2 
EC50 (Log M) -8.02 ± 0.10 -7.74 ± 0.71  -7.69 ± 0.13  
AUC 237.4 ± 13.9 144.5 ± 20.1 167.9 ± 18.9  
 
















4.4.8 Is the redevelopment of vascular tone in the CDNB-treated hearts dependent on COX derived 
prostanoids? 
Previous reports from our laboratory and others (47, 48, 73, 75, 169) have demonstrated that 
COX derived products can mediate endothelium-dependent vasocontractions observed in 
cardiovascular disease states such as hypertension. The endothelium-dependent responses typically 
demonstrate enhanced vasodilation at lower agonist concentrations followed by recontraction at 
higher agonist concentrations (48, 75). Therefore, we wanted to assess whether the recontraction 
seen in the presence of thioredoxin inhibition could be accounted for by COX derived prostanoids 
acting as endothelial derived contracting factors (EDCF). In the initial series of experiments, we utilized 
the non-specific COX inhibitor indomethacin (INDO 10-5M). In the presence of INDO, there was no 
significant alteration in the dilation seen in the control group to either BK or ADO vs the respective no 
drug condition. In the presence of both INDO and CDNB, the vasculature failed to respond to either 
the endothelium-dependent or -independent agonists (Appendix Figure A7, n=6/group). In light of this 
unexpected finding we chose to examine the effects of the selective COX inhibitors in the CON and 
CDNB groups.  
In the presence of either COX-1 or COX-2 inhibition there remained a significant 
redevelopment of vascular tone such that the max in the presence of SC560 was blunted in the CDNB 
compared to the control (68.6±5.7 vs 100.9±1.7), as was the max in the presence of NS398 (40.5±10.7 
vs 99.9±2.5). This was associated with an increased AUC in the controls in the presence of SC560 
compared to the CDNB (290.0±9.7 vs 160.8±21.0) and NS398 (156.9±21.0). No differences were 
observed in the EC50 between the CON and CDNB in the presence of either SC560 or NS398 (Figure 
4.9). These results suggest that COX derived prostanoids are not responsible for the redevelopment of 
vascular tone in the presence of CDNB. This finding was further highlighted by combining SC560 and 
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NS398 with CDNB; much like the control group in the presence of INDO, hearts treated with 
CDNB+SC560+NS398 responded similar to the CDNB no drug condition (Appendix Figure A6 n=6).  
 
 
Figure 4.9. Effect of specific COX inhibitors on BK dose-response curve 
Hearts were allowed to stabilize for 30 minutes with either the COX-1 inhibitor SC560 (3×10-7) or the 
COX-2 inhibitor NS398 (10-6 M) followed by a dose-response curve to BK. Data are presented as 
mean±SE from CON+SC560 (■ ) CON+NS398(□) , CDNB+SC560 (●) and CDNB+NS398 (○).*p<0.05 vs 
respective CON. The respective NO drug curve for the CON (dotted) and CDNB (dashed) were included 
for clarity. Data are presented as mean+SE (n=4-8/group). 
  



















 CON CDNB 
 SC560 NS398 SC560 NS398 
MAX (%) 100.9 ± 1.7 99.9 ± 2.5 68.6 ± 5.7 40.5 ± 10.7 
EC50 (Log M) -8.66 ± 0.15 -8.13 ± 0.15 -8.58 ± 0.17 -8.48 ± 0.58 
AUC 290.0 ± 9.6 246.2 ± 21.1 160.8 ± 21.0 156.9 ± 21.0 
 

















 It is evident that changes in thiol levels play an integral role in the control of vascular tone and 
function. We have described a relationship that exists between baseline vascular tone and the 
GSH:GSSG ratio in the isolated perfused heart. Given the acute nature of the current treatment we 
can make the following conclusions regarding endothelial-mediated vasomotor function in the intact 
coronary vascular bed. Depending on the nature of thiol depletion, BK-mediated dilation appears to 
be unchanged (BCNU, diamide) or is significantly altered as was the case in the presence of 
thioredoxin inhibition and GSH alkylation. In the presence of CDNB (thioredoxin inhibition) or EA (GSH 
alkylation), the impairment in vasomotor function does not appear to be mediated by an altered 
response of the vascular smooth muscle to endogenous NO. Therefore, these two thiol depleting 
agents affect signalling upstream of sGC. This indicates that the impairment in the response to BK is 
not indicative of altered target tissue sensitivity suggesting that these agents affect other aspects of 
NO signalling, production or destruction, or may be independent of NO altogether. More importantly 
we describe a significant relationship between GSH:GSSG ratio and minimal CVR such that the greater 
the GSH:GSSG ratio the lower the minimal CVR. This suggests that changes in intracellular thiol status 
may alter tissue perfusion. 
4.5.1 Thiol modulation alters baseline CVR 
 The inverse relationship between GSH:GSSG and CVR is intriguing and suggests that in the 
intact coronary vascular bed acute oxidation and/or depletion of thiols results in an elevation of 
baseline vascular tone. In the current study both the thiol alkylating agent EA, and the thioredoxin 
inhibitor, CDNB resulted in a significant elevation of baseline coronary vascular resistance. CDNB had 
the most pronounced effect on the GSH:GSSG ratio and resulted in the greatest increase in CVR. In the 
presence of CDNB and EA it is possible that the increase in CVR observed is related to a reduction in 
NO bioavailability. In the current experiments, the presence of LNAME only slightly increased the 
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baseline CVR in the CDNB and EA treated hearts whereas in the control group LNAME caused a 
significant elevation in CVR. Recent reports have suggested that treatment with CDNB (72, 87) and 
altered thioredoxin expression (164) can attenuate NO production. In agreement with these studies 
the lack of effect of LNAME on CVR in the CDNB group suggests that NO production is likely reduced 
under conditions of CDNB exposure. 
 Previous reports utilizing EA, have demonstrated that thiol alkylation impairs the 
replenishment of NO stores (15, 120, 121). In the current study, it can be postulated that in the 
presence of EA, the altered CVR could be related to impaired NO transfer to GSH as a result of a loss of 
GSH through alkylation, leading to a reduction in the formation of nitrosoglutathione. As 
nitrosoglutathione and nitrosothiols have longer half lives than exogenous NO (58, 65), less 
nitrosothiol in the coronary microcirculation could contribute to the increase in basal CVR. Given that 
LNAME did not significantly influence CVR in the presence of EA, it is likely that the ability of RSNO to 
be regenerated plays an important role in determining baseline CVR. Therefore, RSNO are likely 
released and regenerated under basal conditions in response to physiological stimuli such as shear 
stress (174). In the presence of EA alone, de novo NO is able to contribute to baseline CVR, despite the 
impaired ability to regenerate RSNO. Yet when NO synthesis is inhibited, RSNO are being depleted and 
cannot be replenished. Given that the CVR was not greatly enhanced in the presence of EA+LNAME 
compared to EA alone, these results suggest that RSNO play an important role in determining baseline 
CVR. 
 Contrary to the effects of CDNB and EA are the effects of BCNU and Diamide (10 µM) which 
reduced the GSH:GSSG yet did not affect baseline CVR. Thus unlike studies from endothelium-
removed rings where agonist mediated contraction was attenuated (2) and dilation in precontracted 
arteries was observed (79, 80, 88) the current study suggests that the presence of the endothelium 
may augment this overall dilatory response seen in either the presence of BCNU or Diamide. 
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 In the current study, treatment with BCNU did not result in significant overall increase in 
intracellular GSSG compared to the controls, yet the GSSG concentration was significantly elevated 
compared to all other agents which resulted in altered GSH:GSSG ratio (Table 4.1). In light of this 
finding, we can assume that in the current experiment the excess GSSG was likely extruded from the 
cell given the overall reduction in GSH:GSSG. Compared to CDNB and EA which resulted in increases in 
CVR, the lack of elevated tone in the presence of BCNU compared to the CON may reflect the altered 
calcium handling and altered K+ channel open probability seen in denuded coronary vasculature (69, 
79, 88). These results suggest that in the presence of BCNU baseline CVR is not elevated as is the case 
for CDNB and EA. The lack of effect of BCNU on baseline CVR is in agreement with a previous report in 
the isolated perfused heart (33). Taken together, this suggests that treatment with BCNU in 
endothelium-intact preparations does not result in altered CVR.  
 Similarly the lack of increase in CVR in the presence of dimaide can be explained by the ability 
of diamide to dose-dependently activate sGC (193). A 10 µM concentration was demonstrated to 
cause a doubling of basal sGC activity from human platelets (193). This suggests that the reduced tone 
seen in the DIAM10 vs DIAM1 could represent either the activation of sGC (193) or the altered Ca
2+ 
entry into the vascular smooth muscle preventing contraction (88). In the current preparation, higher 
concentrations of diamide resulted in a pronounced decrease in CVR to a similar extent as 
endothelium-independent dilation (Appendix Figure A8). This would have abolished TDC thus higher 
concentrations were not used. 
  In light of these finding, it likely that the different agents used had divergent effects on the 
development of spontaneous vascular tone. These divergent effects may be related to the mechanism 
of thiol depletion and the how the reduction in GSH:GSSG and altered redox balance affect NO 
production, RSNO replenishment and the NO independent effects including altering the ability of the 
vascular smooth muscle to generate tone (100, 173, 190). Importantly we demonstrate that the 
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presence of the endothelium alters the general dilatory effects observed with thiol oxidation seen in 
endothelium-removed preparations.  
 
4.5.2 Effects of thiol depletion on minimal CVR 
 In the current study we demonstrated that minimal CVR was affected by alterations in the 
GSH:GSSG ratio. All hearts dilated to adenosine; albeit, there were differences in the absolute minimal 
CVR seen across groups. Treatment with CDNB, EA and DIAM1 resulted in a significant increase in 
minimal CVR, whereas BCNU and DIAM10 caused a small but non-significant increase in minimal CVR 
compared to the control. When we examined the extent to which the GSH:GSSG ratio was associated 
with minimal CVR, we determined that reductions in GSH:GSSG are related to elevated minimal CVR. 
This suggests that overall depletion of thiols attenuates the ability of the smooth muscle to elicit 
maximal dilation. Similar to the current study, Adachi and Cohen demonstrated a significant 
correlation between GSH content and ability to dilate to endothelium-derived NO, authentic NO and 
SNP derived NO (2). We extend these finding by demonstrating that the reduction in GSH:GSSG ratio is 
associated with an impaired ability to modulate minimal vascular resistance in the intact coronary 
circulation as demonstrated by the significant correlation between GSH:GSSG and minimal CVR. 
Therefore the GSH:GSSG ratio likely influences myocardial perfusion especially during instances of 
increased metabolic demand where dilation is enhanced through both metabolic and endothelial 
derived factors (176, 185).  
4.5.3 Effects of thiol modulation on BK mediated dilation 
 In the presence of CDNB the BK dose-response curve demonstrated an earlier onset of dilation 
to BK (increased EC50), followed by a redevelopment of tone at the higher concentrations of BK >0.1 
µM. Recent work from our laboratory using hypertensive rats has demonstrated that endothelium-
dependent dilation is slightly enhanced at low agonist concentrations; however, a recontraction at 
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higher agonist concentrations is observed (48, 75). It is possible that altered thioredoxin expression 
may play a role in the recontraction as thioredoxin expression has been reported to be reduced in the 
heart and aorta of hypertensive rats (170). In studies examining endothelial derived contracting factor 
(EDCF), this response is dependent on the endothelium and is mediated through alterations in COX 
metabolism, altered TP receptors, and downstream activation of the Rho-Kinase pathway (31, 47). In 
the current study we demonstrated that the redevelopment of CVR in response to BK, was 
independent of COX. However in the presence of TEMPOL, the redevelopment of tone is greatly 
augmented. In non-precontracted carotid artery rings, ACh mediated contraction was enhanced in the 
presence of TEMPOL (47). It is possible that the enhanced recontractions observed in the current 
investigation represent altered redox based signalling including direct activation of Rho-Kinase or 
through altered extracellular signal-related kinase (ERK) signalling (10, 100, 171). In the coronary 
circulation, activation of ERK by mitochondria-derived H2O2 attenuated the hypoxic induced dilation 
(69) which has been previously attributed to altered GSH:GSSG ratio (190). We speculate that the 
altered redox status associated with CDNB treatment shifts the dilatory effects of H2O2 to constrictor 
effects perhaps by increased ROS production from the mitochondria in part as a result of altered 
intracellular thiols (86, 100, 190). 
One interesting finding regarding CDNB was marked blunting of the BK mediated dilation seen 
in presence of LNAME compared to the CDNB no drug condition at lower BK concentrations (≤0.1 µM). 
This result is surprising given that CDNB has been shown to impair NO production (87, 164). The 
enhanced dilation to the lower BK concentrations in the absence of LNAME (CDNB no drug) accounted 
for the maintained AUC compared to the control group, as the sensitivity in the CDNB no drug was not 
different than CDNB+LNAME. This suggests that at the lower agonist concentrations BK mediated 
dilation, even in the presence of CDNB, is mediated in part by NO. This is supported by the data which 
demonstrate that the BK mediated dilatory profile was similar between the CDNB+LNAME and 
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CON+LNAME until 0.1 µM where the recontraction began in the CDNB. Similar to the effects on CVR it 
appears as though in the presence of CDNB basal NO production was not completely abolished but it 
was likely reduced. It is possible therefore that a portion of the enhanced dilation seen in the absence 
of LNAME (CDNB no drug) could be a result of elevated levels of H2O2 as a result of uncoupled eNOS 
(25, 164), which has been demonstrated to mediate dilation in the coronary circulation (144, 148). 
Thus CDNB likely affects BK mediated dilation through both NO and a non-NO dependent process 
mediating both the enhanced dilation (lower BK concentrations) and recontraction at higher BK 
concentrations. 
 EA is a thiol conjugating agent (150) as such EA has been used to prevent the replenishment of 
NO stores thus acting as a nitrosothiol depleting agent (14, 15). We found that EA had no effect on the 
sensitivity of the smooth muscle to exogenous NO (SNP). It is likely that GSH alkylation and depletion 
associated with EA treatment impairs BK-mediated dilation through a NO/thiol-dependent pathway. A 
previous report utilizing the isolated perfused heart suggested that BK mediated relaxation is 
mediated primarily through the release of NO from NO stores (39). Danser and colleagues (1998) 
demonstrated that dilation to BK is not reduced when BK is administered with a single dose of LNAME 
(acute LNAME treatment) limiting de novo NO production; the dilatory response following prolonged 
LNAME treatment, which reduces NO production and limits the generation of stored NO, was 
attenuated (39). Given that the dilation was reduced following prolonged treatment with LNAME only, 
it was concluded that BK mediated dilation was mediated largely due to NO release from NO stores 
(39). In the current study, we extend these findings by demonstrating directly, through the use of EA 
to inhibit the regeneration of NO stores, that replenishment of RSNO is necessary for a portion of the 
BK mediated dilation in the isolated perfused heart.  
In the presence of EA+LNAME there was only a small reduction in curve characteristics (EC50, 
AUC and max) compared to EA alone whereas the control had greater relative decreases in the 
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response to BK. This suggests that at lower concentrations of BK, there is a greater reliance on RSNO. 
The dilation to GSNO is reduced to a greater extent in large coronary arteries compared to small 
coronary arteries in the presence of EA (153). However, the dilation to BK in isolated porcine coronary 
arteries was not shown to be blunted in the presence of EA, yet in the presence of a specific RSNO 
depleting agent, p-hydroxymercurobenzoic acid (PHMBA) dilation was attenuated (14). This suggests 
that in these arteries, NO production and the existing NO stores were sufficient to prevent a reduction 
in dilation in the presence of EA (14). In the current preparation both large and smaller coronary 
arteries/arterioles contribute to the BK-mediated responses. The current findings indicate that in the 
Langendorff preparation, the BK mediated dilation is mediated through both de novo NO synthesis 
and RSNO/GSNO replenishment and release. The inhibitory effects of EA on BK-mediated dilation are 
possibly being mediated both as a result of altered GSNO release in the larger coronary arteries (15, 
153) coupled with altered GSNO/RSNO availability in the coronary microcirculation in which RSNO can 
act as EDHF (16). Thus, replenishment of NO stores and subsequent release by the endothelial agonist 
BK appears to be of importance for maintaining endothelium-dependent dilation in the isolated 
perfused heart.  
 Contrary to the findings with both CDNB and EA are the apparent preserved endothelium-
dependent responses in the presence of both diamide and BCNU. Given the relationship we found 
between minimal CVR and GSH:GSSG ratio and the non-significant reduction in the change in CVR 
seen with both BCNU and DIAM10, we postulate that the preserved function in the presence of these 
agents may in fact be related to a smaller dilatory capacity, not necessarily preserved endothelial 
mediated function. In the BCNU group maximal BK mediated dilation is 23.6±4.5% when expressed 
relative to the baseline coronary vascular resistance, whereas the control group maximal dilation was 
34.5±1.7% (p<0.05). Therefore, when total dilatory capacity is reduced, even small changes in CVR 
may result in large percentage dilation when expressed as maximal dilation, as the capacity to 
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modulate tone is reduced. As such when the dilation to BK is expressed based on the baseline vascular 
resistance; maximal dilation is blunted in the BCNU group compared to the controls, whereas DIAM10 
is not, likely because the TDC is more preserved (Figure 4.3).  
 Previous studies have suggested that diamide treatment (87, 132) could induce a reduction in 
endothelial derived NO. Furthermore, Wang and colleagues (184) and Sugiyama and Michel (164) 
demonstrated that BCNU resulted in altered eNOS phosphorylation in response to flow or stimulation 
with an endothelial agonist respectively. Adachi and Cohen reported that diamide (0.2 mmol/L and 1 
mmol/L) reduced ACh mediated dilation; and that both diamide and BCNU impaired endothelium 
independent dilation to NO (2).Therefore the apparent preserved endothelium dependent dilation is a 
result of smaller TDC. The reduction in TDC in the presence of DIAM10 and BCNU explains why there is 
no correlation between GSH:GSSG and TDC. Both of these agents resulted in small but non-significant 
reductions in baseline CVR and small but non-significant elevations in minimal CVR which slightly 
attenuated TDC. Conversely, CDNB and EA resulted in greater TDC as a result of primarily an elevated 
baseline CVR.  
 
4.5.4 Thiol modulation alters cardiac contractility 
 In agreement the data which suggest altered tissue perfusion following thiol manipulation we 
found that left ventricular systolic pressure and +dP/dt were significantly correlated with GSH:GSSG 
and heart rate was inversely correlated with this ratio. In the presence of all of the thiol manipulating 
agents we demonstrated that there are altered cardiac hemodynamics including a reduction in LVDP 
and altered ±dP/dt. The altered contractility noted in the current study is likely related to altered 
redox state of the myocytes and altered Ca2+ signalling related to alterations in the nitrosylation and 
modification of the sulphydryl groups of the ryanodine receptor (RyR), L-type Ca2+ channel and 
sarco(endo)plasmic reticulum Ca2+ ATPase (for reviews see (113, 197)). In conditions of oxidized thiols, 
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the RyR mediated Ca2+ release is increased transiently then reduced, whereas L-type Ca2+ channel 
activity and sarcoplasmic reticulum Ca2+ ATPase activities are reduced. This could result in a reduction 
in LVDP and altered Ca2+ cycling (197). Similarly, altered nitrosylation of these channels as well as the 
cardiac pacemaking cells contributes to impaired and attenuated cardiac contractility (113). 
  
4.5.5 Conclusion 
 The primary findings of this study are that coronary vascular resistance and endothelium 
dependent dilation are altered in response to changes in the GSH:GSSG. Thioredoxin inhibition and 
glutathione conjugation increase CVR, whereas glutathione reductase inhibition and thiol oxidation do 
not result in increases in CVR. Similarly the effects of thiol modulation on endothelium-dependent 
dilation in the isolated perfused heart vary in response to the nature of reduced GSH:GSSG. In the 
presence of thioredoxin inhibition, BK-mediated dilation was enhanced at the lower agonist 
concentrations, yet resulted in a recontraction at the higher concentrations which were independent 
of COX derived prostanoids. Conversely, EA resulted in an overall blunting of the BK mediated 
response which was only modestly affected by NOS inhibition, suggesting this alteration is likely 
mediated by the ability to regenerate NO stores. Importantly, across all treatment groups there is an 
inverse relationship between GSH:GSSG and baseline and minimal CVR and suggests that alterations in 
GSH:GSSG may impair tissue perfusion because of an inability to properly modulate vascular tone. In 
summary, acute alterations in the GSH:GSSG ratio play an important role in determining both the 
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5.1 General Discussion 
 The purpose of this collective work was to examine how changes in GSH either chronically or 
acutely alter CVR and endothelium-dependent dilation in the isolated perfused heart. The current 
literature suggests that changes in GSH levels have differential effects depending on the experimental 
model. This is highlighted by discrepancies that exist between endothelial-intact preparations 
compared to endothelial removed preparations as well as the discrepancies seen in cellular 
preparations compared to isolated vascular segments. The individual studies discussed above provide 
novel insight into the role that GSH has within the coronary circulation. Contrary to previous studies, 
chronic GSH depletion resulted in an age-dependent increased reliance on NO, such that only adult 
animals demonstrated an adaptive response, which included an increased eNOS protein content and 
reliance on NO. In the second study it was demonstrated that acutely administering GSH at 
physiological concentrations enhances bradykinin-mediated dilation. The enhancement was 
independent of NO production as GSH-mediated enhancement persisted despite NOS inhibition. The 
presence of LNAME and TEMPOL together abolished the GSH mediated effect suggesting a role for 
reactive oxygen species mediating the effects of GSH administration. Acutely modifying thiols 
demonstrated that endothelium-dependent dilation is altered to different degrees depending on the 
method through which GSH:GSSG was reduced. Additionally, inverse correlations exists between the 
GSH:GSSG ratio and baseline CVR and the GSH:GSSG ratio and minimal CVR. 
These studies have used similar treatments, and endothelial agonists that have been 
previously used in isolated vascular segments in order to specifically examine the intact coronary 
circulation using the Langendorff heart. This has allowed the analysis of the influence of changes in 
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glutathione on vasomotor tone (CVR) and endothelium-dependent dilation. In all studies there was 
consistency between the changes that occurred in CVR and BK-mediated dilation. For example in the 
presence of NOS inhibition, there was both an increase in CVR and an increase in EC50. The similarity 
between CVR and endothelium-dependent dilation is extremely important given the unique role NO 
plays within the coronary circulation (61, 64, 98, 115). The results of these studies demonstrate the 
complexity associated with changes in GSH and the role that GSH plays within the vasculature, as 
substantial differences were seen with the acute and chronic depletion of GSH. Furthermore, the 
ability of GSH to enhance BK-mediated dilation independent of changes in baseline CVR was 
determined to extend beyond the perceived antioxidant properties.  
Within each chapter there is an extensive discussion section which is used to highlight the 
current state of the literature and integrate the unique findings of the chapter. The purpose of this 
overall discussion section is not to provide a repetition of these findings but rather to expand on the 
novel findings by providing additional integrative insight, while reconciling discrepancies that exist 
between the studies and expanding on certain findings where relevant. This discussion will include a 
section of the potential limitations of the current studies, and suggest future directions.  
 
5.2 Contrasting effects of different modes of GSH modulation on coronary vascular 
resistance. 
 Based on the findings from the studies the following conclusions can be drawn with respect to 
the effect of thiol modulations on baseline coronary vascular resistance: acutely depleting GSH with 
EA or CNDB resulted in an elevated CVR whereas BCNU and diamide did not, chronic depletion of GSH 
did not alter baseline CVR, and acute GSH administration at concentrations greater than 30 µM was 
able to reduce baseline CVR.  
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In agreement with reports utilizing isolated endothelium-removed coronary segments (79, 
88), and endothelium intact aortic ring preparations (2), acute thiol oxidation with BCNU and diamide 
can induce a reduction in CVR. This reduction appears to be dependent on increases in GSSG as 
demonstrated in the presence of BCNU but not diamide. Similarly, aging is also associated with a 
reduction in baseline CVR, which does not appear to be mediated by altered NO production or as the 
result of increased concentration of GSSG. Conversely, the effects observed with CDNB and EA suggest 
that reductions in the bioavailability of NO, likely mediated by altered production of NO or altered 
RSNO bioavailability, result in increases in CVR. This suggests that RSNO are an important determinant 
of baseline CVR. Given the apparent adaptive response seen in the presence of BSO treatment, no 
increases in baseline CVR were observed despite increased ROS production. In the presence of chronic 
GSH depletion it is apparent that a compensatory mechanism is in place to prevent reduced NO 
bioavailability. Conversely GSH at physiologically relevant concentrations does not itself influence 
baseline CVR, albeit it does blunt the effects of LNAME suggesting that GSH can itself induce a dilatory 
effect (also observed at concentrations >30 µM). Therefore, it can be concluded that the mechanism 
by which GSH, GSSG and GSH:GSSG ratio is altered must be identified in order to understand how 
changes will influence baseline coronary vascular resistance.  
 
5.2.1 Relationship between GSH, GSSG and GSH:GSSG ratio on coronary vascular resistance – a cross 
study comparison. 
Collectively, these studies demonstrate that acute thiol manipulation has a greater effect on 
baseline coronary vascular resistance than chronic alteration. This likely reflects the compensatory 
mechanisms associated with the chronic nature of the BSO treatment including increased ROS 
production and greater reliance on NO. The ability of acute changes in GSH to modulate baseline CVR 
is demonstrated by the ability of GSH at concentrations greater than 30 µM to reduce baseline CVR. 
When GSH is acutely depleted increases in CVR can be observed as demonstrated by the profound 
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increases seen with CDNB and EA; conversely BCNU and diamide moderately reduced baseline CVR. 
The ability to assess how acute and chronic changes in GSH and GSSG can influence CVR can be 
examined as the different agents designed to induce thiol depletion had a differential effect on 
baseline CVR. Similarly, as rats of different ages were used across the 3 studies, the natural effects of 
aging on GSH and GSSG can be examined. Not surprisingly, given the ability of changes in GSH and 
GSSG to augment CVR, we found that as rats age there was a progressive decline in CVR and this was 
associated with an increases in GSH and GSSG content (Figure 5.1A and B). By compiling the baseline 
CVR data across the three studies and including the data regarding the differences in age and GSH and 
GSSG content, there was a significant correlation between all thiol measures and baseline CVR (GSH vs 
CVR: r = -0.71, p<0.01, GSSG vs CVR: r = -0.71, p<0.01 and GSH:GSSG vs CVR r=-0.29, p<0.05, n=58, 
Figure 5.1 C and D). Interestingly, there was a gradual increase in the GSH and GSSG content, despite a 
reduction in GSH:GSSG ratio from 10 weeks to 35 weeks. This altered GSH:GSSG was recovered at 65 
weeks of age likely as a result of the decrease in GSSG observed in this age group. The reduced 
association between GSH:GSSG and CVR likely reflects the age-dependent changes that occur in GSH 
and GSSG. The current data demonstrates that the youngest animals had lowest GSH and GSSG values, 
yet the GSH:GSSG ratio was the highest (Figure 5.1B). GSH and GSSG content and the ratio have been 
reported to be reduced in the left ventricle with age (82-84, 112). Within the aorta, Smith and 
colleagues demonstrated a marked reduction in GSH as well as GSSG in aged rats compared to young 
rats (157). In the heart, several reports have also demonstrated that aging results in a progressive 
decline in GSH content (82, 91, 183). However, a recent report also suggested that there are no 
changes in GSH content with aging in the heart, yet, there is a small increase in GSSG content and 
reduced GSH:GSSG ratio in the oldest group, 26 months compared to the youngest group 4 months 
(140). In agreement with the current data, Leichtweis and colleagues (2001) found that old rats (24 
months) compared to young rats (6 months) had higher GSH, GSSG and similar GSH:GSSG values (109). 
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The current results demonstrate that myocardial GSH and GSSG increase with age, and that aging is 
associated with a reduction in the GSH:GSSG ratio, which is partially recovered at 65 weeks as a result 
of a reduction in the GSSG concentration. The rebound of GSH:GSSG may be in part related to the age 
associated increase in GPx and glutathione reductase activity (44, 109, 112, 142). The increased 
activity of GPx and GR may be a compensatory mechanism that is used in an attempt to maintain an 
adequate level of GSH and GSSG and to help scavenge free radicals and maintain redox balance (109, 
112, 162). 
Because of the chronic nature of BSO treatment these rats were excluded from the analysis as 
compensatory mechanisms likely prevented differences in CVR to be observed in both the adult and 
older BSO treated animals. In the presence of the BSO treated animals correlations between GSH and 
GSSG remained significant albeit they were blunted (GSH vs CVR: r= -0.37, p<0.01, GSSG vs CVR: r=-
0.43, p<0.01 and GSH:GSSG vs CVR r=-0.13, p>0.05, n=69). Therefore, these findings demonstrate 
acute alterations in GSH and GSSG and alterations in GSH and GSSG associated with age are strongly 
inversely correlated with baseline CVR and suggest that the lower these values, the higher the 






Figure 5.1. Relationship between glutathione levels and baseline coronary vascular resistance 
Summary of CVR from all groups excluding BSO treated animals, for clarity the control animals from 
chapters 2 and 3 were collapsed (A). Summary of changes in left ventricle GSH, GSSG and GSH:GSSG 
ratio across study ages (B). There was a significant inverse correlation seen between GSH and CVR (C) 
and GSSG and CVR (D). Data was compiled from all experimental groups from each specific study, with 
the exception of BSO treated animals (both adult and older animals, for details refer to text). Thus this 
graph demonstrates primarily the effects of aging and acute thiol modulation on baseline coronary 






































































































































































r = -0.71, p<0.01 r = -0.71, p<0.01
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5.2.2 Potential mechanisms responsible for altered CVR with thiol manipulation. 
Given the ability of GSH to reduce ROS it could be postulated that in conditions where GSH is 
reduced an increase in ROS mediated NO destruction could account for alterations in baseline CVR. A 
reduction in NO bioavailability as a result of increased ROS was originally postulated to account for the 
increase in CVR in the presence of the acute depletion elicited by thioredoxin inhibition (164, 194),  
glutathione conjugation (49) and BSO treatment (13, 63). Contrary to the findings of chronic thiol 
depletion, acute thiol modulation resulted in a modest increase in ROS in the presence of CDNB, and 
no difference was observed with EA. Further support for a lack of ROS mediated NO destruction is 
demonstrated by the lack of effect that the addition of TEMPOL to the perfusate had on baseline CVR 
in the presence of CDNB or EA (ie CDNB+TEMPOL and EA+TEMPOL compared to CON+TEMPOL, 
chapter 4). Additionally, the other agents utilized, BCNU and diamide (10 µM) also only moderately 
increased ROS, and did not affect baseline CVR. Conversely acute GSH administration was 
demonstrated to reduce basal CVR provided a sufficient extracellular GSH was provided (≥ 30 µM). 
These results indicate that alterations in GSH do result in an increased ROS, and therefore, altered NO 
bioavailability as a result of increased ROS cannot completely explain the alterations in CVR observed. 
Thus it appears that the baseline CVR in response to thiol depletion was not influenced by an overall 
ROS mediated NO destruction.  
Changes in intracellular thiols have been reported to augment NO production (see above); 
therefore, in order to understand the role for NO and how the thiol manipulations influence CVR, 
LNAME was employed to inhibit NO production. NOS inhibition resulted in an increase in CVR in all 
conditions of GSH manipulation, but the increase in CVR varied depending on the experimental 
conditions. Unexpectedly, in the BSO treated animals (adult only) there was an increased reliance on 
NO as suggested by the effects of LNAME on baseline CVR. Concurrent with the effect on CVR was the 
increased eNOS protein content. It is therefore hypothesized that in this model which showed 
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substantial effects on ROS production that the preserved CVR is likely related to the increased NO 
production. This compensatory increase in NO likely accounts for the increased NO-mediated 
destruction by O2∙-. Indeed, in BSO treated animals despite the often reported increase in eNOS 
protein content (13, 63, 90, 195), there is often an increased amount of tissue nitrosylation, indicative 
of elevated levels of peroxynitrite (13, 181, 181, 196). Thus, it is postulated that the lack of effect on 
CVR in the BSO treated animals is a result of increased NO production, accounting for the increased 
NO loss as a result of ROS. 
 Contrary to this are the responses to CDNB and EA, which did not result in a large 
compensatory increase in NO production. The effects of LNAME on CVR that were observed in the 
presence of CDNB and EA were much less than the control group suggesting that overall these agents 
impaired basal NO bioavailability by a mechanism that appears to be unrelated to ROS. Thioredoxin 
function may be important for availability of eNOS cofactors and eNOS activation (87, 164). It is 
therefore, postulated that there is likely a loss in basal NO production in the presence of CDNB. This is 
likely the case as treatment with LNAME resulted in a small increase in CVR in the presence of CDNB 
and suggests that there is not a complete loss in basal NO production, yet it is substantially reduced. 
The increase in CVR in the isolated perfused heart in the presence of EA is postulated to be a 
result of reduced GSNO and/or RSNO replenishment, suggesting that GSNO or RSNO is an important 
source of NO for maintaining baseline CVR. Support for the requirement of RSNO/GSNO is based on 
the data which demonstrate that while EA does not alter endothelium-dependent dilation (14); EA 
prevents the dilation to repeated light exposure (photorelaxation)(15), a condition solely mediated by 
RSNO/GSNO. Therefore, during the 30 minute stabilization period in the presence of EA, shear 
mediated NO production is available, yet the ability of NO stores to be replenished is reduced. Given 
that shear induced release of both RNSO and NO can occur (15, 174), the current results suggest that 
RSNO are constantly being depleted and replenished under normal conditions, and the increase in 
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CVR in the presence of EA represents the inability of RSNO to be regenerated and released. The 
increase in CVR in the EA condition in the presence of LNAME likely reflects a reduction in a portion of 
de novo NO synthesis, coupled with a gradual depletion of NO stores. In the presence of EA and 
LNAME, a mild increase in CVR is observed suggesting that eNOS-derived NO is still able to partially 
control baseline CVR, albeit not to the same extent as GSNO. It could be postulated that the lack of 
similarity achieved in the presence of EA+LNAME and the control+LNAME may represent a 
compensatory mechanism of dilation by the coronary microcirculation in the presence of EA or the 
fact that RSNO are more important in the responses of larger coronary vessels (153).  
 One final explanation of the altered baseline CVR is unrelated to ROS and nitric oxide and 
reflects the ability of changes in intracellular glutathione to impact vasomotor tone and coronary 
vasoconstriction through the ability to modulate Ca2+ release and K+ channels (190). Thus it is possible 
that alterations in GSH and GSSG have an endothelium-independent affects on baseline CVR and 
suggests that alterations in GSH concentration influence vascular smooth muscle contractile state. A 
surprising finding was the effect of aging on CVR. Contrary to the original hypothesis of an elevated 
CVR with age, a clear reduction was observed. As already discussed several potential mechanisms 
have been postulated including altered myogenic tone as a result of increased NO production (154), 
and altered K+ channel contribution (94). While these are likely mechanisms, another potential 
mechanism related to altered thiol status may explain the reduction in CVR seen with age and the 
small changes seen in the presence of BCNU and diamide as these agents typically promote oxidation. 
Thiol oxidation is reported to limit the amount of vascular constriction as demonstrated by a series of 
studies from Wolin’s laboratory in denuded coronary vasculature (79, 80, 88). Similarly in endothelial 
intact aortic rings thiol oxidation resulted in an increased agonist concentration, required to elicit 
~70% vasoconstriction (2). The results with BCNU, diamide and aging demonstrate that thiol oxidation 
resulted in either an impaired ability to generate tone, or sufficient oxidation which failed to affect 
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CVR (ie 1 vs 10 µM diamide). There were no age-dependent increases in the thiol content of LV in the 
older compared to the adult animals (Figure 5.1B). However, we cannot exclude this as a potential 
mechanism as the vascular tissue (whole aortic homogenate) did demonstrate an age-dependent 
increase in GSSG (adult and older controls only: 0.2430±0.0019 vs 0.0352±0.0035 nmol/mg wet 
weight, p<0.05). Similarly, Ferrini and colleagues demonstrated an age-dependent increase in GSSG in 
the aorta (62). Therefore, it could be postulated that with aging altered levels of GSSG may contribute 
to impairment in the development of CVR.  
 Unlike the age-dependent reduction in CVR which is postulated to be in part as a result of 
increased vascular GSSG, the two thiol modulating agents designed to shift the GSH:GSSG ratio 
towards a more oxidized state (increased GSSG) failed to significantly affect baseline CVR. Both BCNU 
and diamide (10 µM) were without effect on CVR, despite a decrease in GSH:GSSG ratio. Higher 
concentrations of diamide are typically used in studies examining the effects of this agent on vascular 
function (2, 88). However, in the current preparation increasing the concentration of diamide to 100 
µM resulted in a substantial drop in CVR which would have significantly limited TDC (Appendix Figure 
A7). In the BCNU animals, there was a small but non-significant increase in GSSG compared to the 
control group. Yet, compared to all other thiol manipulating agents used, BCNU resulted in a 
significant increase in GSSG. This small increase in GSSG may explain the small but non-significant 
decrease seen in CVR. This suggests that relatively small increases in GSSG in endothelial-intact 
preparations also promote a dilatory state. In light of the significant correlation between GSSG and 
CVR it is not surprising that small increases in GSSG impact CVR in the isolated perfused heart. 
 The results of the current studies suggest alterations in GSH, GSSG and GSH:GSSG ratio may 
augment basal NO production as is the case for CDNB. Additionally it has been demonstrated that 
alterations in the ability and availability of GSNO and RSNO, which are reduced with EA, to be 
regenerated play a key role in determining baseline CVR and this appears to be relatively independent 
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of NO production. Conversely, general thiol oxidation (dimaide, BCNU and aging) may impact baseline 
CVR through mechanisms unrelated to NO production per se as the effects that these 
conditions/treatments have on baseline CVR may be related to altered vascular smooth muscle 
contractile properties (Figure 5.2).   
 
Figure 5.2. Contrasting effects of thiol modulating agents and aging on coronary vascular resistance 
The primary determinants of CVR based on the current work are NO, RSNO, ROS and elevated GSSG. 
Each agent altered 1 or more pathways which resulted in augmented CVR. Notably, BCNU and aging 
resulted in an increase in GSSG which reduced CVR. Conversely, CDNB and EA reduced NO and RSNO 
respectively which resulted in an elevated CVR. BSO had a 2 different effects as it both increased ROS, 
which alone should cause an increase in CVR, however there was also increased NO production as a 
result of increased eNOS protein content. The affect of high concentration of GSH which are able to 




5.3 Contrasting effects of GSH modulation on endothelium-dependent dilation 
Individually each of the studies adds to the literature by demonstrating: a compensatory age-
dependent increased reliance on NO in the presence of chronic thiol depletion (chapter 2), 
mechanistic insights into the action of GSH administration on endothelium-dependent dilation 
(chapter 3),  and that different thiol manipulating agents have a varying impact on endothelium-
dependent dilation depending on the mechanism of action and there is a relationship between 
minimal CVR and GSH:GSSG status (chapter 4). Collectively this work highlights the complex nature of 
the interaction between GSH and vasomotor function. Given the recent evidence suggesting a link 
between GSH:GSSG and cardiovascular risk (12, 114), and the beneficial effects of GSH infusion on 
coronary artery dilation (103, 104) these studies provide insight into the potential mechanisms of 
altered GSH, GSSG and GSH:GSSG leading to impaired and improved vasomotor function. 
 Much of the preceding discussion regarding the mechanism of thiol depletion can be restated 
in this section as similar endothelium-dependent responses (typically EC50) were observed compared 
to the effects the different agents had on CVR (Table 5.1). This is not surprising given the effects that 
the endothelial-derived NO has on coronary vascular resistance (61, 71, 110, 115). The following broad 
conclusions can be made regarding the effects of altered thiols on endothelium-dependent dilation: 1) 
administration of GSH at physiological levels is sufficient to enhance endothelium-dependent dilation; 
2) acute thiol depletion through the inhibition of thioredoxin or glutathione conjugation appears to 
augment endothelium-dependent dilation as observed by altered BK-meditated dilation; 3) inhibition 
of glutathione reductase and aging affected BK mediated dilation through a process of altered minimal 
and baseline CVR and therefore altered dilatory capacity. Regardless of the mechanism of thiol 
depletion, previous studies using acute depletion in either isolated endothelial cells (87, 164, 184), 
isolated intact vascular rings (2) or chronic depletion (13, 107) results in augmented NO production 
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and/or impaired dilation. However, the results of the current study provide additional information 
regarding endothelium-dependent dilation and minimal CVR. 
 
 
Table 5.1 Summary of changes in coronary vascular resistance and bradykinin mediated dilation 
across studies. 
 Aging GSH 
(10µM) 
BSO  10 week 
 10 weeks 37.5 weeks 65 
weeks 
 Adult Older  CDNB EA BCNU DIAM 
CVR            
Baseline ↑ REF ↓ ↔ ↔ ↓  ↑↑ ↑ ↔/↓ ↔/↓ 
Minimal  ↑ REF ↓ ↔ ↔ ↓  ↑↑ ↑ ↔/↑ ↔/↑ 
TDC ↑ REF ↓ ↔ ↔ ↓↓  ↑ ↑ ↓ ↓ 
            
Dilation            
EC50 ↑ REF ↓ ↑ ↔ ↔  ↑ ↓ ↔ ↔ 
AUC ↑ REF ↓ ↑ ↔ ↔  ↑ ↓ ↔ ↔ 
Max ↔/↑ REF ↓ ↔ ↔ ↔  ↓↓ ↓ ↔ ↔ 
 
Relative changes in curve characteristics, CVR and TDC (total dilatory capacity) in the absence of other 
pharmacological agents (no drug conditions). The 37.5 group was used as reference (REF) for all 
comparisons across age, GSH, and BSO. The 10 week controls were used as a reference for CDNB, EA 
BCNU and Diamide. ↑, increase; ↑↑, substantial increase; ↓, decrease; ↓↓, substantial decrease; 





5.3.1 Relationship between GSH and GSSG on minimal coronary vascular resistance, total dilatory 
capacity and endothelium-dependent responses 
Cross study analysis revealed a significant inverse correlations between: minimal CVR and GSH 
(r = -0.81, p<0.01), minimal CVR and GSSG (r= -0.78, p<0.01) but not minimal CVR and GSH:GSSG (r = 
0.20, p=0.10, Figure 5.3). Additionally, no relationships between GSH, GSSG or GSH:GSSG and total 
dilatory capacity were observed. This is a result of enhanced TDC seen with CDNB, and EA despite 
lower thiols levels whereas BCNU and aging were associated with reduced TDC despite opposing 
effects on thiol content.   
In order to assess if there were significant relationships between GSH, GSSG, or the GSH:GSSG 
and endothelium dependent responses across studies, both the 1 and 10 µM GSH groups as well as 
the adult and older BSO groups were excluded. There was a small but significant correlation between 
GSH and EC50 (r = 0.36, p<0.05, n=43) and GSH was inversely correlated with AUC (r = -0.30, p=0.05, 
n=43). Similarly the GSSG was significantly correlated with both EC50 (r= 0.35, p<0.05, n=43) and 
inversely correlated with AUC (r = -0.38, p< 0.05, n=43). These results must be interpreted with 
caution as the low GSH and GSSG values associated with CDNB and the enhanced EC50 and AUC 
associated with these results skew this data; without these values all the correlations become non-
significant with the exception of the GSSG with AUC (r = -0.34, p<0.05). The lack of association 
between BK-mediated dilation and thiol content is in agreement with a recent report demonstrating 
no relationship between GSH:GSSG and flow mediated dilation in an apparent healthy population (11). 
Thus while GSH and GSSG are inversely correlated with minimal CVR, the results of the current series 
of experiments suggest that there is no correlation between either GSH or GSSG and the bradykinin 
curve parameters. Thus while, modulation of GSH content does affect endothelium-dependent 





Figure 5.3. Relationship between glutathione levels and minimal coronary vascular resistance 
Summary of minimal CVR from all groups excluding BSO treated animals, for clarity the control 
animals from chapters 2 and 3 were collapsed (A). Summary of changes in left ventricle GSH, GSSG and 
GSH:GSSG ratio across study ages (B). There was a significant inverse correlation seen between GSH 
and minimal CVR (C) and GSSG and CVR (D). Data was compiled from all experimental groups from 
each specific study, with the exception of BSO treated animals (both adult and older animals, for 
details refer to text). Thus this graph demonstrates primarily the effects of aging and acute thiol 
modulation on baseline coronary vascular resistance (n = 71 for correlation analysis). *, p<0.05 vs 10 


















































































































































r = -0.81, p<0.01 r = -0.78, p<0.01
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In the current series of experiments, similar dilatory responses to endothelium-dependent 
dilation were observed in the old animals (chapter 2) and BCNU treated hearts (chapter 4). In both 
groups there was a reduction in TDC. This suggests that changes in GSSG concentration may not impair 
BK-mediated dilation when expressed as percentage of maximal endothelium-independent dilation as 
was the case with BCNU and aging. However, increases in GSSG such as those caused by aging 
(elevated thoracic aorta GSSG content) or BCNU (left ventricle) appear to blunt the total capacity to 
dilate. Therefore, when expressed as maximal dilation, potential differences are minimized as the total 
capacity to augment tone is reduced (Table 5.1, Figure 5.4).  When dilation is expressed relative to 
baseline CVR both aging (chapter 2) and BCNU (chapter 4) were shown to have blunted BK mediated 
dilation. 
 
Figure 5.4. Effects of aging and thiol manipulation on baseline resistance and total dilatory capacity. 
For each condition, the dashed line represents the baseline vascular tone, the closer the lines the 
smaller the radius, the greater the baseline CVR. The solid lines represent the minimal CVR and the 
dotted lines are a continuation of the control condition. Aging results in a reduced TDC as a result of a 
reduction in baseline CVR, similarly BCNU results in a small reduction in baseline CVR and small 
increase in minimal CVR, net loss of TDC. Conversely, TDC is increased with CDNB and EA, yet there is a 
substantial increase in minimal CVR. 
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 As discussed above, the compensatory increase in eNOS protein content observed in the adult 
BSO-treated animals was associated with an exaggerated increase in CVR in the presence of LNAME; a 
similar effect was observed in endothelium-dependent dilation. The sensitivity (baseline in vivo flow 
rate) and maximal dilation (high flow) were reduced in the adult BSO animals to a greater extent than 
all other groups. Unlike previous studies (eg. (13, 107)) in which endothelium-dependent dilation was 
reduced, there was no effect of BSO on endothelium-dependent responses in the absence of LNAME. 
That being said, they were not enhanced compared to the control group as recently reported (90). As 
with CVR, the compensatory increase in eNOS likely normalized total NO produced to account for the 
increased ROS mediated NO destruction. This explains the lack of effect on BK-dilation in the absence 
of LNAME. 
Conversely, acute treatment with both CDNB and EA resulted in marked impairment of the 
BK-mediated response despite a greater minimal CVR and greater TDC. Overall, it appears that 
alterations in GSH:GSSG ratio impacts dilatory capacity and minimal CVR which may have implications 
for adequate perfusion of the myocardium (54, 176, 185). Indeed, both CDNB and EA resulted in 
increased minimal CVR in response to adenosine. Therefore, when the dilatory responses to these 
agents are examined, there is an underestimate of the impairment as the data was expressed relative 
to the adenosine, which is elevated compared to the control group. Interestingly, the ability of the 
coronary circulation to dilate to NO was not altered in the presence of either of these agents as 
demonstrated by the normal SNP responses, albeit this dilation was also normalized to the minimal 
CVR which was elevated. This is an important finding, and suggests that any impairment in BK 
mediated dilation is not a result of an impaired ability of the vascular smooth muscle to respond to 
NO. As discussed in chapter 4 alterations in NO production and the ability of GSNO to regenerate and 




 Acute GSH administration enhanced endothelium-dependent dilation in the isolated heart 
without altering GSH, GSSG or the GSH:GSSG ratio. Similar to in vivo studies where the effects were 
more pronounced in individuals with existing dysfunction (103, 104, 138) the results with TEMPOL and 
LNAME+TEMPOL suggest that GSH administration exerts effects aside from the antioxidant dependent 
effects (103). These beneficial effects were only apparent in the presence of ROS. Preliminary data 
examining the effects of GSH administration in isolated perfused hearts suggests that normotensive 
Wistar Kyoto (WKY) rats were more responsive than the spontaneously hypertensive rats (SHR) to GSH 
(Appendix Figure A9). This finding is unique as previous in vivo work using the same hypertensive 
model in which GSH infusion lowered the mean arterial pressure of the SHR not the WKY (5).  
The current series of studies demonstrate that alterations in GSH, GSSG and GSH:GSSG ratio 
differentially effect endothelial-dependent dilation in the isolated perfused heart. Through the 
utilization of several different pharmacological agents specific conclusions can be drawn with respect 
to the interaction between GSH:GSSG and GSH itself (Figure 5.5). GSH possesses an antioxidant effect; 
as such when co-administered with an endothelial agonist, there is an increased sensitivity to 
endothelium-dependent dilation. The effects extend beyond a simple antioxidant effect as despite 
inhibition of NOS and/or sGC enhanced sensitivity to BK remained, yet there is an abolishment of the 
GSH effect which is apparent in the presence of TEMPOL and LNAME. Conversely, treatment with a 
GSH alkylating agent suggests that a portion of the BK-mediated response seen in the isolated 
perfused heart is through the release and replenishment of RSNO. This finding elaborates on previous 
work from the isolated perfused heart model (39) while suggesting that BK-mediated dilation in the 
isolated perfused heart may differ from isolated coronary vessels (14). It appears that CDNB resulted 
in biphasic response with dilation seen at concentrations ≤1 nM followed by recontraction at higher 
concentrations of BK (≥0.1 µM). Conversely, prolonged GSH depletion resulted in enhanced reliance 
on NO for endothelium dependent dilation; however this was restricted to adult rats. This likely 
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represents a compensatory mechanism to preserve vasomotor function within the coronary 
circulation. Conversely, in conditions where total dilatory capacity is reduced there is often a 
‘preserved’ endothelium-dependent response, albeit this preserved function is not indicative of the 






Figure 5.5. Complex interaction of thiol modulation on endothelium-dependent dilation 
Depending on the nature of thiol depletion or acute GSH infusion, several potential pathways interact 
when determining the effects on BK mediated dilation. BSO results in a compensatory increased 
reliance on NO as a result of increased eNOS protein content as a compensatory mechanism for the 
increased ROS. CDNB likely results in eNOS uncoupling resulting in superoxide formation which is 
converted to H2O2 by either SOD or Tempol (TEMP) which causes vasoconstriction in the presence of 
the altered redox environment. EA prevents the replenishment of the NO stores by conjugating free 
GSH. These stores are released by BK stimulation through an unidentified pathway. Acute treatment 
with GSH enhanced BK mediated dilation through a pathway requiring ROS. It is possible that this may 
be due to increased GSNO stores which may require the interaction between NO and superoxide. For 




5.4 Future directions and limitations 
5.4.1 Limitations 
The previous discussion and synthesis of results highlights the consistency of the data both 
within the individual studies and across the chapters. This is best demonstrated when the effects of 
LNAME on CVR and endothelium-dependent dilation are examined, as in the presence of LNAME 
larger increases in CVR were always accompanied by larger decreases in BK mediated dilation. The 
focus of this work was on vasomotor function; however, for all three studies, the left ventricle was 
used to measure GSH:GSSG as well as the different ROS measures. This was done as the yield of 
vascular tissue from a single heart would not have been sufficient to run the different assays. The LV 
was chosen to make these measures to avoid pooling of sample and provide adequate amount of 
tissue/sample. One caveat that may still exist is highlighted from the BSO study and suggests that the 
vasculature may be better able to preserve GSH content compared to the ventricle. Given that GSH, 
GSSG and GSH:GSSG were correlated with several measures of ventricular function it is likely that 
similar changes in vascular GSH occurred. The ability of the vascular wall to preserve GSH content may 
warrant further investigation. 
Another potential discrepancy that should be noted is the differences in the age cohorts used 
across the current studies. Animals used in chapters 2 and 3 are representative of adult animals, 
whereas the animals used in chapter 4 were younger adults. This discrepancy was a result of 
availability of animals at the onset of each study. As demonstrated in chapter 2, there is an effect of 
aging on CVR and endothelium-dependent dilation in the isolated perfused heart. There is an 
interesting finding which further extends the overall conclusions regarding changes in glutathione 
content and endothelial function. When the control animals are compared across studies, there is a 
reduction in GSH:GSSG from chronic thiol depletion (chapter 2, 11.68±1.16) compared to the acute 
GSH supplementation study (chapter 3, 9.60±0.33) and from the acute depletion study (chapter 4, 
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16.01±1.54). The age and GSH dependent effects have been discussed and summarized above. When 
the sensitivity to BK is also examined, there is a similar trend seen such that the youngest animals had 
the lowest EC50 (-8.42±0.08 LogM) compared to the 37.5 week old animals (-8.06±0.04 Log M) and the 
65 week old animals (-8.20±0.15 Log M). Taken together, despite the apparent age discrepancy across 
the studies, this allowed the unique finding that GSH,GSSG and the GSH:GSSG ratio may influence 
sensitivity to endothelium-dependent dilation in an age-dependent manner. This conclusion may help 
to explain the reduced dilation to NO and H2O2 seen in aging (95), possibly as a function of altered 
GSH:GSSG ratio and therefore redox signalling (163, 173). Furthermore, despite the age-effects seen in 
chapter 2 it could be postulated that the age-dependent effects observed are not as robust as they 
could be had younger rats been utilized instead of the adult rats. Despite this limitation the array of 
ages used in the current studies allowed for the comprehensive analysis provided throughout this 
discussion, and allowed certain age-dependent observations to be made. 
The Langendorff apparatus also provides a potential for limitation as the specific effects of the 
agents across the entire vascular network is assessed. Thus changes that occur within the coronary 
microcirculation cannot be distinguished from changes that occur in the larger coronary arteries or 
arterioles (115, 153, 168, 176). For example Szekeres found that NOS inhibition was more effective in 
the arterioles compared to the arteries (168), this could explain the inability of LNAME to significantly 
impair maximal dilation to BK as other vascular segments could be dilating to a greater extent to 
compensate for the effect of NOS inhibition in the arterioles. Additionally Sellke and colleagues (1991) 
demonstrated that larger coronary microvessels were sensitive to EA whereas smaller coronary 
microvessels were not (153). It could be postulated that the responsiveness of certain branch orders 
of the coronary circulation in the current preparation were more or less responsive to the different 
manipulations used. The inhomogeneity in responsiveness in the coronary circulation could make the 
results difficult to interpret, given the multiple and redundant pathways that exist (115, 176). 
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However the advantage of the isolated perfused heart is in fact the ability to assess changes across the 
entire vascular bed as would occur in vivo. While this technique may lack precise mechanistic insights 
into a specific portion of the coronary vascular network, it provides great detail on the global 
responses of the coronary circulation. These results provide an integrative description of how changes 
in GSH and/or GSSG alter total coronary vascular resistance and endothelial function.  
 
5.4.2 Future directions 
The results obtained in the presence of thioredoxin (TRx) inhibition are intriguing as altered 
TRx may be responsible for several different cardiovascular diseases (86, 191) including hypertension 
(55). Most of the focus on endothelium-derived contracting factors has suggested a role for H2O2-
mediated alterations in prostacylin/IP receptor pathway and dysfunction (48, 73, 75, 169). In the 
current experiments, work with selective COX inhibitors did not abolish the recontraction seen in the 
presence of CDNB. However, using the SOD mimetic TEMPOL, which is believed to increase H2O2 (188), 
it was demonstrated that the recontraction was enhanced. This suggests that the recontraction was 
independent of the COX pathway and enhanced by H2O2. More rigorous experiments are required to 
determine if these effects are specific to H2O2 as the results presented here are speculative.  
Additionally, downstream targets involved in the H2O2 pathway need to be investigated including the 
ERK pathway and Rho Kinase as both appear to be involved in ROS mediated coronary artery 
constriction (69). Therefore, future work should examine if the presence of catalase and selective Rho 
Kinase inhibitor Y27632 can attenuate the recontraction seen with CDNB. Changes in TRx are observed 
in the heart and aorta of hypertensive rats (170). Additionally there are several pathophysiological 
pathways of hypertension that TRx influences (55), and TRx-2 overexpression (mitochondrial specific) 
can be used to prevent angiotensin II mediated hypertension (187). Taken together TRx appears to be 
a key regulator of vasomotor function. The current study outlines a marked dysfunction in the intact 
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coronary circulation. Future work needs to clarify the pathway leading to this dysfunction as well as 
how changes in TRx may influence vasomotor dysfunction in cardiovascular disease states. Potential 
experiments that would provide further insight into this include examining the effects of CDNB on the 
vasomotor responses in the hearts from SHR and WKY animals. 
In the study of chronic GSH depletion there was an increased eNOS protein content which was 
attributed to elevated H2O2 (53, 195). H2O2 causes upregulation of arginase activity (172), which has 
been shown to be partially responsible for the age-mediated reduction in endothelial function (20, 43, 
186). Therefore, if arginase is increased the reduction in L-arginine would result in eNOS uncoupling 
and greater ROS production. The increase in eNOS activity and reliance on NO in the BSO treated 
animals may in fact be deleterious long term. Despite the increase in catalase expression, H2O2 
production was still elevated likely because of altered GSH content. Thus, the initial increase in eNOS 
may represent a early adaptive response that has deleterious consequences long-term as reductions 
in eNOS cofactors contribute to endothelial dysfunction through uncoupling of eNOS and increased 
ROS production (173). Thus, the effects of longer term BSO treatment on coronary artery endothelial 
function needs to be addressed to determine whether this is a transient effect. Increased reliance on 
NO has been reported to occur in isolated perfused hearts in hypertension (96, 97); however, as 
disease progresses, reductions in endothelial function are observed (17). Thus, the long-term effects 
of GSH depletion on the coronary circulation need to be addressed. 
Another potential line of investigation would be an analysis of the age-dependent changes 
that occur in GSH:GSSG and how these changes influence endothelium-dependent dilation in the 
coronary circulation. As discussed above differences were observed in the GSH:GSSG ratio across the 
different studies, and it appears these changes are associated with altered sensitivity to endothelium-
dependent dilation, as well as total dilatory capacity. This would add greater insight into the age 
dependent changes that occur in healthy human aging (11, 114). Included in this could be an 
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examination of how changes in GSH:GSSG contribute to the altered dilatory pattern seen with aging 
(95) with a specific focus on the H2O2 dependent component. 
In the acute GSH administration study, there appears to be a ROS-dependent component that 
is required for GSH to exert its effects. Future studies could utilize ROS generating pathways 
(xanthine/xanthine oxidase, or direct H2O2 administration) to further examine these effects. Similarly a 
chronic model of oxidative stress could be employed by using SHR and WKY rats, although the 10 µM 
concentration utilized in this study may attenuate the baseline CVR in the WKY not the SHR (Figure 
A9). It was postulated that a potential effect was a result of the thiolation of SERCA or through a non-
NO non-prostanoid-dependent pathway. Interestingly, both could require the formation of RSNO. 
Given the effects observed with the GSH alkylating agent EA which putatively prevents the de novo 
synthesis of RSNO, it would be interesting to examine if EA augments the GSH dependent effect or 
conversely if GSH infusion can augment the EA effect. 
The influence of GSH infusion on the ability to blunt coronary constriction was not examined. 
Given that GSH attenuates endothelium-dependent contraction in humans with spastic angina (103), 
the effects of GSH infusion on agonist mediated vasoconstriction would also be warranted. This would 
allow further assessment of the ROS requiring effects of GSH to be examined on a non-dilatory 




6.0 Summary and conclusions 
The results of the present studies provide novel mechanistic insights into the interaction 
between GSH, GSSG, and the GSH:GSSG on the intact coronary vascular bed. It was demonstrated that 
aging and thiol depletion differentially impact coronary vascular resistance and endothelial-dependent 
dilation. Aging is associated with a reduced ability to generate spontaneous vascular tone, and as a 
result, total dilatory capacity is reduced. This does not appear due to an alteration in NO production as 
when these hearts are exposed to flow rates designed to mimic in vivo flow rates LNAME induced a 
similar degree of elevated CVR in the adult and old animals. Conversely, thiol depletion resulted in an 
age-dependent increased reliance on NO. This was demonstrated by the enhanced constriction 
(increased CVR) and greater impairment in BK-mediated dilation compare to all other groups. 
Additionally, it was determined that H2O2 does not appear to modulate the preserved vasomotor 
function with BSO treatment that has been recently reported (90). Unlike the conduit vasculature (13) 
the coronary circulation differentially adapts to chronic thiol depletion by increasing reliance on nitric 
oxide. Thus chronic thiol depletion results in an age-dependent increased reliance on NO and does not 
augment the vascular responses seen with increased age. 
In response to acute GSH infusion, at a physiologically relevant concentration that does not 
alter baseline CVR, it was demonstrated that the enhanced BK-mediated dilation was independent of 
NO and its downstream target sGC, as enhanced sensitivity persisted despite NOS and/or sGC 
inhibition. It was determined that ROS was required for GSH to exert its effect. This is in agreement 
with previous studies (5, 104, 138) and extends them by suggesting that the elevated ROS seen in 
cardiovascular disease allows the GSH effect to be more pronounced. 
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The method of acute thiol depletion is a major determinant of how alterations in the 
GSH:GSSG ratio impact coronary vascular resistance and endothelium-dependent dilation. In the 
presence of both thioredoxin inhibition and GSH alkylation there were increases in baseline CVR and 
marked reductions in endothelial-dependent dilation. In the presence of CDNB, a recontraction was 
observed at the higher concentrations of BK which were independent of COX, yet enhanced in the 
presence of ROS scavenging. Conversely, the altered dilation in the presence of EA was not altered to 
the same extent with LNAME as the control condition, suggesting that de novo NO synthesis does not 
account for the altered dilation. This finding extends earlier work regarding the role of RSNO in the 
dilation to BK in the intact coronary circulation (39) and suggests that in this preparation the inhibition 
of RSNO formation and replenishment play a role in determining both baseline CVR and endothelium-
dependent dilation in the intact coronary vascular bed. In response to BCNU, there was a marked 
reduction in total dilatory capacity as baseline CVR was slightly attenuated, and minimal CVR was 
slightly elevated. 
Cross study analysis revealed strong inverse correlations between GSH and GSSG and both 
baseline and minimal CVR, while no correlations were found between either oxidized or reduced 
glutathione and any of the curve parameters measured. Therefore it is likely that changes in overall 
glutathione content play a role in determining baseline and minimal coronary vascular resistance. One 
intriguing finding is that it was either GSH or GSSG that were highly correlated with these measures, 
the GSH:GSSG ratio was not as strongly correlated with either baseline or minimal CVR. This likely 






 The primary focus of this collective work was on NO bioavailability in response to changes in 
GSH. The results of these studies clearly demonstrated that changes in GSH influence baseline, and 
minimal CVR, and posses the ability to augment BK-mediated dilation. Therefore, the primary 
conclusion is that GSH possess the ability influences several aspects of the production and destruction 
of NO and that depending on the nature of GSH manipulation, the effects are divergent. It was further 
demonstrated that alterations in the content of both GSH and GSSG play significant role in the setting 
of baseline and minimal coronary vascular resistance, thus impacting total dilatory capacity. The 
nature of the availability of GSH and altered GSH:GSSG ratio is complex as is evident from the studies 
described within. The importance of these findings extends beyond the in vitro nature of these studies 
as the results have implications for understanding disease process and potential therapeutic effects of 
GSH. The importance of regulating GSH, GSSG and the GSH:GSSG is highlighted by the potential impact 
that its reduction has on minimal CVR which has implications for adequate cardiac perfusion. The 
ability of GSH to augment endothelium-dependent dilation suggests that GSH may be under-utilized as 
an adjunct for therapy for individuals with cardiovascular disease. There is an age-dependent 
adaptation that occurs during GSH depletion. This highlights the importance of healthy aging and 
suggests that the ability of the vasculature to adapt to an additional oxidative stress in conditions of 
aging is reduced. The ability of GSH to have such divergent affects on both endothelium-dependent 
dilation and coronary vascular resistance highlights the importance of this work.  
A reduction in endothelium-dependent dilation is a hallmark sign of cardiovascular disease 
states and is often attributed to a reduction in NO bioavailability. This loss of NO bioavailability is also 
associated with cardiovascular disease progression as NO plays a significant role in maintaining 
vascular wall homeostasis. These studies clearly illustrate the ability of GSH to enhance, or reduce 
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vasomotor dysfunction, but also highlight the ability of GSH to alter coronary vascular resistance. The 
role that glutathione plays within the vascular wall is complex and this collective work has provided 
additional mechanistic insight into the role that changes in the GSH content plays within the coronary 
circulation.  
These findings provide a new framework and understanding of how manipulations of GSH 
impact that pathophysiology of coronary vascular resistance and endothelium-dependent dilation in 
the intact coronary circulation. Thus providing novel insights into the understanding both the 
pathological consequences of altered GSH, and the ability of GSH to augment endothelium dependent 
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Figure A1 Immunoblots analysis for superoxide dismutase. 
No Differences were seen across all groups for either SOD1 (A) or SOD2 (B) Above each graph is a 
representative immunoblot of n=2/group in the order that they appear on the graph. Data are 




























































CON BSO CON BSO
ADULT OLD









Figure A2. BK Dose response curve in the Con, 1 and 10 µM GSH 
Dilatory curves from the control (■), GSH10 (□) and 1 µM GSH (●). GSH1 was not statistically different 
from the control group although this concentration did slightly enhance the EC50 and AUC but not 
max. *, p<0.05 vs control. Data are presented as mean±SE (n=7/group). 
  








































Figure A3 Bradykinin induced dilation in the presence of ODQ. 
Data are mean±SE (n=6-7/group), for Control (■) and ODQ 10 µM (□).  No Differences were observed 
in maximal dilation, sensitivity or EC50. 
 





































Figure A4. BK Dose response curve in the presence of LNAME and ODQ. 
Dilatory curves from the control (■) and GSH10 (□) in the presence of LNAME (0.1 mM) and ODQ (3 
µM) the GSH10 effect persisted. Data are presented as mean±SE (n=6/group). 
  














  CON GSH10 
EC50 (log M) -7.81 ± 0.08 -8.38 ± 0.05* 
Max (%) 94.6 ± 1.0 95.0 ± 1.3 
























Figure A5 SNP induced dilation in the presence of TEMPOL 
The presence of TEMPOL 0.1 µM did not significantly alter the SNP mediated dilation in either the 
Control (■) or GSH10 (□) groups (n=3/group). 
  





































Figure A6 Effect of combined LNAME and indomethacin on change in CVR 
BK (0.1 µM) induced decrease in CVR. In the presence of INDO there was no difference compared to 
the control (no drug) response. LNAME resulted in an increased change in CVR (owing to the higher 
starting point). In the presence of both INDO and LNAME (BOTH) the decrease in CVR was similar to 
LNAME alone.  *p<0.05 vs No Drug. Data are mean±SE (n=7-17/group). 
  




































Figure A7. Effect of cyclooxygenase inhibition on BK dose-response in control and CDNB treated 
hearts 
Hearts were allowed to equilibrate for 30 minutes in the presence of INDO (10-5 M) followed by dose-
response curve to BK. Data are from the CON (●), CDNB (■) in the absence of INDO or presence INDO 
control (○) or SC560 (3×10-7 M) + NS398 (10-6 M) CDNB (□). In the presence of dual COX-inhibition in 
both groups the responses are not statistically different from the respective no drug condition.  The 
insert shows the dilation relative to baseline from CON (●), CDNB (■) both in the presence of INDO 
(10-5M).  As is evident from this graph CDNB was unresponsive to endothelium-dependent and 
independent dilation in the presence of INDO. All data is presented as mean±SE (n=5-7/group). 
  



























































Figure A8 Diamide dose-response curve 
Hearts were allowed to equilibrate for 30 minutes followed by dose-response curve to diamide. 
Following the highest concentration of diamide, SNP was used to dilate the coronary vasculature. 
Similar to the data from the BK dose-response curves in the presence of diamide at either 1 or 10 µM, 










































Figure A9. GSH dose-response curve from SHR and WKY rats 
Dilatory curves from the control WKY (■) and hypertensive SHR rats (□). *p<0.05 vs WKY. Data are 
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